<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults - Cândido, RCF - 2021 | Cochrane Library</title> <meta content="Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults - Cândido, RCF - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013011.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults - Cândido, RCF - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013011.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013011.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults" name="citation_title"/> <meta content="Raissa Carolina F Cândido" name="citation_author"/> <meta content="Universidade Federal de Minas Gerais (UFMG)" name="citation_author_institution"/> <meta content="Cristiane A Menezes de Padua" name="citation_author"/> <meta content="Universidade Federal de Minas Gerais (UFMG)" name="citation_author_institution"/> <meta content="Su Golder" name="citation_author"/> <meta content="University of York" name="citation_author_institution"/> <meta content="Daniela R Junqueira" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="danijunqueira@gmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD013011.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/01/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013011.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013011.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013011.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents, Second-Generation [administration &amp; dosage]; Anxiety [drug therapy]; Attention Deficit Disorder with Hyperactivity [*drug therapy]; Bias; Bupropion [administration &amp; dosage]; Central Nervous System Stimulants [*administration &amp; dosage, adverse effects]; Depression [drug therapy]; Drug Delivery Systems; Flavonoids [administration &amp; dosage]; Lithium Compounds [administration &amp; dosage]; Methylphenidate [*administration &amp; dosage, adverse effects]; Placebos [administration &amp; dosage]; Plant Extracts [administration &amp; dosage]; Randomized Controlled Trials as Topic [statistics &amp; numerical data]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013011.pub2&amp;doi=10.1002/14651858.CD013011.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013011\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013011\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","ja","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013011.pub2",title:"Immediate\\u2010release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults",firstPublishedDate:"Jan 18, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013011.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013011.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013011.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013011.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013011.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013011.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013011.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013011.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013011.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013011.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10058 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013011.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/appendices#CD013011-sec-0124"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/supinfo/CD013011StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/supinfo/CD013011StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information#CD013011-cr-0004">Raissa Carolina F Cândido</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information#CD013011-cr-0005">Cristiane A Menezes de Padua</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information#CD013011-cr-0006">Su Golder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information#CD013011-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Daniela R Junqueira</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information/en#CD013011-sec-0138">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 January 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013011.pub2">https://doi.org/10.1002/14651858.CD013011.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013011-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013011-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013011-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013011-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013011-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013011-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013011-abs-0001" lang="en"> <section id="CD013011-sec-0001"> <h3 class="title" id="CD013011-sec-0001">Background</h3> <p>Attention deficit hyperactivity disorder (ADHD) is characterized by symptoms of inattention or impulsivity or both, and hyperactivity, which affect children, adolescents, and adults. In some countries, methylphenidate is the first option to treat adults with moderate or severe ADHD. However, evidence on the efficacy and adverse events of immediate‐release (IR) methylphenidate in the treatment of ADHD in adults is limited and controversial. </p> </section> <section id="CD013011-sec-0002"> <h3 class="title" id="CD013011-sec-0002">Objectives</h3> <p>To evaluate the efficacy and harms (adverse events) of IR methylphenidate for treating ADHD in adults. </p> </section> <section id="CD013011-sec-0003"> <h3 class="title" id="CD013011-sec-0003">Search methods</h3> <p>In January 2020, we searched CENTRAL, MEDLINE, Embase, eight additional databases and three trial registers. We also searched internal reports on the European Medicines Agency and the US Food and Drug Administration websites. We checked citations of included trials to identify additional trials not captured by the electronic searches. </p> </section> <section id="CD013011-sec-0004"> <h3 class="title" id="CD013011-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) comparing IR methylphenidate, at any dose, with placebo or other pharmacological interventions (including extended‐release formulations of methylphenidate) for ADHD in adults. Primary outcomes comprised changes in the symptoms of ADHD (efficacy) and harms. Secondary outcomes included changes in the clinical impression of severity and improvement, level of functioning, depression, anxiety and quality of life. Outcomes could have been rated by investigators or participants. </p> </section> <section id="CD013011-sec-0005"> <h3 class="title" id="CD013011-sec-0005">Data collection and analysis</h3> <p>Two review authors extracted data independently on the characteristics of the trials, participants, interventions; outcomes and financial conflict of interests. We resolved disagreements by discussion or consulting a third review author. We obtained additional, unpublished information from the authors of one included trial that had reported efficacy data in a graph. We calculated mean differences (MDs) or standardized MDs (SMDs) with 95% confidence intervals (CIs) for continuous data reported on the same or different scales, respectively. We summarized dichotomous variables as risk ratios (RRs) with 95% CI. </p> </section> <section id="CD013011-sec-0006"> <h3 class="title" id="CD013011-sec-0006">Main results</h3> <p>We included 10 trials published between 2001 and 2016 involving 497 adults with ADHD. Three trials were conducted in Europe and one in Argentina; the remaining trials did not report their location. The RCTs compared IR methylphenidate with placebo, an osmotic‐release oral system (OROS) of methylphenidate (an extended‐release formulation), an extended‐release formulation of bupropion, lithium, and Pycnogenol® (maritime pine bark extract). Participants comprised outpatients, inpatients in addiction treatment, and adults willing to attend an intensive outpatient program for cocaine dependence. The duration of the follow‐up ranged from 6 to 18 weeks. </p> <p><b>IR methylphenidate versus placebo</b> </p> <p>We found very low‐certainty evidence that, compared with placebo, IR methylphenidate may reduce symptoms of ADHD when measured with investigator‐rated scales (MD −20.70, 95% CI −23.97 to −17.43; 1 trial, 146 participants; end scores; Adult ADHD Investigator Symptom Report Scale (AISRS), scored from 0 to 54), but the evidence is uncertain. The effect of IR methylphenidate on ADHD symptoms when measured with participant‐rated scales was moderate, but the certainty of the evidence is very low (SMD −0.59, 95% CI −1.25 to 0.06; I<sup>2</sup> = 69%; 2 trials, 138 participants; end scores). </p> <p>There is very low‐certainty evidence that, compared with placebo, IR methylphenidate may reduce the clinical impression of the severity of ADHD symptoms (MD −0.57, 95% CI −0.85 to −0.28; 2 trials, 139 participants; I<sup>2</sup> = 0%; change and end scores; Clinical Global Impression (CGI)‐Severity scale (scored from 1 (very much improved) to 7 (very much worse))). There is low‐certainty evidence that, compared with placebo, IR methylphenidate may slightly impact the clinical impression of an improvement in symptoms of ADHD (MD −0.94, 95% CI −1.37 to −0.51; 1 trial, 49 participants; end scores; CGI‐Improvement scale (scored from 1 (very much improved) to 7 (very much worse))). There is no clear evidence of an effect on anxiety (MD −0.20, 95% CI −4.84 to 4.44; 1 trial, 19 participants; change scores; Hamilton Anxiety Scale (HAM‐A; scored from 0 to 56); very low‐certainty evidence) or depression (MD 2.80, 95% CI −0.09 to 5.69; 1 trial, 19 participants; change scores; Hamilton Depression Scale (HAM‐D; scored from 0 to 52); very low‐certainty evidence) in analyses comparing IR methylphenidate with placebo. </p> <p><b>IR methylphenidate versus lithium</b> </p> <p>Compared with lithium, it is uncertain whether IR methylphenidate increases or decreases symptoms of ADHD (MD 0.60, 95% CI −3.11 to 4.31; 1 trial, 46 participants; end scores; Conners’ Adult ADHD Rating Scale (scored from 0 to 198); very low‐certainty evidence); anxiety (MD −0.80, 95% CI −4.49 to 2.89; 1 trial, 46 participants; end scores; HAM‐A; very low‐certainty evidence); or depression (MD −1.20, 95% CI −3.81 to 1.41, 1 trial, 46 participants; end scores; HAM‐D scale; very low‐certainty evidence). None of the included trials assessed participant‐rated changes in symptoms of ADHD, or clinical impression of severity or improvement in participants treated with IR methylphenidate compared with lithium. </p> <p>Adverse events were poorly assessed and reported. We rated all trials at high risk of bias due to selective outcome reporting of harms and masking of outcome assessors (failure to blind outcome assessor to measure adverse events). Overall, four trials with 203 participants who received IR methylphenidate and 141 participants who received placebo described the occurrence of harms. The use of IR methylphenidate in these trials increased the risk of gastrointestinal complications (RR 1.96, 95% CI 1.13 to 2.95) and loss of appetite (RR 1.77, 95% CI 1.06 to 2.96). Cardiovascular adverse events were reported inconsistently, preventing a comprehensive analysis. One trial comparing IR methylphenidate to lithium reported five and nine adverse events, respectively. </p> <p>We considered four trials to have notable concerns of vested interests influencing the evidence, and authors from two trials omitted information related to the sources of funding and conflicts of interest. </p> </section> <section id="CD013011-sec-0007"> <h3 class="title" id="CD013011-sec-0007">Authors' conclusions</h3> <p>We found no certain evidence that IR methylphenidate compared with placebo or lithium can reduce symptoms of ADHD in adults (low‐ and very low‐certainty evidence). Adults treated with IR methylphenidate are at increased risk of gastrointestinal and metabolic‐related harms compared with placebo. Clinicians should consider whether it is appropriate to prescribe IR methylphenidate, given its limited efficacy and increased risk of harms. Future RCTs should explore the long‐term efficacy and risks of IR methylphenidate, and the influence of conflicts of interest on reported effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013011-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013011-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013011-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013011-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013011-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013011-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013011-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013011-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013011-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013011-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013011-abs-0002" lang="en"> <h3>IR methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults</h3> <p><b>What is the aim of this review?</b> </p> <p>We reviewed the evidence about the effects of treating adults with ADHD with a stimulant drug called immediate‐release (IR) methylphenidate. </p> <p><b>Key messages</b> </p> <p>Compared with placebo (a dummy pill), IR methylphenidate may promote a small reduction in the symptoms of ADHD and may increase the doctor’s perception of an improvement in symptoms. IR methylphenidate increased the risk of adverse effects such as loss of appetite, dry mouth, nausea and stomach aches. </p> <p>Compared with lithium (a drug to treat overactivity and excitement), IR methylphenidate may promote few or no changes in the symptoms of ADHD, anxiety and depression. </p> <p>These results are uncertain, and we do not know if we can trust them.</p> <p><b>What was studied in this review?</b> </p> <p>ADHD is a mental‐health impairment. The problem is diagnosed in adults who show signs of inattention (e.g. trouble concentrating), hyperactivity (e.g. unable to sit still) and impulsivity (e.g. doing things without thinking). </p> <p>We looked for trials comparing IR methylphenidate, at any dose, with other drugs (including extended‐release formulations of methylphenidate where the drug is released slowly over time) or placebo, to treat ADHD in adults. We wanted to know the effect of IR methylphenidate on the symptoms of ADHD and if people had adverse events. We also wanted to know if people treated with the drug or their doctors perceived changes in their symptoms (getting worse or better), mental health (depression, anxiety) or quality of life. </p> <p><b>What are the main results of the review?</b> </p> <p>We found 10 trials, involving 497 adults. Three trials were carried out in Europe and one in Argentina; the remaining trials did not report their location. Six trials compared IR methylphenidate with placebo. In the other trials, IR methylphenidate was compared to an extended‐release form of bupropion (an antidepressant), lithium, an extended‐release form of methylphenidate named osmotic‐release oral system (OROS), and Pycnogenol® (a medicine derived from the bark of a pine tree). People were treated for 6 to 18 weeks. Participants were mainly outpatients; some participants were inpatients for addiction treatment, or individuals willing to attend an intensive outpatient program for cocaine dependence. </p> <p><i>IR methylphenidate versus placebo</i> </p> <p>One trial with 146 participants reported that IR methylphenidate may reduce symptoms of ADHD when judged by the doctors. When participants judge their own symptoms, there may be a moderate positive effect. We are however uncertain about these results and they may change with the addition of more data. IR methylphenidate appears to have little or no effect in reducing symptoms of anxiety and depression. We have concerns about the methods and conflicts of interest presented by this trial and the other nine trials that were evaluated. </p> <p><i>IR methylphenidate versus lithium</i> </p> <p>IR methylphenidate may have little or no effect on symptoms of ADHD (judged by the doctors), or anxiety and depression, but the results are uncertain. None of the included trials assessed changes in symptoms of ADHD rated by participants, or the clinical impression of severity or improvement in participants treated with IR methylphenidate compared with lithium. </p> <p><i>Adverse events</i> </p> <p>Adverse events (side effects) were poorly assessed and reported in all trials. Overall, four trials with 203 participants who received IR methylphenidate and 141 participants who received placebo described the occurrence of harms. The use of IR methylphenidate reported in these trials increased the risk of digestive complications and loss of appetite. Harm to the heart and circulation was reported, but in a limited and inconsistent manner. One trial comparing IR methylphenidate to lithium reported five and nine adverse events, respectively. </p> <p>We considered almost all trials to have notable concerns related to their sources of funding and conflicts of interest. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The evidence is current to 3 January 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013011-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013011-sec-0119"></div> <h3 class="title" id="CD013011-sec-0120">Implications for practice</h3> <section id="CD013011-sec-0120"> <p>We are uncertain whether IR methylphenidate improves ADHD symptoms in adults with ADHD. We rated the evidence as low or very low certainty and we are uncertain whether the estimated magnitude of effects reflects the true effects. The evidence is limited by the high or unclear risks of bias in the included trials and wide variation in the scales used to measure the outcomes. There is also uncertainty about the occurrence of adverse events in response to IR methylphenidate, as these outcomes were poorly assessed or reported by the available studies. We did not evaluate whether IR methylphenidate improves ADHD quality of life due to the absence of evidence for this outcome in the included studies. </p> <p>Evidence from this review does not provide a sound basis to support the use of IR methylphenidate for ADHD in adults. If IR methylphenidate treatment is considered, clinicians should monitor the increased risk of gastrointestinal and metabolic‐related harms, and discontinue treatment if these or other events occur. It is also important to note that the trials considered in this review used early diagnostic criteria, prior to the DSM‐5, which did not allow for a comorbid diagnosis of ADHD and ASD. Clinicians should consider this when contemplating this treatment option for these patients. </p> </section> <h3 class="title" id="CD013011-sec-0121">Implications for research</h3> <section id="CD013011-sec-0121"> <p>Future studies should attempt to use core outcome sets and core outcome measurement instruments to ascertain the benefits and risks of IR methylphenidate for ADHD in adults. The high heterogeneity among the clinical rating scales precludes robust analysis and interpretation of the available evidence. This may result in significant differences between isolated conclusions from individual RCT reports and a meta‐analysis of the comparable data available. Future RCTs should also explore the long‐term efficacy and risks of IR methylphenidate. </p> <p>Research on the efficacy and risks of IR methylphenidate for ADHD in adults may also benefit from improvement in the external validity of the studies, which can be achieved by the inclusion of participants with comorbidities, especially psychiatric disorders that are very common among adults with ADHD. For instance, the use of updated diagnostic criteria, i.e. DSM‐5 that is calibrated for this multiple diagnosis, is also fundamental. </p> <p>In addition, conflicts of interest, including research or individual sponsorship, should be considered a potentially important source of bias in the current research (<a href="./references#CD013011-bbs2-0088" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3] [PMID: 28207928]">Lundh 2017a</a>; <a href="./references#CD013011-bbs2-0089" title="LundhA , BeroL . The ties that bind. BMJ2017;356:j176. [DOI: 10.1136/bmj.j176] [PMID: 28096082]">Lundh 2017b</a>). Future studies (both RCTs and systematic reviews) should assess to what extent these factors can influence the report of beneficial effects and harms associated with treatment. </p> <p>Among the included trials, only one appears to be registered in any clinical trial registry. The registration was not mentioned in the studies' reports and a dedicated search could not locate the studies' registers. Efforts to encourage the registration of clinical trials should be expanded to ensure greater transparency in the publication of the results of these studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013011-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013011-sec-0008"></div> <div class="table" id="CD013011-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Immediate‐release methylphenidate versus placebo for attention deficit hyperactivity disorder (ADHD) in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Immediate‐release methylphenidate versus placebo for attention deficit hyperactivity disorder (ADHD) in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with ADHD (available evidence for participants aged between 25 to 53 years old)<br/><b>Setting:</b> outpatients and inpatients<br/><b>Intervention:</b> immediate‐release methylphenidate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with</b> </p> <p><b>placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with immediate‐release methylphenidate</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy (changes in symptoms of ADHD): investigator‐rated</b><br/>Assessed with: Adult ADHD Investigator Symptom Report Scale (AISRS; scores range from 0 to 54); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy score</p> <p>in the control group was <b>33.8 points</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy score in the intervention group was <b>20.70 points lower</b> (23.97 lower to 17.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may reduce symptoms of ADHD when rated by investigators but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy (changes in symptoms of ADHD): participant‐rated</b> <br/>Assessed with: Barkley's ADHD Problem Behaviours Scale (scores range from 0 to 42); ADHD Rating Scale‐IV (scores range from 0 to 54)); higher scores indicate an increase in symptom occurrence or illness severity </p> <p>Follow‐up: range = 7 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean efficacy score in the intervention group was <b>0.59 points lower</b> (1.25 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may have a moderate to no effect on symptoms of ADHD when rated by participants but the evidence is very uncertain. </p> <p><i>The effect would represent a moderate difference between the control and the intervention group. As a rule of thumb, 0.2 points represents a small difference, 0.5 a moderate and 0.8 a large effect.</i> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical impression: severity </b><br/>Assessed with: Clinical Global Impression ‐ Severity index (scored from 1 = very much improved to 7 = very much worse)<br/>Follow‐up: range = 7 weeks to 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical impression of symptom severity score in the intervention groups was <b>0.57 points lower</b> (0.85 lower to 0.28 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores and Change scores. IR methylphenidate may reduce clinicians' impressions of the severity of ADHD symptoms but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical impression: improvement</b><br/>Assessed with: Clinical Global Impression ‐ Improvement index (scored from 1 = very much improved to 7 = very much worse)<br/>Follow‐up: mean = 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical impression of improvement score in the control group was <b>3.54 points</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical impression of improvement score in the intervention group was <b>0.94 points lower</b> (1.37 lower to 0.51 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>L<b>ow</b><sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may slightly increase clinicians' impressions of improvement in ADHD symptoms. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anxiety: investigator‐rated</b><br/>Assessed with: Hamilton Anxiety Scale (scores range from 0 to 56); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score in the intervention group was <b>0.20 points lower</b> (4.84 lower to 4.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change scores. There is no clear evidence of an effect, but the evidence is very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression: investigator‐rated</b><br/>Assessed with: Hamilton Depression Scale (scores range from 0 to 52); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression score in the intervention group was <b>2.80 points higher</b> (0.09 lower to 5.69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change scores. There is no clear evidence of an effect, but the evidence is very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: adverse events</b> (poorly assessed and reported) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Among participants experiencing at least 1 adverse event, the use of IR methylphenidate increased the risk of gastrointestinal complications (RR 1.96, 95% CI 1.13 to 2.95) and loss of appetite (RR 1.77, 95% CI 1.06 to 2.96). Cardiovascular adverse events were reported inconsistently, preventing a comprehensive analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IR methylphenidate may increase the risk of gastrointestinal adverse events and loss of appetite. It is unclear whether IR methylphenidate induces cardiovascular adverse events. </p> <p>Overall, adverse events were poorly assessed and reported in all included studies. We considered all studies to be at high risk of bias due to selective outcome reporting of harms and masking of the outcome assessor (failure to blind outcome assessor to measure harms). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b>  was the median control group risk across studies. The <b>corresponding risk</b>  (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADHD:</b> Attention deficit hyperactivity disorder; <b>CI:</b> Confidence interval; <b>IR:</b> immediate‐release; <b>IV:</b> Fourth version; <b>MD:</b>  Mean difference; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to high and unclear risk of bias in multiple criteria (random sequence generation, allocation concealment, blinding of outcome assessors, incomplete outcome data, and selective outcome reporting).<br/><sup>b</sup>Downgraded once for imprecision caused by small sample size or single study results, or both.<br/><sup>c</sup>Downgraded twice due to high and unclear risk of bias in multiple criteria (allocation bias, blinding of outcome assessors, incomplete outcome data, and selective outcome reporting).<br/><sup>d</sup>Downgraded once for unclear risk of bias of outcome assessment and selective outcome reporting.<br/><sup>e</sup>Downgraded twice due to high and unclear risk of bias in multiple criteria (random sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessors). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013011-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Immediate‐release methylphenidate versus lithium for attention deficit hyperactivity disorder (ADHD) in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Immediate‐release methylphenidate versus lithium for attention deficit hyperactivity disorder (ADHD) in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with ADHD (available evidence for participants aged between 25 to 53 years old)<br/><b>Setting:</b> inpatients receiving treatment for various substance‐use disorders<br/><b>Intervention:</b> immediate‐release methylphenidate<br/><b>Comparison:</b> lithium </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with lithium</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with immediate‐release methylphenidate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy (changes in symptoms of ADHD): investigator‐rated</b><br/>Assessed with: Conners’ Adult ADHD Rating Scale (scores range from 0 to 198); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 18 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy score in the control group was <b>28.4 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy score in the intervention group was <b>0.60 points higher</b> (3.11 lower to 4.31 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. It is uncertain whether IR methylphenidate is more effective than lithium.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Efficacy (changes in symptoms of ADHD): participant‐rated ‐ not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical impression: severity</b> <br/><b>‐ not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical impression: improvement</b> <br/><b>‐ not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anxiety: investigator‐rated</b><br/>Assessed with: Hamilton Anxiety Scale (scores range from 0 to 56); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 18 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score in the control group was <b>6.2 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score in the intervention group was <b>0.80 points lower</b> (4.49 lower to 2.89 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may have little to no effect on anxiety but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression: investigator‐rated</b><br/>Assessed with: Hamilton Depression Scale (scores range from 0 to 52); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 18 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression score in the control group was <b>7.8 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression score in the intervention group was <b>1.20 points lower</b> (3.81 lower to 1.41 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may have little to no effect on depression but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms:</b>  <b>adverse events</b> (poorly assessed and reported) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 trial comparing IR methylphenidate to lithium reported 5 and 9 adverse events, respectively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were poorly assessed and reported in all included studies. We considered all studies to be at high risk of bias due to selective outcome reporting of harms and masking of the outcome assessor (failure to blind outcome assessor to measure harms). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b>  was the median control group risk across studies. The <b>corresponding risk</b>  (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADHD:</b> Attention deficit hyperactivity disorder; <b>CI:</b> Confidence interval; <b>IR:</b> immediate‐release; <b>MD:</b>  Mean difference; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to unclear risk of bias in several domains (random sequence generation, allocation concealment, blinding of outcome assessment, incomplete and selective outcome reporting) and high risk of bias due to incomplete outcome data.<br/><sup>b</sup>Downgraded once due to small sample size and single‐study effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013011-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013011-sec-0009"></div> <section id="CD013011-sec-0010"> <h3 class="title" id="CD013011-sec-0010">Description of the condition</h3> <p>Attention deficit hyperactivity disorder (ADHD) is defined as a mental health disability, which usually begins before 12 years of age, and is characterized by three main symptoms: inattention, impulsivity, and hyperactivity. The intensity of the symptoms tends to decrease with ageing, but in 40% to 50% of people diagnosed with ADHD in childhood, symptoms may persist during adolescence and adulthood (<a href="./references#CD013011-bbs2-0100" title="National Institute of Mental Health. Attention-deficit-hyperactivity disorder. www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml (accessed 18 March 2016).">NIMH 2016</a>; <a href="./references#CD013011-bbs2-0118" title="SibleyMH , MitchellJT , BeckerSP . Method of adult diagnosis influences estimated persistence of childhood ADHD: a systematic review of longitudinal studies. Lancet Psychiatry2016;3(12):1157–65. [DOI: 10.1016/S2215-0366(16)30190-0] [PMID: 27745869]">Sibley 2016</a>). Recent studies have shown that symptoms of ADHD may appear only in adulthood (<a href="./references#CD013011-bbs2-0029" title="Agnew-BlaisJC , PolanczykGV , DaneseA , WertzJ , MoffittTE , ArseneaultL . Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. JAMA Psychiatry2016;73(7):713-20. [DOI: 10.1001/jamapsychiatry.2016.0465] [PMC5475268] [PMID: 27192174]">Agnew‐Blais 2016</a>; <a href="./references#CD013011-bbs2-0047" title="CayeA , RochaTB , AnselmiL , MurrayJ , MenezesAM , BarrosFC , et al. Attention-deficit hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry2016;73(7):705-12. [DOI: 10.1001/jamapsychiatry.2016.0383] [PMID: 27192050]">Caye 2016</a>; <a href="./references#CD013011-bbs2-0094" title="MoffittTE , HoutsR , AshersonP , BelskyDW , CorcoranDL , HammerleM , et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. American Journal of Psychiatry2015;172(10):967–77. [DOI: 10.1176/appi.ajp.2015.14101266] [PMC4591104] [PMID: 25998281]">Moffitt 2015</a>), yet it is a controversial issue (<a href="./references#CD013011-bbs2-0067" title="FrankeB , MicheliniG , AshersonP , BanaschewskiT , BilbowA , BuitelaarJK , et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. European Neuropsychopharmacology2018;28(10):1059-88. [DOI: 10.1016/j.euroneuro.2018.08.001] [PMC6379245] [PMID: 30195575]">Franke 2018</a>; <a href="./references#CD013011-bbs2-0097" title="MoncrieffJ , TimimiS . Critical analysis of the concept of adult attention-deficit hyperactivity disorder. Psychiatrist2011;35(9):334-8. [DOI: 10.1192/pb.bp.110.033423]">Moncrieff 2011</a>). In some cases, ADHD remains undiagnosed until adulthood because it is not recognized during childhood, or it presents in a mild form (<a href="./references#CD013011-bbs2-0101" title="National Institute of Mental Health. Could I have attention-deficit/hyperactivity disorder (ADHD)?www.nimh.nih.gov/health/publications/could-i-have-adhd/index.shtml (accessed 17 May 2017).">NIMH 2017</a>). Symptoms may also be associated with the onset and persistence of secondary disorders or diseases (<a href="./references#CD013011-bbs2-0052" title="ChengYS , ShyuYC , LeeSY , YuanSS , YangCJ , YangKC , et al. Trends, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit hyperactivity disorder: a nationwide survey in Taiwan. Neuropsychiatric Disease and Treatment2017;13:643-51. [DOI: 10.2147/NDT.S126438] [PMC5338966] [PMID: 28280346]">Cheng 2017</a>; <a href="./references#CD013011-bbs2-0066" title="FayyadJ , SampsonNA , HwangI , AdamowskiT , Aguilar-GaxiolaS , Al-HamzawiA , et al. The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. Attention Deficit and Hyperactivity Disorders2017;9(1):47-65. [DOI: 10.1007/s12402-016-0208-3] [ PMC5325787] [PMID: 27866355]">Fayyad 2017</a>; <a href="./references#CD013011-bbs2-0100" title="National Institute of Mental Health. Attention-deficit-hyperactivity disorder. www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml (accessed 18 March 2016).">NIMH 2016</a>), which reinforces the discussion of whether this is a different clinical condition (<a href="./references#CD013011-bbs2-0097" title="MoncrieffJ , TimimiS . Critical analysis of the concept of adult attention-deficit hyperactivity disorder. Psychiatrist2011;35(9):334-8. [DOI: 10.1192/pb.bp.110.033423]">Moncrieff 2011</a>). The persistence of symptoms of inattention, hyperactivity and impulsivity may negatively affect the individual's social, academic or professional activities (<a href="./references#CD013011-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>). </p> <p>The diagnosis of ADHD is based on the presence of at least six (in children and adolescents) or five (in adults older than 17 years) of the 18 symptoms that are indicative of inattention, hyperactivity and impulsivity. This core list of symptoms was developed by the fifth edition of the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM‐5; <a href="./references#CD013011-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>), to be applied for the diagnosis of ADHD in children; it is also listed in the <i>International Classification of Diseases</i> 10th and 11th editions (ICD‐10 and ICD‐11; <a href="./references#CD013011-bbs2-0135" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva (CH): World Health Organization, 1992.">WHO 1992</a>; <a href="./references#CD013011-bbs2-0137" title="World Health Organization. ICD-11: International Classification of Diseases for Mortality and Morbidity Statistics, Eleventh Revision. Geneva (CH): WHO, 2018.">WHO 2018</a>, respectively) as Attention Deficit Hyperactivity Disorder. The symptoms should be observed in different circumstances of the individual's daily life and must represent a negative disruption to regular activities and tasks related to one or more contexts of life. In addition, the symptoms may be recognized in a variety of degrees of intensity, depending on the specific characteristics of each individual, their overall behavior, and on the predominance of one symptom or another. Considering the predominance of one symptom or another, ADHD may be classified into three presentations/subtypes: predominantly inattentive; predominantly hyperactive or impulsive; or combined (in which all symptoms are present, but there is no clear predominance among them), which can change over time. Inattentive presentation is characterized by becoming distracted or struggling to concentrate when performing tasks, combined with a lack of persistence, a lack of a sense of planning and an inability to organize tasks or things. Hyperactivity is a pattern of excessive motor activity in children and restlessness in adults. Finally, the impulsiveness presentation is manifested when the individual takes actions or has attitudes with no judgment or awareness of the possible consequences or associated risks (<a href="./references#CD013011-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>). The Adult ADHD Self‐Report Scale (ASRS) was developed to support the diagnosis of ADHD in adults; it consists of a set of structured questions, based on the DSM‐5 criteria (<a href="./references#CD013011-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>), and has been demonstrated to have high sensitivity and specificity in detecting ADHD symptoms in adults (<a href="./references#CD013011-bbs2-0129" title="UstunB , AdlerLA , RudinC , FaraoneSV , SpencerTJ , BerglundP , et al. The World Health Organization Adult Attention-Deficit Hyperactivity Disorder Self-report Screening Scale for DSM-5. JAMA Psychiatry2017;74(5):520-6. [DOI: 10.1001/jamapsychiatry.2017.0298] [PMC5470397] [PMID: 28384801]">Ustun 2017</a>). </p> <p>The diagnostic criteria for ADHD in the DSM‐5 was amended to include the criteria for a diagnosis of ADHD in adults (<a href="./references#CD013011-bbs2-0132" title="WakefieldJC . Diagnostic issues and controversies in DSM-5: return of the false positives problem. Annual Review of Clinical Psychology2016;12:105-32. [DOI: 10.1146/annurev-clinpsy-032814-112800] [PMID: 26772207]">Wakefield 2016</a>). In this revision, the age of onset of the first symptoms was increased to 12 years, which reduced the diagnostic threshold for individuals aged 17 or older, and the description of some situations used in the diagnosis was modified to make it appropriate for adults (<a href="./references#CD013011-bbs2-0065" title="EpsteinJN , LorenRE . Changes in the definition of ADHD in DSM-5: subtle but important. Neuropsychiatry2013;3(5):455-8. [DOI: 10.2217/npy.13.59] [PMC3955126] [PMID: 24644516]">Epstein 2013</a>; <a href="./references#CD013011-bbs2-0132" title="WakefieldJC . Diagnostic issues and controversies in DSM-5: return of the false positives problem. Annual Review of Clinical Psychology2016;12:105-32. [DOI: 10.1146/annurev-clinpsy-032814-112800] [PMID: 26772207]">Wakefield 2016</a>). Furthermore, Autism Spectrum Disorder (ASD) was no longer an exclusionary diagnosis, allowing the comorbid diagnosis of ADHD and ASD (<a href="./references#CD013011-bbs2-0065" title="EpsteinJN , LorenRE . Changes in the definition of ADHD in DSM-5: subtle but important. Neuropsychiatry2013;3(5):455-8. [DOI: 10.2217/npy.13.59] [PMC3955126] [PMID: 24644516]">Epstein 2013</a>). Adults with ADS experience high rates of comorbidities, the most common being mood disorders, anxiety disorder and ADHD (<a href="./references#CD013011-bbs2-0076" title="HofvanderB , DelormeR , ChasteP , NydénA , WentzE , StåhlbergO , et al. Psychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders. BMC Psychiatry2009;9:35. [DOI: 10.1186/1471-244X-9-35] [PMC2705351] [PMID: 19515234]">Hofvander 2009</a>). Epidemiological and clinical data on this psychiatric disorder in adulthood are limited, since the diagnostic criteria in the DSM‐5's predecessors precluded a dual diagnosis of ADHD and ASD (<a href="./references#CD013011-bbs2-0104" title="PehlivanidisA , PapanikolaouK , MantasV , KalantziE , KorobiliK , Xenaki L-A, et al. Lifetime co-occurring psychiatric disorders in newly diagnosed adults with attention deficit hyperactivity disorder (ADHD) or/and autism spectrum disorder (ASD). BMC Psychiatry2020;20(1):423.">Pehlivanidis 2020</a>). Thus, trials that used diagnostic criteria available prior to the DSM‐5 may not be directly applicable to the clinical practice of patients with both ADHD and ASD. </p> <p>The prevalence of ADHD in adults is lower than the prevalence in children and adolescents, which ranges between 3% and 7% (<a href="./references#CD013011-bbs2-0108" title="PolanczykG , De LimaMS , HortaBL , BiedermanJ , RohdeLA . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry2007;164(6):942–8. [DOI: 10.1176/ajp.2007.164.6.942] [PMID: 17541055]">Polanczyk 2007</a>; <a href="./references#CD013011-bbs2-0126" title="ThomasR , SandersS , DoustJ , BellerE , GlasziouP . Prevalence of attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Pediatrics2015;135(4):e994-1001. [DOI: 10.1542/peds.2014-3482] [PMID: 25733754]">Thomas 2015</a>). The variation in the estimates of the prevalence of ADHD in children is probably due to the diagnostic criteria used (<a href="./references#CD013011-bbs2-0109" title="PolanczykGV , WillcuttEG , SalumGA , KielingC , RohdeLA . ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International Journal of Epidemiology2014;43(2):434-42. [DOI: 10.1093/ije/dyt261] [PMC4817588] [PMID: 24464188]">Polanczyk 2014</a>; <a href="./references#CD013011-bbs2-0126" title="ThomasR , SandersS , DoustJ , BellerE , GlasziouP . Prevalence of attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Pediatrics2015;135(4):e994-1001. [DOI: 10.1542/peds.2014-3482] [PMID: 25733754]">Thomas 2015</a>). Overall, prevalence estimates using the third, revised edition of the DSM (<a href="./references#CD013011-bbs2-0031" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd edition. Washington (DC): American Psychiatric Association, 1987.">APA 1987</a>) are 2.4% to 3% lower than prevalence estimates using the third (<a href="./references#CD013011-bbs2-0030" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd edition. Washington (DC): American Psychiatric Association, 1980.">APA 1980</a>) or fourth (<a href="./references#CD013011-bbs2-0032" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington (DC): American Psychiatric Association, 1994.">APA 1994</a>) editions of the DSM (<a href="./references#CD013011-bbs2-0126" title="ThomasR , SandersS , DoustJ , BellerE , GlasziouP . Prevalence of attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Pediatrics2015;135(4):e994-1001. [DOI: 10.1542/peds.2014-3482] [PMID: 25733754]">Thomas 2015</a>). Similarly, prevalence estimates using the ICD‐10 are 4.1% lower in comparison with prevalence estimates using the DSM‐IV (<a href="./references#CD013011-bbs2-0126" title="ThomasR , SandersS , DoustJ , BellerE , GlasziouP . Prevalence of attention-deficit hyperactivity disorder: a systematic review and meta-analysis. Pediatrics2015;135(4):e994-1001. [DOI: 10.1542/peds.2014-3482] [PMID: 25733754]">Thomas 2015</a>). Nevertheless, prevalence rates of ADHD in children have remained stable in the last 30 years (<a href="./references#CD013011-bbs2-0109" title="PolanczykGV , WillcuttEG , SalumGA , KielingC , RohdeLA . ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International Journal of Epidemiology2014;43(2):434-42. [DOI: 10.1093/ije/dyt261] [PMC4817588] [PMID: 24464188]">Polanczyk 2014</a>). The average prevalence of ADHD in adults is estimated to be at 2.8% and appears to be associated with the economic development of the country, with higher resource‐rich settings presenting higher prevalence estimates (average of 3.3%) (<a href="./references#CD013011-bbs2-0066" title="FayyadJ , SampsonNA , HwangI , AdamowskiT , Aguilar-GaxiolaS , Al-HamzawiA , et al. The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. Attention Deficit and Hyperactivity Disorders2017;9(1):47-65. [DOI: 10.1007/s12402-016-0208-3] [ PMC5325787] [PMID: 27866355]">Fayyad 2017</a>). Differences in the prevalence of prescribing and dispensing medicines are observed also between regions within the same country, which have different socioeconomic characteristics of access to healthcare services and medications (<a href="./references#CD013011-bbs2-0105" title="PeriniE , JunqueiraDR , LanaLG , LuzTC . Prescription, dispensation and marketing patterns of methylphenidate. Revista de Saúde Pública2014;48(6):873-80. [DOI: 10.1590/S0034-8910.2014048005234] [PMC4285829] [PMID: 26039389]">Perini 2014</a>). </p> <p>ADHD is more frequent in males than in females, with a ratio varying from 2:1 to 5:1 in children and from 1:1 to 6:1 in adults (<a href="./references#CD013011-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>). However, symptoms of inattention tend to appear much later in males than in females, while the inattentive presentation is most prevalent in adults with ADHD (<a href="./references#CD013011-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>; <a href="./references#CD013011-bbs2-0052" title="ChengYS , ShyuYC , LeeSY , YuanSS , YangCJ , YangKC , et al. Trends, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit hyperactivity disorder: a nationwide survey in Taiwan. Neuropsychiatric Disease and Treatment2017;13:643-51. [DOI: 10.2147/NDT.S126438] [PMC5338966] [PMID: 28280346]">Cheng 2017</a>). The presence of multimorbidity in individuals with ADHD is extremely common, and the manifestation of the condition in childhood often overlaps with the occurrence of other disorders ( e.g. challenging disorder and conduct disorder), imposing an additional layer of complexity to the diagnosis of the spectrum of individuals' problems (<a href="./references#CD013011-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>; <a href="./references#CD013011-bbs2-0099" title="National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87); March 2018 (last updated September 2019). www.nice.org.uk/guidance/ng87.">NICE 2018</a>). In adulthood, ADHD commonly co‐exists with other psychiatric conditions such as anxiety, depression, nervous tic, and intellectual disability (<a href="./references#CD013011-bbs2-0052" title="ChengYS , ShyuYC , LeeSY , YuanSS , YangCJ , YangKC , et al. Trends, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit hyperactivity disorder: a nationwide survey in Taiwan. Neuropsychiatric Disease and Treatment2017;13:643-51. [DOI: 10.2147/NDT.S126438] [PMC5338966] [PMID: 28280346]">Cheng 2017</a>; <a href="./references#CD013011-bbs2-0082" title="KesslerRC , AdlerL , BarkleyR , BiedermanJ , ConnersCK , DemlerO , et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of Psychiatry2006;163(4):716–23. [DOI: 10.1176/ajp.2006.163.4.716] [PMC2859678] [PMID: 16585449]">Kessler 2006</a>). </p> </section> <section id="CD013011-sec-0011"> <h3 class="title" id="CD013011-sec-0011">Description of the intervention</h3> <p>Psychostimulant medications, such as amphetamines, have been used in the treatment of ADHD in children and adolescents since the 1930s (<a href="./references#CD013011-bbs2-0042" title="BradleyC . The behavior of children receiving benzedrine. American Journal of Psychiatry1937;94(3):577-85. [DOI: 10.1176/ajp.94.3.577]">Bradley 1937</a>). Currently, methylphenidate, dexamphetamine, and atomoxetine are recommended treatments for individuals with ADHD (<a href="./references#CD013011-bbs2-0083" title="KolarD , KellerA , GolfinopoulosM , CumynL , SyerC , HechtmanL . Treatment of adults with attention-deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2008;4(2):389–403. [PMC2518387]">Kolar 2008</a>; <a href="./references#CD013011-bbs2-0099" title="National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87); March 2018 (last updated September 2019). www.nice.org.uk/guidance/ng87.">NICE 2018</a>). There is some evidence suggesting that stimulants are effective in reducing ADHD symptoms, contributing to better productivity at work and a decrease in suicidal behavior (<a href="./references#CD013011-bbs2-0051" title="ChenQ , SjölanderA , RunesonB , D’OnofrioBM , LichtensteinP , LarssonH . Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ2014;348:g3769. [DOI: 10.1136/bmj.g3769] [PMC4062356] [PMID: 24942388]">Chen 2014</a>; <a href="./references#CD013011-bbs2-0093" title="MészárosA , CzoborP , BálintS , KomlósiS , SimonV , BitterI . Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. International Journal of Neuropsychopharmacology2009;12(8):1137–47. [DOI: 10.1017/S1461145709990198] [PMID: 19580697]">Mészáros 2009</a>; <a href="./references#CD013011-bbs2-0138" title="WigalT , BramsM , GasiorM , GaoJ , SquiresL , GiblinJ , et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behavioral and Brain Functions2010;6(1):34. [DOI: 10.1186/1744-9081-6-34] [PMC2908054] [PMID: 20576091]">Wigal 2010</a>). However, some authors have been unable to establish whether the benefits of immediate‐release methylphenidate (IR methylphenidate) in the treatment of ADHD in children and adolescents would be more significant than the associated harms (i.e. adverse events), in comparison with placebo or no treatment (<a href="./references#CD013011-bbs2-0123" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009885. [DOI: 10.1002/14651858.CD009885.pub2]">Storebø 2015</a>). A recent systematic review and network meta‐analysis including children, adolescents and adults with ADHD concluded that short‐term treatment with IR methylphenidate is more efficacious and more tolerable than placebo in children, and more efficacious and less well tolerated in adults (<a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a>). </p> <p>In Europe, pharmacological treatment is considered the first‐line treatment for adults with moderate or severe ADHD, with lisdexamfetamine or methylphenidate being the first choice (<a href="./references#CD013011-bbs2-0099" title="National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87); March 2018 (last updated September 2019). www.nice.org.uk/guidance/ng87.">NICE 2018</a>). The second line of pharmacological treatment is atomoxetine, a non‐stimulant drug with lower potential for abuse than stimulant drugs; atomoxetine is also recommended as a first‐line treatment option in people with comorbid substance‐use disorder (<a href="./references#CD013011-bbs2-0059" title="DynaMed Plus. Attention deficit hyperactivity disorder (ADHD) in adults: record number 231898. www.dynamed.com/topics/dmp~AN~T231898/Attention-deficit-hyperactivity-disorder-ADHD-in-adults (accessed August 30 2016).">DynaMed Plus 2016</a>). A third‐line option includes bupropion, modafinil and desipramine. Cognitive behavioral therapy is an option for people who do not tolerate drug therapy or choose not to use medications, and this approach can also be used in combination with pharmacological treatment (<a href="./references#CD013011-bbs2-0059" title="DynaMed Plus. Attention deficit hyperactivity disorder (ADHD) in adults: record number 231898. www.dynamed.com/topics/dmp~AN~T231898/Attention-deficit-hyperactivity-disorder-ADHD-in-adults (accessed August 30 2016).">DynaMed Plus 2016</a>). For instance, the Canadian ADHD Resource Alliance recommends a multimodal approach, including psychosocial treatment combined with medications when appropriate (<a href="./references#CD013011-bbs2-0044" title="CADDRA - Canadian ADHD Resource Alliance. Canadian ADHD Practice Guidelines. In: CADDRA. 4.1 Edition. Toronto, ON: CADDRA, 2020.">CADDRA 2020</a>). In the USA, psychostimulant compounds, such as methylphenidate and amphetamines, are the most widely used medications for the management of ADHD symptoms in adults. With the exception of atomoxetine, non‐stimulant medications have generally been considered second‐line medications (<a href="./references#CD013011-bbs2-0140" title="WolraichML , Hagan JF Jr, AllanC , ChanE , DavisonD , EarlsM , et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics2019;144(4):e20192528. Erratum in: Pediatrics 2020; 145(3): e20193997 [DOI: 10.1542/peds.2019-3997]. [DOI: 10.1542/peds.2019-2528]">Wolraich 2019</a>). Behavior‐management strategies to minimize distractions and increase organization are encouraged as part of the treatment (<a href="./references#CD013011-bbs2-0034" title="American Psychiatric Association. What is ADHD?www.psychiatry.org/patients-families/adhd/what-is-adhd2017.">APA 2017</a>; <a href="./references#CD013011-bbs2-0127" title="UrionDK . Attention-deficit/hyperactivity disorder. In: KliegmanRM , St Geme IIIJW , BlumNJ , ShahSS , TaskerRC , WilsonKM , et al, editors(s). Nelson Textbook of Pediatrics. 21st edition. Vol. 2. Philadelphia (PA): Elsevier, 2020:262-6.e1.">Urion 2020</a>). </p> <p>Methylphenidate is available in different formulations: immediate‐release and extended‐ or sustained‐release preparations. Immediate‐release formulations are absorbed instantly after the tablet or capsule is ingested. A maximum concentration of the medication in the blood is achieved in a short period, and the onset of action is fast. Extended‐release formulations are absorbed more slowly. The concentration in the blood increases gradually, and the drug's effect is maintained for a more extended period (<a href="./references#CD013011-bbs2-0106" title="PerrieY , RadesT . Pharmaceutics - Drug Delivery and Targeting. 2nd edition. London (UK): Pharmaceutical Press, 2012.">Perrie 2012</a>). </p> <p>Factors such as dose, type of formulation, and the presence of comorbid substance‐use disorders appear to modify the efficacy of methylphenidate in the treatment of ADHD in adults (<a href="./references#CD013011-bbs2-0045" title="CastellsX , Ramos-QuirogaJA , RigauD , BoschR , NogueiraM , VidalX , et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs2011;25(2):157-69. [DOI: 10.2165/11539440-000000000-00000] [PMID: 21254791]">Castells 2011</a>). An individualized approach is extremely important in the treatment of adults, with special consideration given to conditions co‐existing with ADHD. The ideal dose of IR methylphenidate varies between individuals, and treatment should be initiated in small doses with weekly increments. This allows for an optimal dosage to control symptoms and manage adverse effects (<a href="./references#CD013011-bbs2-0099" title="National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87); March 2018 (last updated September 2019). www.nice.org.uk/guidance/ng87.">NICE 2018</a>). </p> <p>It is recommended that initial treatment begins with doses of 5 mg, two or three times daily for immediate‐release preparations, and equivalent doses for other preparations. The dosages can be increased until the maximum doses are reached that offer the optimum dose of the medicine for each person, with maximum treatment benefits and the lowest risk of harms, i.e. the lowest risk of adverse events (<a href="./references#CD013011-bbs2-0099" title="National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87); March 2018 (last updated September 2019). www.nice.org.uk/guidance/ng87.">NICE 2018</a>). The recommended Defined Daily Dose (DDD) of methylphenidate by the World Health Organization is 30 mg/day for adults (<a href="./references#CD013011-bbs2-0136" title="WHO Collaborating Centre for Drug Statistic Methodology. ATC/DDD Index 2020. www.whocc.no/atcddd (accessed 31 October 2020).">WHO 2017</a>). </p> </section> <section id="CD013011-sec-0012"> <h3 class="title" id="CD013011-sec-0012">How the intervention might work</h3> <p>Methylphenidate is a central nervous system stimulant of indirect sympathomimetic action. Although its mechanism of action has not yet been fully elucidated, it is thought to present a mode of action similar to dexamphetamine (<a href="./references#CD013011-bbs2-0124" title="SweetmanSC , editor(s). Martindale: The Complete Drug Reference. 38 edition. London (UK): Pharmaceutical Press, 2014. [ISBN 9780857111395 0857111396]">Sweetman 2014</a>). It facilitates dopaminergic and noradrenergic transmission by inhibiting dopamine and norepinephrine transporters, decreasing receptivity and consequently increasing the extracellular concentration of neurotransmitters (<a href="./references#CD013011-bbs2-0064" title="EngertV , PruessnerJC . Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Current Neuropharmacology2008;6(4):322–8. [DOI: 10.2174/157015908787386069] [PMC2701285] [PMID: 19587853]">Engert 2008</a>; <a href="./references#CD013011-bbs2-0114" title="SchabramI , HenkelK , MohammadkhaniSS , DietrichC , SchmaljohannJ , WinzO , et al. Acute and sustained effects of methylphenidate on cognition and presynaptic dopamine metabolism: an [18F]FDOPA PET study. Journal of Neuroscience2014;34(44):14769-76. [DOI: 10.1523/JNEUROSCI.1560-14.2014] [PMC6608425] [PMID: 25355228]">Schabram 2014</a>; <a href="./references#CD013011-bbs2-0130" title="VolkowND , WangG , FowlerJS , LoganJ , GerasimovM , MaynardL , et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. Journal of Neuroscience2001;21(2):RC121. [DOI: 10.1523/JNEUROSCI.21-02-j0001.2001] [PMC6763805] [PMID: 11160455]">Volkow 2001</a>). </p> <p>Research findings suggest that individuals with ADHD have a higher number of dopamine transporter binding sites. Methylphenidate binds to these transporters and prevents re‐uptake of dopamine. The decrease in the availability of these receivers for connection is directly related to a clinical improvement in ADHD symptoms (<a href="./references#CD013011-bbs2-0057" title="DreselS , KrauseJ , KrauseKH , LaFougereC , BrinkbäumerK , KungHF , et al. Attention deficit hyperactivity disorder: binding of [99mTc]-TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. European Journal of Nuclear Medicine2000;27(10):1518-24. [PMID: 11083541]">Dresel 2000</a>). The increase of dopamine in the synaptic cleft as a function of methylphenidate action results in improved attention and decreased distraction, modulating the sense of motivation and interest in performing tasks that consequently improve performance (<a href="./references#CD013011-bbs2-0131" title="VolkowND , FowlerJS , WangG , DingY , GatleySJ . Mechanism of action of methylphenidate: insights from PET imaging studies. Journal of Attention Disorders2002;6(Suppl 1):S31-43. [PMID: 12685517]">Volkow 2002</a>). In animal models, it has been observed that the inhibition of norepinephrine re‐uptake by methylphenidate is more prominent than that seen in previous studies, and may result in persistent improvements in ADHD symptoms in those treated from adolescence to adulthood (<a href="./references#CD013011-bbs2-0120" title="SomkuwarSS , KantakKM , DwoskinLP . Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder. Journal of Neuroscience Methods2015;252:55-63. [DOI: 10.1016/j.jneumeth.2015.02.002] [PMC4522381] [PMID: 25680322]">Somkuwar 2015</a>). This sympathomimetic activity is linked to one of the greatest current concerns about the use of methylphenidate: the risk of cardiovascular adverse effects associated with the drug. The inhibition of norepinephrine re‐uptake is the most likely cause of an increase in blood pressure and heart rate in people using methylphenidate (<a href="./references#CD013011-bbs2-0073" title="HealDJ , PierceDM . Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs2006;20(9):713-38. [PMID: 16953648]">Heal 2006</a>). Furthermore, at low doses, the use of stimulants may result in an increase in wakefulness, attention, ability to sustain focus and vigor. This can further explain the effects observed with the use of these substances for increasing focused attention and reducing hyperactivity (<a href="./references#CD013011-bbs2-0141" title="WoodS , SageJR , ShumanT , AnagnostarasSG . Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacological Reviews2013;66(1):193-221. [DOI: 10.1124/pr.112.007054] [PMC3880463] [PMID: 24344115]">Wood 2013</a>). Regarding the pharmacokinetic profile, the oral bioavailability of methylphenidate ranges from 11% to 53%, with the maximum concentration given by the immediate‐release formulation approximately two hours after the administration of the drug; the terminal half‐life of the drug is two hours (<a href="./references#CD013011-bbs2-0048" title="ChanYP , SwansonJM , SoldinSS , ThiessenJJ , MacleodSM , LoganW . Methylphenidate hydrochloride given with or before breakfast: effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics1983;72(1):56-9. [PMID: 6866592]">Chan 1983</a>; <a href="./references#CD013011-bbs2-0134" title="WarginW , PatrickK , KiltsC , GualtieriCT , EllingtonK , MuellerRA , et al. Pharmacokinetics of methylphenidate in man, rat and monkey. Journal of Pharmacology and Experimental Therapeutics1983;226(2):382−86. [PMID: 6410043]">Wargin 1983</a>). </p> </section> <section id="CD013011-sec-0013"> <h3 class="title" id="CD013011-sec-0013">Why it is important to do this review</h3> <p>Several clinical trials have been conducted to investigate the efficacy and harms of IR methylphenidate for treating ADHD in children and adolescents. A number of systematic reviews and meta‐analyses have also been published, evaluating the effect of IR methylphenidate in this population (<a href="./references#CD013011-bbs2-0049" title="CharachA , YeungE , ClimansT , LillieE . Childhood attention-deficit hyperactivity disorder and future substance use disorders: comparative meta-analyses. Journal of the American Academy of Child and Adolescent Psychiatry2011;50(1):9-21. [DOI: 10.1016/j.jaac.2010.09.019] [PMID: 21156266]">Charach 2011</a>; <a href="./references#CD013011-bbs2-0050" title="CharachA , CarsonP , FoxS , AliMU , BeckettJ , LimCG . Interventions for preschool children at high risk for ADHD: a comparative effectiveness review. Pediatrics2013;131(5):e1584–604. [DOI: 10.1542/peds.2012-0974] [PMID: 23545375]">Charach 2013</a>; <a href="./references#CD013011-bbs2-0072" title="HanwellaR , SenanayakeM , De SilvaV . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry2011;11:176. [DOI: 10.1186/1471-244X-11-176] [PMC3229459] [PMID: 22074258]">Hanwella 2011</a>; <a href="./references#CD013011-bbs2-0081" title="KambeitzJ , RomanosM , EttingerU . Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Pharmacogenomics Journal2014;14(1):77–84. [DOI: 10.1038/tpj.2013.9] [PMID: 23588108]">Kambeitz 2014</a>; <a href="./references#CD013011-bbs2-0090" title="MaiaCR , CorteseS , CayeA , DeakinTK , PolanczykGV , PolanczykCA , et al. Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis. Journal of Attention Disorders2017;21(1):3-13. [DOI: 10.1177/1087054714559643] [PMID: 25501355]">Maia 2017</a>; <a href="./references#CD013011-bbs2-0110" title="PunjaS , ZorzelaL , HartlingL , UrichukL , VohraS . Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy. BMJ Open2013;3(3):e002312. [DOI: 10.1136/bmjopen-2012-002312] [PMC3612754] [PMID: 23503579]">Punja 2013</a>; <a href="./references#CD013011-bbs2-0112" title="ReichowB , VolkmarFR , BlochMH . Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders2013;43(10):2435–41. [DOI: 10.1007/s10803-013-1793-z] [PMC3787525] [PMID: 23468071]">Reichow 2013</a>; <a href="./references#CD013011-bbs2-0123" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009885. [DOI: 10.1002/14651858.CD009885.pub2]">Storebø 2015</a>). Fewer studies have focused on the use of IR methylphenidate in adults with ADHD; as a result, many countries contraindicate its use in this age group (<a href="./references#CD013011-bbs2-0062" title="European Medicines Agency. Elements recommended for inclusion in summaries of product characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Methylphenidate_31/WC500011184.pdf (accessed 22 January 2018).">EMA 2009</a>). </p> <p>Currently, the available evidence for the likely efficacy and harms of using IR methylphenidate to treat adults with ADHD is controversial and incomplete, which precludes firm conclusions (<a href="./references#CD013011-bbs2-0091" title="MaidmentID . Efficacy of stimulants in adult ADHD. Annals of Pharmacotherapy2003;37(12):1884-90. [DOI: 10.1345/aph.1D028] [PMID: 14632541]">Maidment 2003</a>; <a href="./references#CD013011-bbs2-0139" title="WilensTE . Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs2003;63(22):2395-411. [DOI: 10.2165/00003495-200363220-00002] [PMID: 14609347]">Wilens 2003</a>). For instance, in a narrative review that included six controlled clinical trials, three suggested treatment efficacy, while two studies failed to show efficacy, and the results from one study were considered conflicting (<a href="./references#CD013011-bbs2-0091" title="MaidmentID . Efficacy of stimulants in adult ADHD. Annals of Pharmacotherapy2003;37(12):1884-90. [DOI: 10.1345/aph.1D028] [PMID: 14632541]">Maidment 2003</a>). Another narrative review suggested that IR methylphenidate was more efficacious than placebo in the treatment of ADHD in adults (<a href="./references#CD013011-bbs2-0068" title="FredriksenM , HalmøyA , FaraoneSV , HaavikJ . Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. European Neuropsychopharmacology2013;23(6):508-27. [DOI: 10.1016/j.euroneuro.2012.07.016] [PMID: 22917983]">Fredrikesen 2013</a>); the conclusions were based on five randomized controlled trials (RCTs), and 10 open‐label extension studies of initial short‐term RCTs. Adults with childhood‐onset of symptoms have been observed with significant improvements in their symptoms of ADHD, with therapeutic response as high as 78% when receiving IR methylphenidate compared with 4% improvement when receiving placebo (<a href="./references#CD013011-bbs2-0121" title="SpencerT , WilensT , BiedermanJ , FaraoneSV , AblonJS , LapeyK . A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Archives of General Psychiatry1995;52(6):434-43. [PMID: 7771913]">Spencer 1995</a>). However, another study found no significant difference between IR methylphenidate and placebo (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>). </p> <p>Systematic reviews and network meta‐analyses of the efficacy and harms of using IR methylphenidate to treat adults with ADHD have reached different conclusions. A systematic review and network meta‐analysis of placebo‐controlled trials compared shorter‐acting stimulant drugs (including IR methylphenidate, mixed amphetamine and dextroamphetamine), longer‐acting stimulant drugs and longer‐acting forms of bupropion (<a href="./references#CD013011-bbs2-0107" title="PetersonK , McDonaghMS , FuR . Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology2008;197(1):1-11. [DOI: 10.1007/s00213-007-0996-4] [PMID: 18026719]">Peterson 2008</a>). The study authors found a higher rate of clinical response (30% in the reduction of ADHD symptoms) among adults receiving shorter‐acting stimulant drugs in direct comparison to placebo and in indirect comparisons to longer‐acting stimulant drugs and longer‐acting forms of bupropion. People treated with shorter‐acting stimulant drugs were found to have a higher risk of appetite loss and sleep disturbances compared with people treated with placebo. Conversely, a higher risk of appetite loss was demonstrated among participants receiving longer‐acting stimulant drugs compared with people treated with shorter‐acting stimulant drugs (<a href="./references#CD013011-bbs2-0107" title="PetersonK , McDonaghMS , FuR . Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology2008;197(1):1-11. [DOI: 10.1007/s00213-007-0996-4] [PMID: 18026719]">Peterson 2008</a>). Additional research did not demonstrate differences in efficacy between osmotic‐controlled release oral delivery system (OROS) methylphenidate and atomoxetine (indirect comparison), although both drugs were shown to be more efficacious than placebo (<a href="./references#CD013011-bbs2-0043" title="BusheC , DayK , ReedV , KarlsdotterK , BerggrenL , PitcherA , et al. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. Journal of Psychopharmacology2016;30(5):444-58. [DOI: 10.1177/0269881116636105] [PMID: 27005307]">Bushe 2016</a>). Another systematic review with a network meta‐analysis (<a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a>) showed that IR methylphenidate is more efficacious than placebo, but not so for amphetamines, in the short term. Methylphenidate was less acceptable than placebo and increased weight loss and systolic and diastolic blood pressure (<a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a>). However, it is important to consider some limitations of this review that included double‐blind RCTs (parallel group, cross‐over, or cluster) published and unpublished until 2017 that assessed treatments for ADHD as oral monotherapy of at least one week's duration. First, the searches are current to April 2017, and therefore there is a value in updating the review, particularly considering that there is still controversy about the efficacy of methylphenidate to treat ADHD. Secondly, although cross‐over trials were included in the review, data from the pre‐cross‐over phase were included in the analysis. It has been shown that cross‐over trials and parallel‐group trials provided similar relevant data in the context of ADHD (<a href="./references#CD013011-bbs2-0070" title="GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180-7. [DOI: 10.1097/00004583-200102000-00012] [PMID: 11211366]">Greenhill 2001</a>; <a href="./references#CD013011-bbs2-0084" title="KroghHB , StorebøOJ , FaltinsenE , TodorovacA , Ydedahl-JensenE , Løgstrup MagnussonF , et al. Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses. BMJ Open2019;9(3):e026478. [DOI: 10.1136/bmjopen-2018-026478] [PMC6475340] [PMID: 30928951]">Krogh 2019</a>; <a href="./references#CD013011-bbs2-0122" title="SteinMA , BlondisTA , SchnitzlerER , O'BrienT , FishkinJ , BlackwellB , et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics1996;98(4 Pt 1):748-56. [PMID: 8885956]">Stein 1996</a>), and it is relevant to include this additional information in an updated systematic review. Third, the authors of that review assessed the overall evidence contributing to the indirect comparisons as low and very low certainty of evidence. Indirect or mixed comparisons may have biases similar to those in observational studies and may therefore be downgraded to a lower evidence level similar to those studies (<a href="./references#CD013011-bbs2-0053" title="CiprianiA , HigginsJP , GeddesJR , SalantiG . Conceptual and technical challenges in network meta-analysis. Annals of Internal Medicine2013;159(2):130-7. [DOI: 10.7326/0003-4819-159-2-201307160-00008] [PMID: 23856683]">Cipriani 2013</a>). Finally, some of the authors of that review declared receiving funding from pharmaceutical industries. The way in which a review is conducted is an important issue to consider when assessing its results. A systematic review may be carried out with methodological rigor and yet its results may be biased if they are influenced by conflicts of interest, particularly those pertaining to research or individual sponsorship (<a href="./references#CD013011-bbs2-0037" title="BarnesDE , BeroLA . Why review articles on the health effects of passive smoking reach different conclusions. JAMA1998;279(19):1566-70.">Barnes 1998</a>; <a href="./references#CD013011-bbs2-0039" title="Bes-RastrolloM , SchulzeMB , Ruiz-CanelaM , Martinez-GonzalezMA . Financial conflicts of interest and reporting bias regarding the association between sugar-sweetened beverages and weight gain: a systematic review of systematic reviews. PLOS Med2013;10(12):e1001578; discussion e10015787. [DOI: 10.1371/journal.pmed.1001578] [PMC3876974] [PMID: 24391479]">Bes‐Rastrollo 2013</a>; <a href="./references#CD013011-bbs2-0058" title="DunnAG , ArachiD , HudginsJ , TsafnatG , CoieraE , BourgeoisFT . Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. Annals of Internal Medicine2014;161(7):513-8. [DOI: 10.7326/M14-0933] [PMID: 25285542]">Dunn 2014</a>). </p> <p>The reasons for the variability in the available evidence are not clearly documented in the literature, but they appear to be related to factors such as dose, type of formulation and treatment regimen (<a href="./references#CD013011-bbs2-0045" title="CastellsX , Ramos-QuirogaJA , RigauD , BoschR , NogueiraM , VidalX , et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs2011;25(2):157-69. [DOI: 10.2165/11539440-000000000-00000] [PMID: 21254791]">Castells 2011</a>), as well as the comparison methods used (<a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a>). The inconsistency of this evidence and the absence of systematic reviews of methodological rigor might have a negative impact on clinical decision‐making (<a href="./references#CD013011-bbs2-0091" title="MaidmentID . Efficacy of stimulants in adult ADHD. Annals of Pharmacotherapy2003;37(12):1884-90. [DOI: 10.1345/aph.1D028] [PMID: 14632541]">Maidment 2003</a>; <a href="./references#CD013011-bbs2-0139" title="WilensTE . Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs2003;63(22):2395-411. [DOI: 10.2165/00003495-200363220-00002] [PMID: 14609347]">Wilens 2003</a>). Our systematic review therefore evaluates the efficacy and harms of IR methylphenidate as reported in RCTs. The contribution of this systematic review is to examine the benefit and harm profile of IR methylphenidate for the treatment of ADHD in adults, in accordance with a rigorous methodological approach (<a href="./references#CD013011-bbs2-0075" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>), and the PRISMA guidelines (<a href="./references#CD013011-bbs2-0085" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GötzschePC , IoannidisJA , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700. [DOI: 10.1136/bmj.b2700] [PMC2714672] [PMID: 19622552]">Liberati 2009</a>; <a href="./references#CD013011-bbs2-0096" title="MoherD , ShamseerL , ClarkeM , GhersiD , LiberatiA , PetticrewM , et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews2015;4(1):1. [DOI: 10.1186/2046-4053-4-1] [PMC4320440] [PMID: 25554246]">Moher 2015</a>). A Cochrane Review evaluating extended‐release formulations of methylphenidate for adults with ADHD is also in progress (<a href="./references#CD013011-bbs2-0040" title="BoesenK , DanborgPB , GøtzschePC , JørgensenKJ . Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD012857. [DOI: 10.1002/14651858.CD012857]">Boesen 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013011-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013011-sec-0014"></div> <p>To evaluate the efficacy and harms (adverse events) of IR methylphenidate for treating ADHD in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013011-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013011-sec-0015"></div> <section id="CD013011-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013011-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) of parallel and cross‐over designs.</p> </section> <section id="CD013011-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults aged 18 years or older with a diagnosis of ADHD according to the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) <i>Third Edition</i> (DSM‐III; <a href="./references#CD013011-bbs2-0030" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd edition. Washington (DC): American Psychiatric Association, 1980.">APA 1980</a>), <i>Third Edition Revised</i> (DSM‐III‐R; <a href="./references#CD013011-bbs2-0031" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd edition. Washington (DC): American Psychiatric Association, 1987.">APA 1987</a>), <i>Fourth Edition</i> (DSM‐IV; <a href="./references#CD013011-bbs2-0032" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington (DC): American Psychiatric Association, 1994.">APA 1994</a>) or <i>Fifth Edition</i> (DSM‐5; <a href="./references#CD013011-bbs2-0033" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington (DC): American Psychiatric Association, 2013.">APA 2013</a>); or with a diagnosis of hyperkinetic disorders according to the <i>International Statistical Classification of Diseases and Related Health Problems Ninth Revision</i> (ICD‐9), and <i>Tenth Revision</i> (ICD‐10) (<a href="./references#CD013011-bbs2-0135" title="World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva (CH): World Health Organization, 1992.">WHO 1992</a>). </p> </section> <section id="CD013011-sec-0019"> <h4 class="title">Types of interventions</h4> <p>IR methylphenidate administered at any dosage as part of any treatment regimen, compared with placebo or other pharmacological interventions (including methylphenidate extended‐release formulations). </p> <p>An extended‐release formulation refers to the different extended‐release drug‐delivery systems, including OROS, which is a specific osmotic type of extended‐release system. Extended‐release formulations are a type of pharmacological intervention and were therefore considered eligible for inclusion when compared with IR methylphenidate. </p> </section> <section id="CD013011-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We addressed the following outcomes in this review.</p> <section id="CD013011-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013011-list-0001"> <li> <p>Efficacy: changes in symptoms of ADHD (hyperactivity, impulsivity, and inattentiveness), based on clinical assessment by a physician or by self‐report, and measured by any validated clinical scale reported in the trials (e.g. Adult ADHD Self‐Report Screening Scale (<a href="./references#CD013011-bbs2-0129" title="UstunB , AdlerLA , RudinC , FaraoneSV , SpencerTJ , BerglundP , et al. The World Health Organization Adult Attention-Deficit Hyperactivity Disorder Self-report Screening Scale for DSM-5. JAMA Psychiatry2017;74(5):520-6. [DOI: 10.1001/jamapsychiatry.2017.0298] [PMC5470397] [PMID: 28384801]">Ustun 2017</a>)). </p> </li> <li> <p>Harms: all adverse events, classified as serious or non‐serious, including but not restricted to: cardiovascular, neurological, gastrointestinal, metabolic events, and psychiatric disorders. Serious events were defined as any adverse effect that resulted in death or was life‐threatening, required hospital admission or prolonged hospitalization, caused persistent or significant disability or incapacity, or required intervention to prevent permanent damage to a body structure or impairment of a body function (<a href="./references#CD013011-bbs2-0077" title="International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline for Good Clinical Practice E6(R2). www.ich.org/page/efficacy-guidelines (accessed 10 July 2019).">ICH 2016</a>). See <a href="#CD013011-sec-0142">Differences between protocol and review</a>. </p> </li> </ol> </p> </section> <section id="CD013011-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013011-list-0002"> <li> <p>Changes in the clinical impression of severity or improvement, level of functioning, depression and anxiety, based on a clinical assessment by a physician (e.g. Clinical Global Impressions Scale; <a href="./references#CD013011-bbs2-0071" title="GuyW . 028 CGL: Clinical Global Impressions. In: GuyW , editors(s). ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare; Public Health Service: Alcohol, Drug Abuse, and Mental Health Administration, 1976:217-22. [archive.org/details/ecdeuassessmentm1933guyw/mode/2up]">Guy 1976</a>) or participant self‐report. </p> </li> <li> <p>Quality of life, measured by validated psychometric instruments (e.g. the World Health Organization Quality of Life: Brief version (WHOQOL‐BREF; <a href="./references#CD013011-bbs2-0119" title="SkevingtonSM , LotfyM , O'ConnellKA , WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Quality of Life Research2004;13(2):299-310. [DOI: 10.1023/B:QURE.0000018486.91360.00] [PMID: 15085902 ]">Skevington 2004</a>), or the 12‐Item Short‐Form Health Survey (<a href="./references#CD013011-bbs2-0133" title="Ware J Jr, KosinskiM , KellerSD . A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical Care1996;34(3):220-33. [DOI: 10.1097/00005650-199603000-00003] [PMID: 8628042]">Ware 1996</a>). </p> </li> </ol> </p> <p>We considered outcomes according to the follow‐up durations reported in the included studies. </p> </section> </section> </section> <section id="CD013011-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013011-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases up to January 2020.</p> <p> <ol id="CD013011-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 1) in the Cochrane Library, which includes the Cochrane Developmental, Psychosocial and Learning Problems Specialised Register (searched 6 January 2020). </p> </li> <li> <p>MEDLINE Ovid (1946 to 3 January 2020).</p> </li> <li> <p>MEDLINE In‐Process &amp; Other Non‐Indexed Citations Ovid (searched 3 January 2020).</p> </li> <li> <p>MEDLINE Epub Ahead of Print Ovid (searched 3 January 2020).</p> </li> <li> <p>Embase Ovid (1980 to 10 January 2020).</p> </li> <li> <p>PsycINFO Ovid (1806 to 13 January 2020).</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL EBSCOhost); 1980 to 6 January 2020). </p> </li> <li> <p>Science Citation Index Web of Science, Clarivate (SCI; 1970 to 7 January 2020).</p> </li> <li> <p>Social Sciences Citation Index Web of Science (SSCI; 1970 to 7 January 2020).</p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science Web of Science Web of Science, Clarivate (CPCI‐S; 1990 to 7 January 2020). </p> </li> <li> <p>Conference Proceedings Citation Index ‐ Social Science &amp; Humanities Web of Science, Clarivate (CPCI‐SS&amp;H; 1990 to 7 January 2020). </p> </li> <li> <p><i>Cochrane Database of Systematic Reviews</i> (CDSR; 2020, Issue 1) part of the Cochrane Library (searched 6 January 2020). </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE; Final Issue: 2015, Issue 2) part of the Cochrane Library (searched 6 January 2020). </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 13 January 2020). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 13 January 2020). </p> </li> <li> <p>Drug Industry Documents (<a href="http://www.industrydocumentslibrary.ucsf.edu/drug" target="_blank">www.industrydocumentslibrary.ucsf.edu/drug</a>; searched 13 January 2020). </p> </li> </ol> </p> <p>SG ran the searches, adapting the MEDLINE search strategy published in the protocol (<a href="./references#CD013011-bbs2-0142" title="CândidoRCF , GolderS , Menezes de PaduaCA , PeriniE , JunqueiraDR . Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD013011. [DOI: 10.1002/14651858.CD013011]">Cândido 2018</a>) for the remaining databases; see <a href="./appendices#CD013011-sec-0125">Appendix 1</a> for detailed search strategies. </p> </section> <section id="CD013011-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched for internal reports on the websites of the European Medicines Agency (EMA; <a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema</a>), and the US Food and Drug Administration (FDA; <a href="https://www.fda.gov/" target="_blank">www.fda.gov</a>). We checked citations of included RCTs to identify additional trials not captured by the electronic searches. </p> </section> </section> <section id="CD013011-sec-0026"> <h3 class="title" id="CD013011-sec-0026">Data collection and analysis</h3> <p>We were not able to use all of the planned methods in the review protocol (<a href="./references#CD013011-bbs2-0142" title="CândidoRCF , GolderS , Menezes de PaduaCA , PeriniE , JunqueiraDR . Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD013011. [DOI: 10.1002/14651858.CD013011]">Cândido 2018</a>). In the following sections, we report only methods applied. See <a href="#CD013011-sec-0142">Differences between protocol and review</a> and <a href="#CD013011-tbl-0003">Table 1</a> for unused methods. </p> <div class="table" id="CD013011-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method section</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Reason for non‐use</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Types of outcomes</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to measure the primary efficacy outcome over the short term (within six months) and long term (longer than 6 months) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data were not available as no study lasted more than 4.5 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to measure serious adverse events as the primary outcome of harms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies assessed serious adverse events according to the definition of the International Council for Harmonisation (<a href="./references#CD013011-bbs2-0077" title="International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline for Good Clinical Practice E6(R2). www.ich.org/page/efficacy-guidelines (accessed 10 July 2019).">ICH 2016</a>) </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Selection of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to contact the authors of studies whenever there was insufficient information available to decide whether a study was eligible for inclusion. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This action was not necessary for the ongoing studies</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assessment of risk of bias</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to revise the 'Risk of bias' domains for randomized controlled trials if new guidelines were released during the development of this review. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When we came to the completion of this review, Cochrane had released a new 'risk of bias' tool but had not yet made it mandatory for all Cochrane Reviews; it is being piloted with only a few reviews within Cochrane. Future updates of this review will take any related updates into account </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Measures of treatment effect &gt; Continuous outcomes</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For studies reporting outcome values other than the mean and standard deviation, we planned to apply standard errors, CI, t values and P values to estimate the results, whenever possible </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of these additional data were reported and thus we were not able to estimate any missing results. We contacted study authors to request the additional information but have not received response </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If skewed data were detected, we planned to consult a statistician on the best data transformation approach </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not encounter this situation; therefore, it was not necessary to consult a statistician </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Unit of analysis issues &gt; Cross‐over trials</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to estimate within‐participant differences between the intervention groups at the end of the study follow‐up period, using the MD and standard deviation to conduct a paired analysis and avoid a unit‐of‐analysis error (<a href="./references#CD013011-bbs2-0061" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9. [PMID: 11914310]">Elbourne 2002</a>; <a href="./references#CD013011-bbs2-0075" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported participant‐level differences between intervention groups</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assessment of heterogeneity</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to investigate clinical heterogeneity through subgroup analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient data evaluated and reported in the included studies to allow us to undertake subgroup analyses </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assessment of reporting bias</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to use funnel plots to investigate the presence of publication bias (the selective publication of trials with positive findings), and other small‐study effects, among the studies included in the review (<a href="./references#CD013011-bbs2-0103" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Page 2020</a>). We planed to use Egger's test to assess for funnel plot asymmetry (<a href="./references#CD013011-bbs2-0060" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMC2127453] [PMID: 9310563]">Egger 1997</a>), providing 10 or more trials were included in a meta‐analysis. We planned to consult a statistician in situations where we were unable to interpret the asymmetries objectively and when we might have considered alternative statistical tests (<a href="./references#CD013011-bbs2-0103" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Page 2020</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not assess reporting bias due to there being an insufficient number of trials (fewer than 10) in the quantitative analyses </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Data synthesis</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where considerable heterogeneity (I<sup>2</sup> statistic greater than 75%) was detected, particularly in the presence of high inconsistency in the direction of effect, we planned not to calculate the average effect of the intervention through a meta‐analysis </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study contributed data for most of the outcomes and comparisons; therefore, the insufficient data prevented an appropriate assessment of heterogeneity </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subgroup analysis and investigation of heterogeneity</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to explore potential sources of heterogeneity if the available data from the studies allowed us to stratify participant subgroups by the following characteristics. </p> <p> <ol id="CD013011-list-0004"> <li> <p>Age of participants (trials with participants aged 19 to 35 years, 36 to 54 years or aged 55 years or more) </p> </li> <li> <p>Sex (female versus male participants)</p> </li> <li> <p>Dosage of methylphenidate (low dose (30 mg or less) versus high dose (more than 30 mg)) </p> </li> <li> <p>Multimorbidities (participants with multimorbidity versus participants without multimorbidity)</p> </li> <li> <p>Type of clinical scales used in diagnosis</p> </li> <li> <p>Duration of treatment (short‐term trials (six months or less) versus long‐term trials (more than 6 months)) </p> </li> <li> <p>Subtype of ADHD (predominantly inattentive type, or hyperactive or impulsive type, or combined type) </p> </li> </ol> </p> <p>We planned to calculate a pooled effect size for each subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient data evaluated and reported in the included studies to allow us to undertake subgroup analyses </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sensitivity analysis</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If there were an adequate number of studies (2 or more), we planned to perform a sensitivity analysis to explore the causes of heterogeneity and test the robustness of the results to decisions made during the development of the review. Specifically, we planned to reanalyze the data: </p> <p> <ol id="CD013011-list-0005"> <li> <p>excluding studies that we judged to be at high risk of selection bias, performance bias, detection bias or reporting bias; </p> </li> <li> <p>excluding studies in which more than 20% of participants were lost to follow‐up; and</p> </li> <li> <p>comparing unpublished versus published studies</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient studies included in the meta‐analyses to perform any of our preplanned sensitivity analyses </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Summary of findings and assessment of the certainty of the evidence</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to describe the outcomes of interest over short (within 6 months) and long (longer than 6 months) periods of treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials investigated the effects of treatment with IR methylphenidate in adults for a period longer than 18 weeks (4.5 months) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: Confidence interval<br/>IR: immediate release<br/>MD: Mean difference </p> </div> </div> <section id="CD013011-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We used the reference manager software EndNote (<a href="./references#CD013011-bbs2-0063" title="EndNote X8. Version 8.2. Philadelphia (PA): Thomson Reuters, 2017.">EndNote 2017</a>), to merge records returned from the searches and remove any duplicates. Working in pairs, three review authors independently screened titles and abstracts to remove clearly irrelevant records. Next, we screened the full texts of potentially relevant reports for eligibility, in accordance with the aforementioned inclusion criteria (<a href="#CD013011-sec-0016">Criteria for considering studies for this review</a>); note that outcomes measurement and reporting were not used as eligibility criteria. At this stage, we linked together multiple reports of the same study. We resolved disagreements in the selection process by consensus or by consulting a third review author. We recorded the selection process in a PRISMA diagram (<a href="./references#CD013011-bbs2-0095" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ2009;339:b2535. [DOI: 10.1136/bmj.b2535] [PMC2714657] [PMID: 19622551]">Moher 2009</a>). </p> </section> <section id="CD013011-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (DJ, RC) independently extracted data from each included trial using a standardized data extraction form. We resolved disagreements in the data extraction process by discussion or by consulting a third review author (CP). Our data extraction form was piloted and tailored to record data on the: </p> <p> <ol id="CD013011-list-0006"> <li> <p>Characteristics of the studies;</p> </li> <li> <p>Characteristics of the participants;</p> </li> <li> <p>Characteristics of the treatment and comparator interventions;</p> </li> <li> <p>Methods used to measure the outcomes and follow‐up duration;</p> </li> <li> <p>Outcomes measurements (any measures related to primary or secondary outcomes, as described under <a href="#CD013011-sec-0020">Types of outcome measures</a>); and </p> </li> <li> <p>Disclosure of financial conflict of interests.</p> </li> </ol> </p> <p>We obtained additional information from the authors of the one included trial that had efficacy data reported only in a graphic illustration. </p> </section> <section id="CD013011-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risks of bias of the included studies across the following six domains, as described in Cochrane’s 'Rsk of bias' tool (<a href="./references#CD013011-bbs2-0074" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>): </p> <p> <ol id="CD013011-list-0007"> <li> <p>Sequence generation (selection bias);</p> </li> <li> <p>Allocation sequence concealment (selection bias);</p> </li> <li> <p>Blinding of participants and personnel (performance bias);</p> </li> <li> <p>Blinding of outcome assessment (detection bias);</p> </li> <li> <p>Incomplete outcome data (attrition bias); and</p> </li> <li> <p>Selective outcome reporting (reporting bias).</p> </li> </ol> </p> <p>Two review authors (DJ, RC) independently assessed the risks of bias, resolving any disagreements by discussion or by consulting a third review author (CP). </p> <p>We assessed the risk of bias resulting from some domains for different groups or outcomes separately, in accordance with the instructions outlined by Cochrane (<a href="./references#CD013011-bbs2-0074" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). Specifically, we assessed: </p> <p> <ol id="CD013011-list-0008"> <li> <p>Blinding of participants and personnel separately for a) participants and b) personnel;</p> </li> <li> <p>Blinding of outcome assessment separately for a) beneficial outcomes and b) harmful outcomes; and </p> </li> <li> <p>Selective outcome data separately for a) primary beneficial outcomes and b) harmful outcomes. </p> </li> </ol> </p> <p>We rated the risk of bias in each domain as high, low or unclear, and accompanied each rating by a statement to support our judgments. </p> <section id="CD013011-sec-0030"> <h5 class="title">Conflicts of interest</h5> <p>Some author teams have included information on financial conflict of interest as a 'risk of bias' domain (<a href="./references#CD013011-bbs2-0079" title="JørgensenL , Paludan-MlülerAS , LaursenDR , SavovićJ , BoutronI , SterneJA , et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Systematic Reviews2016;5:80. [DOI: 10.1186/s13643-016-0259-8] [PMC4862216]">Jorgensen 2016</a>). However, this element does not reflect an independent methodological domain and its inclusion is considered inappropriate according to Cochrane standards (<a href="./references#CD013011-bbs2-0074" title="HigginsJP , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). Specific 'Risk of bias' domains recognized as being influenced by financial conflicts of interest are already included in the tool; for example, incomplete outcome data and selective outcome reporting. We also considered the 'selective outcome reporting' domain when evaluating the certainty of the evidence (see 'Summary of findings' table under <a href="#CD013011-sec-0042">Data synthesis</a>). </p> <p>Complying with Cochrane guidelines, we extracted data about the trials' sources of funding and conflicts of interest and judged whether there were reasons for concern about their impact on the results analyzed from the included trials (<a href="./references#CD013011-bbs2-0041" title="BoutronI , PageMJ , HigginsJP , AltmanDG , LundhA , HróbjartssonA . Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Boutron 2020</a>). More specifically, we considered there to be 'no concerns' when study authors did not receive funding or declared receiving funding from research grants, 'notable concerns' when study authors declared receiving grants from companies with a vested interest, or 'unclear concerns' when there was insufficient information to support a judgment of 'no concerns' or 'notable concerns'. </p> </section> </section> <section id="CD013011-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <section id="CD013011-sec-0032"> <h5 class="title">Continuous outcomes</h5> <p>To summarize results measured as continuous variables and reported using the same rating scales, we calculated the mean difference (MD) and presented it with a 95% confidence interval (CI). When outcomes were measured and reported on different rating scales, we used standard deviations to standardize the MD and calculated a standardized mean difference (SMD). We selected change scores rather than endpoint scores when both results were available in the same trial. If change scores were not reported, we extracted data on endpoint scores. </p> <p>Significant heterogeneity in outcomes measurements and incomplete reporting of the results prevented the conduction of meta‐analyses for most of the outcomes assessed in this review. See <a href="#CD013011-sec-0042">Data synthesis</a>. When combining outcome data in the meta‐analysis, we conducted analyses of the MD of change scores and endpoint scores when information was available for both measures (<a href="./references#CD013011-bbs2-0056" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). When combining outcome data in the meta‐analysis using the SMD, we analyzed change scores and endpoint scores reported on different scales separately (<a href="./references#CD013011-bbs2-0056" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). </p> <p>To calculate the above described estimators from cross‐over trials, we needed to extract data on a paired analysis of within‐participant differences (<a href="./references#CD013011-bbs2-0061" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9. [PMID: 11914310]">Elbourne 2002</a>). This analysis was not reported in any of the cross‐over trials included in this review. We therefore adopted an approach to treat cross‐over trials as parallel trials, since were able to summarize data comparing all measures of the intervention groups from all treatment periods (<a href="./references#CD013011-bbs2-0075" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD013011-sec-0033"> <h5 class="title">Dichotomous outcomes</h5> <p>To summarize results measured as dichotomous outcomes, we calculated the risk ratio (RR) with a 95% CI. To calculate the RR, we needed to extract data on absolute numbers related to the sample size and the frequency of each specific outcome. </p> <p>For harms outcomes, in addition to the above we categorized reported adverse events according to organ system and calculated the absolute risks of each individual event. As one person can experience more than one adverse event, the sample size of the trials could not be pooled in an analysis. We therefore calculated the total of adverse events reported in each treatment group and calculated the RR of experiencing an adverse event among participants who had experienced at least one event. </p> </section> <section id="CD013011-sec-0034"> <h5 class="title">Incomplete and narrative reports of outcomes</h5> <p>We included and described in the review trials reporting results of effect measures and measures of uncertainty, and trials providing a narrative description of the results; however, trials providing only narrative descriptions are not included in quantitative syntheses. </p> </section> </section> <section id="CD013011-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <section id="CD013011-sec-0036"> <h5 class="title">RCTs with parallel design</h5> <p>We recorded loss to follow‐up data for risk of bias purposes and analyzed beneficial data according to an intention‐to‐treat (ITT) analysis whenever the data were available. This means that the unit of analysis in this review is the participant, and their outcomes were considered in the intervention group to which they were randomized, regardless of whether they received the intervention or not. </p> </section> <section id="CD013011-sec-0037"> <h5 class="title">RCTs with cross‐over design</h5> <p>We did not anticipate any major concern about a carry‐over effect in relation to the treatment of ADHD, considering that it is mostly a stable condition and the treatment effects of IR methylphenidate and other pharmacological interventions are expected to be reversible and short‐lived. Our assumptions have been confirmed in studies assessing the possible occurrence of carry‐over effects with IR methylphenidate (<a href="./references#CD013011-bbs2-0070" title="GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180-7. [DOI: 10.1097/00004583-200102000-00012] [PMID: 11211366]">Greenhill 2001</a>; <a href="./references#CD013011-bbs2-0084" title="KroghHB , StorebøOJ , FaltinsenE , TodorovacA , Ydedahl-JensenE , Løgstrup MagnussonF , et al. Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses. BMJ Open2019;9(3):e026478. [DOI: 10.1136/bmjopen-2018-026478] [PMC6475340] [PMID: 30928951]">Krogh 2019</a>; <a href="./references#CD013011-bbs2-0122" title="SteinMA , BlondisTA , SchnitzlerER , O'BrienT , FishkinJ , BlackwellB , et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics1996;98(4 Pt 1):748-56. [PMID: 8885956]">Stein 1996</a>). Nevertheless, a unit‐of‐analysis error can occur in cross‐over data, if the analysis overlooks issues with correlation among the participants' measurements during the different treatment periods. Paired analyses took into consideration issues with correlation, but were not available in the included studies. We therefore treated the treatment periods of the cross‐over trials as treatment groups in a parallel design, to include the results in the analysis (<a href="./references#CD013011-bbs2-0075" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). This approach could lead to a unit‐of‐analysis error, although it is considered a conservative approach, as each cross‐over trial receives less weight in the analysis (<a href="./references#CD013011-bbs2-0075" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). </p> </section> <section id="CD013011-sec-0038"> <h5 class="title">Harms</h5> <p>For data on harms, we accepted a modified ITT analysis, where the participants and their outcome data would be included in the analysis for those who received at least one dose of the tested interventions. Additionally, as one participant can experience more than one adverse event during a treatment period, we recorded data on all participants experiencing each reported event. </p> </section> </section> <section id="CD013011-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>Whenever possible, we based the analysis on ITT data from the individual clinical trials, accounting for dropout data. We attempted to access trial registries, when available, and contacted the authors of the most recent trials to obtain complete information about missing outcome data not fully covered in the reports of the included trials. We took missing data into consideration in the 'Risk of bias' analysis. </p> </section> <section id="CD013011-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We avoided excessive methodological heterogeneity by combining data, whenever appropriate, only among trials with similar designs (i.e. RCTs of parallel design were not pooled with RCTs of cross‐over design). Where we deemed it possible and appropriate to combine trials of different designs, we conducted a sensitivity analysis (<a href="#CD013011-sec-0047">Sensitivity analysis</a>), to assess the robustness of the results. We assessed statistical heterogeneity between trials using the I<sup>2</sup> statistic for quantification of variability and reported Tau<sup>2</sup>, Chi<sup>2</sup> and P values (<a href="./references#CD013011-bbs2-0056" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). </p> <p>Due to insufficient trials, we were not able to investigate clinical heterogeneity through subgroup analyses (see <a href="https://archie.cochrane.org/sections/documents/view?version=z1804191627100513771475382518184&amp;format=REVMAN#SUBGROUP_ANALYSIS" target="_blank">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> <section id="CD013011-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We could not assess reporting bias due to the insufficient number of trials included in the quantitative analyses. Ten or more trials need to be included in the meta‐analysis to allow us to use Egger’s test to assess for funnel plot asymmetry (<a href="./references#CD013011-bbs2-0060" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMC2127453] [PMID: 9310563]">Egger 1997</a>); a funnel plot with fewer studies would not have the power to distinguish chance from real asymmetry. </p> </section> <section id="CD013011-sec-0042"> <h4 class="title">Data synthesis</h4> <section id="CD013011-sec-0043"> <h5 class="title">Efficacy</h5> <p>For most of the outcome data and comparisons, only one trial contributed data and a meta‐analysis was not possible. Whenever possible, we combined the efficacy outcomes in a meta‐analysis using the generic inverse variance technique. The inverse variance method is a “common and simple version of the meta‐analysis” and is the method implemented in the software where Cochrane Reviews are developed (<a href="./references#CD013011-bbs2-0056" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). We performed meta‐analysis using a random‐effects model to account for the heterogeneity between trials (<a href="./references#CD013011-bbs2-0056" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Deeks 2020</a>). We reported the heterogeneity using the I<sup>2</sup> statistic; however, the insufficient number of trials and available data contributing to the quantitative analysis prevented an appropriate assessment of heterogeneity. </p> </section> <section id="CD013011-sec-0044"> <h5 class="title">Effect size multiplicity</h5> <p>Problems with multiplicity of effect size can happen whenever an included trial reports on more than two arms or on more than one scale to measure the same outcome (<a href="./references#CD013011-bbs2-0087" title="López-LópezJA , PageMJ , LipseyMW , HigginsJP . Dealing with effect size multiplicity in systematic reviews and meta-analyses. Research Synthesis Methods2018;9(3):336-51. [DOI: 10.1002/jrsm.1310] [PMID: 29971966]">López‐López 2018</a>). To avoid introducing statistical dependency into the results estimated in the meta‐analysis, we selected the comparison of main interest to the review research question and combined the treatment effects of this comparison only. Consequently, we considered the effect sizes of trials with more than one arm (i.e. comparing IR methylphenidate with placebo and other interventions), whenever appropriate, in a meta‐analysis comparing IR methylphenidate with placebo. </p> <p>The rationale for the application of the above‐described method considers that the following interventions identified in this review are not standard options in the treatment of adults with ADHD: bupropion, lithium and Pycnogenol®. </p> </section> <section id="CD013011-sec-0045"> <h5 class="title">Harms</h5> <p>We recorded adverse events reported by participants receiving IR methylphenidate, placebo and other interventions. We then classified the reported adverse events according to organ systems. We calculated the RR with its 95% CI of the number of events according to organ systems and the intervention groups, whenever appropriate. Finally, we plotted the RRs with the 95% CI of the events according to organ systems and intervention groups in a forest plot. </p> </section> </section> <section id="CD013011-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>There were insufficient data evaluated and reported in the included trials to allow us to undertake any subgroup analyses. </p> </section> <section id="CD013011-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>There were not enough trials (two or more) included in the meta‐analyses to perform most of the sensitivity analysis preplanned in the review protocol (<a href="./references#CD013011-bbs2-0142" title="CândidoRCF , GolderS , Menezes de PaduaCA , PeriniE , JunqueiraDR . Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD013011. [DOI: 10.1002/14651858.CD013011]">Cândido 2018</a>). We were able to evaluate the impact of the meta‐analysis model (fixed‐effect model or random‐effects model) and the different RCT designs (parallel versus cross‐over) in one analysis of the efficacy of IR methylphenidate as rated by the participants compared with placebo. </p> </section> <section id="CD013011-sec-0048"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two review authors (DJ, RC) independently assessed the results of the review for the certainty of the evidence, the magnitude of the effect of the interventions examined, and the sum of available data on the main outcomes using the GRADE approach (<a href="./references#CD013011-bbs2-0116" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020a</a>). We resolved disagreements by discussion or by consulting a third review author (CP). The GRADE approach consists of five judgment considerations on the certainty of a body of evidence: risk of bias, inconsistency, indirectness, imprecision and publication bias. We presented the reconciled main findings of the certainty of the evidence analyzed in this review in a 'Summary of findings' table, according to four levels of the certainty of the evidence: high, moderate, low and very low (<a href="./references#CD013011-bbs2-0116" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020a</a>). </p> <p>We presented the certainty ratings, along with the magnitude of the effect of the interventions examined, and the sum of available data on the outcomes listed below in a 'Summary of findings' table for the following comparisons: IR methylphenidate versus placebo and IR methylphenidate versus lithium. </p> <p> <ol id="CD013011-list-0009"> <li> <p>Efficacy: changes in symptoms of ADHD assessed by the investigator</p> </li> <li> <p>Efficacy: changes in symptoms of ADHD assessed by the participant</p> </li> <li> <p>Harms (adverse events)</p> </li> <li> <p>Clinical impression‐severity</p> </li> <li> <p>Clinical impression‐improvement</p> </li> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> <p>The outcomes were measured in the included trials at different follow‐up time points, and we therefore describe the means or ranges of the follow‐up period in the 'Summary of findings' tables. We selected change scores rather than endpoint scores when data were available for the same outcome and could not be combined in a meta‐analysis. Results calculated using SMDs were interpreted according to the rule of thumb described by <a href="./references#CD013011-bbs2-0054" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates: Routledge, 1988.">Cohen 1988</a>, which suggests that a SMD of 0.2 represents a “small” difference, an SMD of 0.5 represents a “medium” difference, and an SMD of 0.8 represents a “large” difference (<a href="./references#CD013011-bbs2-0117" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook..">Schünemann 2020b</a>; <a href="./references#CD013011-bbs2-0125" title="TakeshimaN , SozuT , TajikaA , OgawaY , HayasakaY , FurukawaTA . Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?BMC Medical Research Methodology2014;14(1):30. [DOI: 10.1186/1471-2288-14-30] [PMC3936842] [PMID: 24559167]">Takeshima 2014</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013011-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013011-sec-0049"></div> <section id="CD013011-sec-0050"> <h3 class="title">Description of studies</h3> <section id="CD013011-sec-0051"> <h4 class="title">Results of the search</h4> <p>Our searches identified a total of 20,796 records (<a href="./appendices#CD013011-sec-0135">Appendix 2</a>). We screened 9808 records after duplicates were removed. After screening titles and abstracts, 72 full‐text reports were considered to be potentially relevant. Assessment of the full‐text reports led to the inclusion of 10 RCTs (from 10 reports) that met our inclusion criteria (<a href="#CD013011-sec-0016">Criteria for considering studies for this review</a>). One study is awaiting classification (<a href="./references#CD013011-bbs1-0003" title="">Studies awaiting classification</a>), and one study is ongoing (<a href="./references#CD013011-bbs1-0004" title="">Ongoing studies</a>). See <a href="#CD013011-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013011-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram illustrating the results of the study selection process." data-id="CD013011-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram illustrating the results of the study selection process.</p> </div> </div> </div> </section> <section id="CD013011-sec-0052"> <h4 class="title">Included studies</h4> <p>We included 10 RCTs in this review. Below, we summarize the key characteristics of the included trials. Further details of the trials' methods, participants, interventions, and outcomes are shown in the <a href="./references#CD013011-sec-0160" title="">Characteristics of included studies</a> tables. </p> <section id="CD013011-sec-0053"> <h5 class="title">Study design</h5> <p>The included RCTs comprised five trials with a parallel design (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>) and five trials with a cross‐over design (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>), published between 2001 and 2016. </p> </section> <section id="CD013011-sec-0054"> <h5 class="title">Location and setting</h5> <p>Three trials reported having been conducted in Europe (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>) and one in Argentina (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>); the remaining studies did not report the location where they were conducted. Most trials recruited outpatient participants but one was conducted in an addiction treatment facility and included participants receiving concomitant inpatient treatment for various substance‐use disorders (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>). An additional trial assessed participants with ADHD and substance‐use disorder if they were willing to enter an intensive outpatient program to treat their cocaine dependence (<a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>). </p> </section> <section id="CD013011-sec-0055"> <h5 class="title">Samples size </h5> <p>The included trials randomized a total of 497 participants. Among the trials with a parallel design, 173 people were randomized to receive IR methylphenidate, 142 to receive placebo, and 11 to receive sustained‐release bupropion (SR bupropion) formulations. Among the trials with a cross‐over design, 147 participants were randomized to sequential treatment with IR methylphenidate and placebo, and 24 people to sequential treatment with IR methylphenidate, Pycnogenol® and placebo. The number of participants included in each of the studies is described in the <a href="./references#CD013011-sec-0160" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD013011-sec-0056"> <h5 class="title">Follow‐up and attrition</h5> <p>The duration of the treatment and follow‐up periods varied significantly among the trials. Among those with a parallel design, treatment duration and follow‐up were six weeks (<a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>), eight weeks (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>), 12 weeks (<a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>), and 16 weeks (<a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>). Among the trials with a cross‐over design, treatment duration and follow‐up were five weeks (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>), seven weeks with one week washout between treatments (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>), eight weeks (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>), 17 weeks with one week washout between treatments (<a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>), and 18 weeks with two weeks washout between treatments (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>). </p> <p>Attrition rates varied and were taken into account in the 'Risk of bias' assessment (<a href="http://Risk of bias in included studies" target="_blank">Risk of bias in included studies</a>). <a href="http://Table 2" target="_blank">Table 2</a> details the follow‐up time points of each of the included RCTs. </p> </section> <section id="CD013011-sec-0057"> <h5 class="title">Interventions and comparators</h5> <p>Six two‐arm trials compared IR methylphenidate with placebo (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>). One trial tested the continuous efficacy of switching from IR methylphenidate to osmotic release oral system (OROS) methylphenidate in adults who responded to treatment with IR methylphenidate (<a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). Treatment with IR methylphenidate was compared with lithium in one trial (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>). </p> <p>One three‐arm trial compared IR methylphenidate with SR bupropion and placebo (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>); another compared IR methylphenidate with Pycnogenol® and placebo (<a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). Pycnogenol® is the US registered trademark name for a commercially‐available maritime pine bark extract (<a href="./references#CD013011-bbs2-0092" title="MedlinePlus. Maritime Pine. medlineplus.gov/druginfo/natural/1019.html (accessed 17 December 2019).">MedlinePlus 2019</a>). </p> <p>We did not identify eligible RCTs that compared IR methylphenidate with extended‐release formulations of methylphenidate other than OROS. </p> <p>In most trials, IR methylphenidate was administered following a dose‐titration scheme, starting at small doses (5 to 10 mg) given two or three times daily, and increasing to a maximum of 40 to 60 mg daily. </p> <p><a href="#CD013011-tbl-0004">Table 2</a> describes the comparators investigated in each of the included RCTs. </p> <div class="table" id="CD013011-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to comparators, time points and measurements of the primary outcome of efficacy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time points</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Investigator measurements</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Self‐report measurements</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measurements with complete data</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with parallel design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0010"> <li> <p>Bupropion SR</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks following a single‐blind, 7‐day placebo lead‐in</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult ADHD Symptom Checklist Severity Scale (ADHDRS); updated and validated for DSM‐IV ADHD criteria </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change scores and end scores</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]"><b>Schrantee 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult ADHD Symptom Checklist Severity Scale (ADHDRS); updated and validated for the DSM‐IV ADHD criteria </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks of treatment (13 weeks in total, including 1 week of baseline testing and 12 weeks of treatment) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barkley's ADHD Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barkley's ADHD Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores for self‐reported measurements; investigator‐rated scores reported narratively</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult ADHD Investigator Symptom Report Scale (AISRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OROS methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult ADHD Investigator System Symptom Report Scale (AISRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data reported narratively</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with cross‐over design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0011"> <li> <p>Conners’ Adult ADHD Rating Scale</p> </li> <li> <p>Barkley ADHD Problem Behaviours Scale</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None. Only incomplete data (end means with P value and range)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]"><b>Carpentier 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks (4 treatment phases of 2 weeks each)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0012"> <li> <p>Barkley ADHD Problem Behaviours Scale</p> </li> <li> <p>ADHD Rating Scale‐IV</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None. Only incomplete data (t‐test values)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 weeks with a 2‐week washout period in between treatment periods</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperactivity, Impulsivity, Learning Problems, Conduct Disorder, Restlessness, and Antisocial Behavior subscales of the Conners’ Adult ADHD Rating Scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 weeks, with 1 week of washout in between treatments periods</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Rating Scale ‐ IV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores of the first period of treatment</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]"><b>Tenenbaum 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0013"> <li> <p>Pycnogenol®</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 weeks (2 weeks in each treatment separated by 1 washout week)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0014"> <li> <p>Barkley ADHD Problem Behaviours Scale<sup>a</sup> </p> </li> <li> <p>Attention Deficit Scales for Adults (ADSA)<sup>a</sup> </p> </li> <li> <p>Copeland Symptom Checklist for Adult Attention Deficit Disorders<sup>a</sup> </p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0015"> <li> <p>Barkley ADHD Problem Behaviours Scale</p> </li> <li> <p>Attention Deficit Scales for Adults (ADSA)</p> </li> <li> <p>Barratt Impulsiveness Scale</p> </li> <li> <p>Copeland Symptom Checklist for Adult Attention Deficit Disorders</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None. Only incomplete data (initial scores)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADHD: Attention deficit hyperactivity disorder<br/>OROS: osmotic release oral system<br/>SR: Sustained‐release </p> <p><sup>a</sup>Measurements reported by the individual’s significant other, not the trial investigator. </p> </div> </div> </section> <section id="CD013011-sec-0058"> <h5 class="title">Characteristics of the participants</h5> <p>All included trials used DSM‐IV criteria, alone or in combination with other scales, to diagnose ADHD in the adults recruited into the trials. </p> <p>The mean age of the participants ranged from 25 to 40 years old in nine studies; one trial reported only the age range of the participants, which varied from 17 to 51 years old (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>). Most trials included individuals of both sexes (range = 8% to 75%). One trial included only male participants (<a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>). </p> <p>Two trials reported the subtypes of ADHD that characterized the participants recruited: predominantly inattentive, predominantly hyperactive‐impulsive, or combined (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>). In <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>, participants presenting with the combined subtype comprised 54% of those receiving IR methylphenidate and 79% of those receiving placebo. Participants presenting with the predominantly inattentive subtype were 46% and 21% in the IR methylphenidate and placebo groups, respectively. In <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>, 76% of participants presented with the combined ADHD subtype, 20% with the predominantly inattentive subtype, and 4% with the hyperactive‐impulsive subtype. </p> </section> <section id="CD013011-sec-0059"> <h5 class="title">Outcomes and outcome measurements</h5> <section id="CD013011-sec-0060"> <h6 class="title">Primary outcomes</h6> <section id="CD013011-sec-0061"> <p><b>Efficacy: changes in the symptoms of ADHD</b></p> <p>Changes in the symptoms of ADHD (the primary outcome of efficacy) were assessed using different scales; commonly, the trials applied multiple symptom‐rating scales to measure the effects of the treatments under investigation. Nevertheless, complete and extractable data were available from only a few of the trials (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>). Data from one trial, <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>, were provided following email correspondence with the contact author (<a href="./references#CD013011-bbs2-0080" title="JunqueiraDR . Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder [personal communication]. Email to: L Reneman 7 July 2019.">Junqueira 2019 [pers comm]</a>). </p> <p>The scales used to assess the primary outcome of efficacy (changes in the symptoms of ADHD) measure the frequency or severity of ADHD symptoms, with higher scores generally indicating an increase in symptoms occurrence or illness severity. </p> <p> <ol id="CD013011-list-0016"> <li> <p>The Adult ADHD Symptom Checklist Severity Scale (ADHDRS); updated and validated for the DSM‐IV ADHD criteria (scores range from 0 to 54): used in two trials (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>); </p> </li> <li> <p>Barkley's ADHD Rating Scale (scores range from one to seven): used in one trial (<a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>); </p> </li> <li> <p>The Adult ADHD Investigator Symptom Report Scale (AISRS; scores range from 0 to 54): used in two trials (<a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>); </p> </li> <li> <p>Conners’ Adult ADHD Rating Scale (scores range from 0 to 198): used in two trials (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>); </p> </li> <li> <p>Barkley's ADHD Problem Behaviours Scale (scores range from 0 to 42): used in three trials (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>); </p> </li> <li> <p>The ADHD Rating Scale‐IV (scores range from zero to three): used in two trials (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>); </p> </li> <li> <p>Attention Deficit Scale for Adults (ADSA; scores range from 0 to 54): used in one trial (<a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>); </p> </li> <li> <p>Barratt Impulsiveness Scale (30 items scored on a four‐point Likert scale, ranging from one (rarely/never) to four (almost always/always)): used in one trial (<a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>); </p> </li> <li> <p>Copeland Symptom Checklist for Adult Attention Deficit Disorders (eight categories scored on a three‐point Likert scale, ranging from zero (not at all) to three (very much); percentages are computed for each category): used in one trial (<a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). </p> </li> </ol> </p> <p><a href="#CD013011-tbl-0004">Table 2</a> describes the measures used in the included RCTs to assess the primary outcome of efficacy. </p> </section> <section id="CD013011-sec-0062"> <p><b>Harms</b></p> <p>With the exception of <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>, nine included studies reported some data on harms; however, among these trials, only four described the measurement methods planned or implemented to detect adverse events occurring among participants receiving treatment (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). Four trials reported information on the specific time points when adverse events were assessed (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). Data on adverse events were reported as a general statement in one trial (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>), while the remaining RCTs provided data on a subset of the total events (<a href="#CD013011-tbl-0005">Table 3</a>). </p> <div class="table" id="CD013011-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reporting of harms in RCTs assessing the treatment of ADHD with IR methylphenidate</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reporting of harms outcomes</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0017"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on most common complaints</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0018"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on worst occurrence during the study</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0019"> <li> <p>Data on selected/composite outcomes</p> </li> <li> <p>Specific numbers of the results of the cardiovascular measurement not reported, only statistical results (e.g. “no statistically significant changes”) </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0020"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected cardiovascular events</p> </li> <li> <p>Remaining data not reported or reported in a non‐extractable way</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0021"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected events</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0022"> <li> <p>Physiological, cardiovascular, measures reported as continuous data with statistically significant/non‐significant analysis </p> </li> <li> <p>Data on selected events</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0023"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected events</p> </li> <li> <p>Additional cardiovascular events reported narratively with general statements of statistically significance/non‐significance </p> </li> </ol> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder<br/>IR: immediate release<br/>RCTs: randomized controlled trials </p> </div> </div> <p><a href="#CD013011-tbl-0006">Table 4</a> provides a comprehensive description of the harms assessed and reported in the included RCTs. </p> <div class="table" id="CD013011-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to the assessment and reporting of outcomes of harms</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Harms assessed?</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measurement method</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time points</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>What results were reported?</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with parallel design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0024"> <li> <p>Bupropion SR</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At each return visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0025"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on most common complaints</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]"><b>Schrantee 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported, only a general statement included in the paper</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0026"> <li> <p>Adverse Effects Checklist based on <a href="./references#CD013011-bbs2-0035" title="BarkleyRA . Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York (NY): Guilford Press, 1990.">Barkley 1990</a> </p> </li> <li> <p>Cardiac symptoms</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0027"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on worst occurrence of the adverse events during the study</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0028"> <li> <p>Open‐ended questions</p> </li> <li> <p>Electrocardiogram, heart rate, and blood pressure</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At each visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0029"> <li> <p>Data on adverse events that the participant indicated the severity as 'pretty much' or 'very much' on a 4‐point Likert‐type scale ranging from 0 (not at all) to 3 (very much) </p> </li> <li> <p>Specific numbers of the results of the cardiovascular measurement not reported, only statistical results (e.g. “no statistically significant changes”). </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OROS methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0030"> <li> <p>Spontaneous reports prompted by open‐ended questions</p> </li> <li> <p>Tolerability index (Clinical Global Impression (CGI) Scale)</p> </li> <li> <p>Weight, vital signs and electrocardiogram</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0031"> <li> <p>At each visit: spontaneous reports, tolerability, weight and vital signs</p> </li> <li> <p>Study endpoint: electrocardiogram</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0032"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on cardiovascular events: systolic and diastolic blood pleasure, pulse</p> </li> </ol> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with cross‐over design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0033"> <li> <p>Physiological and cardiovascular measures reported as continuous data with statistically significant/non‐significant analysis </p> </li> <li> <p>Data on selected adverse events: weight, appetite loss, trouble sleeping, headache</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]"><b>Carpentier 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported, only a general statement included in the paper</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0034"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected adverse events: headaches, diarrhea, nausea, chest discomfort, orthostatic hypotension </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Side Effects Rating Scale from <a href="./references#CD013011-bbs2-0036" title="BarkleyRA , MurphyKR . Attention-Deficit Hyperactivity Disorder: A Clinical Workbook. 2nd edition. New York (NY): Guilford Press, 1998.">Barkley 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0035"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected adverse events: tachycardia, dry mouth, dizziness, loss of appetite, abdominal complains, headache, tics, sleeping problems </p> </li> <li> <p>Additional cardiovascular events reported narratively with general statements of statistically significance/non‐significance </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]"><b>Tenenbaum 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0036"> <li> <p>Pycnogeno®l</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial did not access outcomes of harms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>N/A: not applicable<br/>OROS: osmotic release oral system<br/>SR: sustained release </p> </div> </div> </section> </section> <section id="CD013011-sec-0063"> <h6 class="title">Secondary outcomes</h6> <p>The included trials used multiple scales to assess the secondary efficacy outcomes, as described below. The scales measure the frequency or severity of the symptoms, and generally higher scores indicate an increase in symptom occurrence or illness severity, unless otherwise specified. </p> <section id="CD013011-sec-0064"> <p><b>Changes in the clinical impression measures of severity or improvement</b></p> <p> <ol id="CD013011-list-0037"> <li> <p>Clinical Global Impression (CGI) ‐ Severity (‐S) or ‐ Improvement (‐I) scale (scores range from one (very much improved) to seven (very much worse)): used in six trials (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). </p> </li> </ol> </p> </section> <section id="CD013011-sec-0065"> <p><b>Changes in the level of functioning</b></p> <p> <ol id="CD013011-list-0038"> <li> <p>Global Assessment of Functioning (GAF; scores range from 0 to 100): used in four trials (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). </p> </li> </ol> </p> </section> <section id="CD013011-sec-0066"> <p><b>Changes in depression</b></p> <p> <ol id="CD013011-list-0039"> <li> <p>Hamilton Depression Scale (HAM‐D; scores range from 0 to 52): used in six trials (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). </p> </li> <li> <p>Beck Depression Inventory (BDI; scores range from 0 to 63): used in four trials (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). </p> </li> </ol> </p> </section> <section id="CD013011-sec-0067"> <p><b>Changes in anxiety</b></p> <p> <ol id="CD013011-list-0040"> <li> <p>Hamilton Anxiety Scale (HAM‐A; scores range from 0 to 56): used in six trials (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). </p> </li> <li> <p>Beck Anxiety Inventory (BAI; scores range from 0 to 63): used in one trial (<a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). </p> </li> </ol> </p> </section> <section id="CD013011-sec-0068"> <p><b>Quality of life</b></p> <p>None of the included studies assessed quality of life.</p> <p><a href="#CD013011-tbl-0007">Table 5</a> describes the measures used in each of the included RCTs to assess the secondary outcomes. </p> <div class="table" id="CD013011-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to comparators and measurements of the secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measurement methods</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>What results were reported?</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b><i>RCTs with parallel design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0041"> <li> <p>Bupropion SR</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0042"> <li> <p>Clinical impression of improvement</p> </li> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0043"> <li> <p>Clinical Global Impression (CGI) scale – Improvement (‐I)</p> </li> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0044"> <li> <p>Narrative results with general statements: CGI‐I</p> </li> <li> <p>Change scores: HAM‐A and HAM‐D</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]"><b>Schrantee 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0045"> <li> <p>Clinical impression of severity and improvement</p> </li> <li> <p>Global level of functioning</p> </li> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0046"> <li> <p>Clinical Global Impression Scale (CGI) – Severity (‐S) and Improvement (‐I)</p> </li> <li> <p>Global Assessment Functioning (GAF) scale</p> </li> <li> <p>Beck Depression Inventory (BDI)</p> </li> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change scores, end scores and baseline scores: CGI‐I and CGI‐S<sup>a</sup> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0047"> <li> <p>Clinical impression of severity</p> </li> <li> <p>Global level of functioning</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0048"> <li> <p>Clinical Global Impression (CGI) scale – Severity (‐S)</p> </li> <li> <p>Global Assessment Functioning (GAF) scale</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narrative report with general statements: GAF</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>OROS methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0049"> <li> <p>Clinical impression of severity and improvement</p> </li> <li> <p>Global level of functioning</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0050"> <li> <p>Clinical Global Impression (CGI) scale – Severity (‐S) and Improvement (‐I)</p> </li> <li> <p>Global Assessment Functioning (GAF) scale</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with cross‐over design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0051"> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0052"> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Beck Depression Inventory (BDI)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data reported narratively with general statements for both outcomes</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]"><b>Carpentier 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0053"> <li> <p>Clinical impression improvement</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0054"> <li> <p>Clinical Global Impression (CGI) scale – Improvement (‐I), adapted for ADHD symptoms</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data reported incompletely for all outcomes</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0055"> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0056"> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on end scores for both outcomes</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0057"> <li> <p>Clinical impression of severity and improvement</p> </li> <li> <p>Global level of functioning</p> </li> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0058"> <li> <p>Clinical Global Impression (CGI) scale – Severity (‐S)</p> </li> <li> <p>Global assessment of functioning (GAF) scale</p> </li> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on end scores for CGI‐S</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]"><b>Tenenbaum 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0059"> <li> <p>Pycnogenol®</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0060"> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0061"> <li> <p>Beck Anxiety Inventory (BAI)</p> </li> <li> <p>Beck Depression Inventory (BDI)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on initial scores for both outcomes</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder<br/>OROS: osmotic release oral system<br/>SR: Sustained‐release </p> <p><sup>a</sup>Full dataset shared by the study authors. </p> </div> </div> </section> </section> </section> <section id="CD013011-sec-0069"> <h5 class="title">Clinical trials registration</h5> <p>With the exception of one trial (<a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>), none of the included trials appeared to be registered in a clinical trial registry. The trial reports did not mention registration, and a dedicated search could not locate them in any trial registry. </p> </section> <section id="CD013011-sec-0070"> <h5 class="title">Conflicts of interest</h5> <p>Funding sources and potential conflict of interests were reported in all but two included trials (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>). Amongst the eight trials reporting sources of funding: two reported support from research grants and several companies with a vested interest, and also disclosed that the trials' authors received consulting fees and sat on the advisory boards of pharmaceutical companies (<a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>); two reported support from research grants and a company with a vested interest (<a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>); one reported being fully supported by a pharmaceutical company (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>); and three reported being supported entirely by research grants from public and private institutions (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>). Additional details are described at the <a href="./references#CD013011-sec-0160" title="">Characteristics of included studies</a> tables. </p> <p>Based on the sources of funding and conflict of interests disclosed in the trial publications, we have concerns about the impact of the conflicts of interest on the results analyzed from the included trials (<a href="./references#CD013011-bbs2-0041" title="BoutronI , PageMJ , HigginsJP , AltmanDG , LundhA , HróbjartssonA . Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Boutron 2020</a>) (<a href="#CD013011-tbl-0008">Table 6</a>). We detected notable reasons for concern in four trials (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>); reasons for concern were unclear in two RCTs (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>), since sources of funding and conflict of interests were not reported in these trials. </p> <div class="table" id="CD013011-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Impact of sources of funding and conflict of interests on the results analyzed from the trials assessing the treatment of adults with ADHD with IR methylphenidate</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Judgment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rationale</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b><i>RCTs with parallel design</i> </b> <br/>  </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0062"> <li> <p>Trial fully supported by a pharmaceutical company with a vested interest</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]"><b>Schrantee 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0063"> <li> <p>Research support received from research grants</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0064"> <li> <p>Research supported by research grants</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0065"> <li> <p>Authors have received consulting fees and sit on the advisory boards of pharmaceutical companies </p> </li> <li> <p>Research support received from several companies with a vested interest</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable concerns<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0066"> <li> <p>Authors have received consulting fees and sit on the advisory boards of pharmaceutical companies </p> </li> <li> <p>Research support received from several companies with a vested interest</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b><i>RCTs with cross‐over design</i> </b> <br/>  </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0067"> <li> <p>Research supported by research grants</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]"><b>Carpentier 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0068"> <li> <p>Sources of funding and conflict of interests not reported </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0069"> <li> <p>Sources of funding and conflict of interests not reported</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0070"> <li> <p>Research supported by research grants</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]"><b>Tenenbaum 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0071"> <li> <p>Research support received from a company with a potential vested interest</p> </li> </ol> </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD013011-sec-0071"> <h4 class="title">Excluded studies</h4> <p>We excluded 60 reports (54 studies) at the full‐text screening stage. We documented the reasons for excluding these reports, which comprised: </p> <p> <ol id="CD013011-list-0072"> <li> <p>Study design not eligible (13 reports);</p> </li> <li> <p>Interventions investigated not eligible (16 reports);</p> </li> <li> <p>Treatment comparisons not eligible (7 reports);</p> </li> <li> <p>Population included in the primary study not eligible (17 reports); and</p> </li> <li> <p>Studies investigating effects on IR methylphenidate in diverse outcomes (e.g. participants' performance on the Continuous Paired‐Associate Learning Test (7 reports). </p> </li> </ol> </p> <p>We selected 16 studies (from 19 reports) to report in more detail in the <a href="./references#CD013011-sec-0161" title="">Characteristics of excluded studies</a> tables. These are studies which at first sight appeared to be eligible for inclusion, but proved ineligible on closer inspection. We documented the reasons for excluding these reports, which comprised: </p> <p> <ol id="CD013011-list-0073"> <li> <p>Study design not eligible (2 studies);</p> </li> <li> <p>Interventions investigated not eligible (1 study);</p> </li> <li> <p>Treatment comparisons not eligible (2 studies);</p> </li> <li> <p>Population included in the primary study not eligible (4 studies); and</p> </li> <li> <p>Studies investigating effects on IR methylphenidate in diverse outcomes (7 studies).</p> </li> </ol> </p> <p>Seven studies investigated research questions and outcomes not related to the objectives of this review. </p> <p> <ol id="CD013011-list-0074"> <li> <p><a href="./references#CD013011-bbs2-0014" title="KinsbourneM , De QuirosGB , Tocci RufoD . Adult ADHD. Controlled medication assessment. Annals of the New York Academy of Sciences2001;931:287-96. [DOI: 10.1111/j.1749-6632.2001.tb05785.x] [PMID: 11462747]">Kinsbourne 2001</a> sought to assess participants' performance on the Continuous Paired‐Associate Learning Test (CPALT) after a single administration of three doses (5, 10, and 20 mg) of methylphenidate and placebo. </p> </li> <li> <p><a href="./references#CD013011-bbs2-0018" title="NiHC , ShangCY , GauSS , LinYJ , HuangHC , YangLK . A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. International Journal of Neuropsychopharmacology2013;16(9):1959-73. [DOI: 10.1017/S1461145713000357] [PMID: 23672818]">Ni 2013</a> compared the long‐term efficacy of methylphenidate and atomoxetine in improving executive functions in drug‐naïve adults with ADHD. </p> </li> <li> <p><a href="./references#CD013011-bbs2-0019" title="Ni H-C, Hwang Gu S-L, Lin H-Y, Lin Y-J, Yan L-K, Huang H-C, et al. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: a head-to-head randomized clinical trial. Journal of Psychopharmacology2016;30(5):459-67. [DOI: 10.1177/0269881116632377] [PMID: 26905919]">Ni 2016</a> evaluated the effects of methylphenidate in intra‐individual variability in reaction time (IIV‐RT) in people with ADHD. </p> </li> <li> <p><a href="./references#CD013011-bbs2-0023" title="VansickelAR ,  StoopsWW , GlaserPE , PooleMM , RushCR . Methylphenidate increases cigarette smoking in participants with ADHD. Psychopharmacology2011;218(2):381-90. [DOI: 10.1007/s00213-011-2328-y] [PMC3189423] [PMID: 21590284]">Vansickel 2011</a> evaluated the acute effects of methylphenidate on cigarette‐smoking behavior in individuals diagnosed with ADHD. </p> </li> <li> <p><a href="./references#CD013011-bbs2-0024" title="VersterJC , BekkerEM , De RoosM , MinovaA , EijkenEJ , KooijJJS , et al. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial. Journal of Psychopharmacology2008;22(3):230-7. [DOI: 10.1177/0269881107082946]">Verster 2008</a> evaluated the effects of methylphenidate on driving performance of adults with ADHD. </p> </li> <li> <p><a href="./references#CD013011-bbs2-0011" title="BouzianeC , FilatovaOG , SchranteeA , CaanMW , VosFM , RenemanL . White matter by diffusion MRI following methylphenidate treatment: a randomized control trial in males with attention-deficit/hyperactivity disorder. Radiology2019;293(1):186-92. [DOI: 10.1148/radiol.2019182528] [PMID: 31407970]">Bouziane 2019</a> evaluated whether methylphenidate modulates human brain white matter in an age‐dependent manner. </p> </li> <li> <p><a href="./references#CD013011-bbs2-0017" title="NCT02477280. Effects of expectation, medication and placebo on objective and self-rated performance [Effects of expectation, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in patients with untreated ADHD and substance use disorder]. clinicaltrials.gov/ct2/show/NCT02477280 (first received 12 June 2015). ">NCT02477280</a> sought to examine the effects of methylphenidate on objective and self‐rated task performance during the Quantified Behavior Test. </p> </li> </ol> </p> <section id="CD013011-sec-0072"> <h5 class="title">Studies awaiting classification</h5> <p>We were unable to access the abstract or full text of one trial (<a href="./references#CD013011-bbs2-0027" title="IRCT20110802007202N15. Comparison of the effectiveness of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in adult patients. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20110802007202N15 (first received 8 November 2018). [en.irct.ir/trial/7635]">IRCT20110802007202N15</a>); this trial is awaiting classification (<a href="./references#CD013011-sec-0162" title="">Characteristics of studies awaiting classification</a>). The author team made extensive efforts to retrieve this study by searching several databases, the libraries of two different institutions and requesting the support of the Information Specialist of the Cochrane Developmental, Psychosocial and Learning Problems. </p> </section> <section id="CD013011-sec-0073"> <h5 class="title">Studies ongoing</h5> <p>One clinical trial was classified as 'Ongoing' according to the record in the European Union Clinical Trial Register (EU‐CTR): <a href="./references#CD013011-bbs2-0028" title="EU CTR 2012-005246-38. The effects of Ritalin treatment on decision making and learning, and on brain activation, in adult ADHD [The effects of methylphenidate on brain processes for decision making in adult attention deficit hyperactivity disorder]. www.clinicaltrialsregister.eu/ctr-search/trial/2012-005246-38/NO (first received 7 February 2013). [EUCTR2012-005246-38-NO]">EU CTR 2012‐005246‐38</a>. See the <a href="./references#CD013011-sec-0163" title="">Characteristics of ongoing studies</a> table for more information. </p> </section> </section> </section> <section id="CD013011-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p>We judged most of the included trials to be at unclear risk of selection, performance and detection bias. We considered most trials to be at high risk of attrition and reporting bias for both the efficacy (symptoms of ADHD) and harms (adverse events) outcomes. For harms, we rated all the included trials at high risk of reporting bias. </p> <p>A comprehensive description of the risk of bias for each trial across each domain is provided in the 'Risk of bias' tables (beneath the <a href="./references#CD013011-sec-0160" title="">Characteristics of included studies</a> tables). We summarize the risks of bias below and in <a href="#CD013011-fig-0002">Figure 2</a> and <a href="#CD013011-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD013011-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013011-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD013011-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013011-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD013011-sec-0075"> <h4 class="title">Allocation</h4> <section id="CD013011-sec-0076"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>We judged three trials at low risk of selection bias for this domain (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>), as they described adequate methods to generate the randomization sequence. Two trials did not report the method used to generate the randomization sequence of allocation and had high imbalance in the numbers and baseline characteristics of the participants between intervention groups. We judged these RCTs to be at high risk of bias (<a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). Five trials provided insufficient information to permit a judgement so we rated them at unclear risk of bias (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). </p> </section> <section id="CD013011-sec-0077"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>We deemed one trial to be at low risk of selection bias for this domain, as allocation concealment was ensured by the use of a central clinical unit to generate the sequence of allocation (<a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>). We judged the nine remaining trials to be at unclear risk of bias as they provided insufficient information to permit a judgment (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>).   </p> </section> </section> <section id="CD013011-sec-0078"> <h4 class="title">Blinding</h4> <section id="CD013011-sec-0079"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>We assessed performance bias separately for participants and personnel.</p> <section id="CD013011-sec-0080"> <h6 class="title">Blinding of participants</h6> <p>Six trials described adequate methods to blind participants, mostly by the use of identical‐looking tablets, and we judged these trials to be at low risk of performance bias for the blinding of participants (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). Three trials were described as single‐blinded but it was not clear who was blinded; we judged these trials to be at high risk of performance bias (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). One trial provided insufficient information to permit a judgement, so we rated it at unclear risk of bias (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>). </p> </section> <section id="CD013011-sec-0081"> <h6 class="title">Blinding of personnel</h6> <p>Four trials described adequate methods to blind personnel, mostly by the use of identical‐looking tablets; we rated these trials at low risk of performance bias for the blinding of personnel (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). Three trials were described as single‐blinded, but it was not clear who was blinded; we judged these trials to be at high risk of performance bias (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>). Three trials provided insufficient information to permit a judgment, so we rated them at unclear risk of bias (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). </p> </section> </section> <section id="CD013011-sec-0082"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>We assessed blinding of outcome assessment separately for the primary outcomes of efficacy (symptoms of ADHD) and harms (adverse events). </p> <section id="CD013011-sec-0083"> <h6 class="title">Efficacy</h6> <p>Two trials reported that the investigators rating the symptoms of ADHD were blinded to the treatment allocation of the participants; we rated these trials at low risk of detection bias for symptoms of ADHD (<a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). The remaining eight trials provided insufficient information to permit a judgment and were rated at unclear risk of detection bias (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). </p> </section> <section id="CD013011-sec-0084"> <h6 class="title">Harms</h6> <p>One trial reported that the assessment of harms was performed by unblinded clinicians; we judged this trial (<a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>) at high risk of detection bias for adverse events. The remaining nine trials provided insufficient information to permit a judgment, so we rated them at unclear risk of detection bias (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). </p> </section> </section> </section> <section id="CD013011-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>In three trials, reasons for missing outcome data appeared unlikely to be related to the true outcome; we considered these trials to be at low risk of attrition bias (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>). </p> <p>We detected imbalances in dropout rates and retention rates at follow‐up that we considered likely to be related to the true outcome in the reports of five trials; we rated these trials at high risk of attrition bias (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). Two trials provided insufficient information to permit a judgment, so we rated these RCTs at unclear risk of bias (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>). </p> </section> <section id="CD013011-sec-0086"> <h4 class="title">Selective reporting</h4> <p>We assessed selective reporting (reporting bias) for the primary outcomes of efficacy (symptoms of ADHD) and harms (adverse events) separately. </p> <section id="CD013011-sec-0087"> <h5 class="title">Efficacy</h5> <p>We deemed one RCT (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>) to be at low risk of reporting bias for symptoms of ADHD, as the outcomes planned in the Methods section of the study report were fully covered in the Results section. The results related to the outcomes of efficacy were incompletely reported in eight trials; we judged these trials to be at high risk of selective reporting bias (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). One trial (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>) provided insufficient information to permit judgment, so we rated it at unclear risk of reporting bias. </p> </section> <section id="CD013011-sec-0088"> <h5 class="title">Harms</h5> <p>In all trials, the methods used to identify outcomes of harms were not reported or were deemed inappropriate. We also judged that the assessment of harms was likely to differ between intervention groups and could be influenced by knowledge of the intervention received. For these reasons, we rated all 10 trials at high risk of selective reporting bias for adverse events (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). </p> </section> </section> <section id="CD013011-sec-0089"> <h4 class="title">Other potential sources of bias</h4> <p>We did not assess other potential sources of bias in the included trials (See <a href="#CD013011-sec-0142">Differences between protocol and review</a>). </p> </section> </section> <section id="CD013011-sec-0090"> <h3 class="title" id="CD013011-sec-0090">Effects of interventions</h3> <p>See: <a href="./full#CD013011-tbl-0001"><b>Summary of findings 1</b> Immediate‐release methylphenidate versus placebo for attention deficit hyperactivity disorder (ADHD) in adults</a>; <a href="./full#CD013011-tbl-0002"><b>Summary of findings 2</b> Immediate‐release methylphenidate versus lithium for attention deficit hyperactivity disorder (ADHD) in adults</a> </p> <p>See <a href="./full#CD013011-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013011-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013011-sec-0091"> <h4 class="title">IR methylphenidate versus placebo</h4> <p>Four trials reported data on changes in the symptoms of ADHD: one reported results on investigator‐rated scales (<a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>) and three on participant‐rated scales (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>). </p> <section id="CD013011-sec-0092"> <h5 class="title">Primary outcomes</h5> <section id="CD013011-sec-0093"> <h6 class="title">Efficacy: changes in symptoms of ADHD</h6> <p>The trials assessed the outcomes using different rating scales and reported results using change scores and end scores, which prevented us from pooling the data in a meta‐analysis. </p> <p>The available data suggest that IR methylphenidate might reduce symptoms of ADHD when measured by investigator‐rated scales (MD −20.70, 95% CI −23.97 to −17.43; <a href="./references#CD013011-fig-0006" title="">Analysis 1.1</a>; very low‐certainty evidence), namely the AISRS (scores range from 0 to 54). This analysis was based on one RCT with parallel design and 146 participants (<a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>). </p> <p>One trial (<a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>) measured changes in symptoms of ADHD rated by the investigators and the participant; however, the trial enrolled a small sample of participants (n = 24) and data were incompletely reported. Overall, after 12 weeks, 33% (8/24) of the participants treated with IR methylphenidate were classified by physicians as showing moderate improvement (a reduction of one or two points on a scale ranging from one (very much improved) to seven (very much worse), compared with 46% (11/24) of participants treated with placebo. When participants rated their own symptoms, 73% (18/24) of those treated with IR methylphenidate reported moderate improvement compared with 42% (10/24) of those treated with placebo. </p> <p>When measured by participant‐rated scales, it was unclear whether IR methylphenidate could reduce or increase the symptoms of ADHD. For this analysis, two sets of trials contributed data; the available data were derived from different scales and were reported for different point measures (change scores and end scores), thus preventing pooling. <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a> (a RCT with a parallel design) reported change scores from 19 participants on the ADHDRS (scores range from 0 to 54) (MD 2.30, 95% CI −6.20 to 10.80; <a href="./references#CD013011-fig-0007" title="">Analysis 1.2</a>; very low‐certainty evidence); <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a> and <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a> (trials with parallel and cross‐over designs, respectively) provided end scores from 138 participants (SMD −0.59, 95% CI −1.25 to 0.06; Tau<sup>2</sup> = 0.16; Chi<sup>2</sup> = 3.26 (P = 0.07); I<sup>2</sup> = 69%; <a href="./references#CD013011-fig-0008" title="">Analysis 1.3</a>; <a href="#CD013011-fig-0004">Figure 4</a>; very low‐certainty evidence). </p> <div class="figure" id="CD013011-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Comparison 1 IR methylphenidate versus Placebo, Outcome: Symptom of ADHD" data-id="CD013011-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 IR methylphenidate versus Placebo, Outcome: Symptom of ADHD</p> </div> </div> </div> <p>We observed slightly different results when repeating the analyses using a fixed‐effect model (SMD −0.51, 95% CI −0.85 to −0.17; I<sup>2</sup> = 69%), and with the cross‐over trial excluded (SMD −0.97, 95% CI −1.57 to −0.37; versus SMD −0.59, 95% CI −1.25 to 0.06 (with cross‐over trial): <a href="./references#CD013011-fig-0008" title="">Analysis 1.3</a>; <a href="#CD013011-fig-0004">Figure 4</a>). </p> </section> <section id="CD013011-sec-0094"> <h6 class="title">Harms</h6> <p>None of the included trials reported ascertaining or evaluating participants for serious adverse events as defined by the <a href="http://ICH 2016" target="_blank">ICH 2016</a> (see <a href="http://Types of outcome measures" target="_blank">Types of outcome measures</a>). One trial reported that "no serious adverse events were noted in any of the individuals studied" (<a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>), although the method of assessing adverse events was not described in the trial report. It is therefore not clear how these events were defined. </p> <p>One trial comparing IR methylphenidate with placebo provided data on the total number of participants experiencing at least one adverse event (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>). The available data did not allow a conclusion of the difference between participants receiving IR methylphenidate compared with placebo on the risk of harms (RR 1.19, 95% CI 0.94 to 1.52; <a href="./references#CD013011-fig-0009" title="">Analysis 1.4</a>). Three trials reported data on discontinuation due to adverse events (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>), with one participant discontinuing treatment with placebo and seven discontinuing treatment while receiving IR methylphenidate. </p> <p>Data on the occurrence of harms, as reported by four trials (<a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>; <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>) were described for a total of 203 participants who received IR methylphenidate and for a total of 141 participants who received placebo. These participants experienced 651 adverse events in total: 438 events were experienced by people receiving IR methylphenidate (median number of events experienced by people who had events = 12, interquartile range (IQR) = 8 to 28), while 213 were experienced by people receiving placebo (median number of events experienced by people who had events = 8, IQR = 5 to 11). </p> <p>Amongst the adverse events reported, participants receiving IR methylphenidate had an increased risk of developing gastrointestinal complications (e.g. dry mouth, nausea and stomach aches; RR 1.96, 95% CI 1.13 to 2.95) and metabolism and nutrition complications (e.g. decreased appetite or loss of appetite; RR 1.77, 95% CI 1.06 to 2.96) (<a href="#CD013011-fig-0005">Figure 5</a>). <a href="#CD013011-tbl-0009">Table 7</a> summarizes the reported harms according to organ systems and individual events. </p> <div class="figure" id="CD013011-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Comparison 2 IR methylphenidate vs Placebo, Outcome: Harms (total of events among patients who had experienced at least one event)" data-id="CD013011-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 IR methylphenidate vs Placebo, Outcome: Harms (total of events among patients who had experienced at least one event) </p> </div> </div> </div> <div class="table" id="CD013011-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Harms according to organ system classification and individual events in participants treated with IR methylphenidate versus placebo</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with IR methylphenidate</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Organ system category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Organ system category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tachycardia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tachycardia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Elevated blood pressure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palpitations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="7" scope="col" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7</p> </td> <th align="left" class="headercell" colspan="1" rowspan="7" scope="col" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal complaints</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal complaints</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal problem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal problem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or upset stomach</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or upset stomach</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stomach aches</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metabolism and nutrition disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased in appetite/Loss of appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metabolism and nutrition disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased in appetite/Loss of appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Nervous system disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Nervous system disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="11" scope="col" valign="top"> <p><b>Psychiatric disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <th align="left" class="headercell" colspan="1" rowspan="11" scope="col" valign="top"> <p><b>Psychiatric disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disorientation, insomnia, and anxiety lasting several hours</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Euphoric, unusually happy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Euphoric, unusually happy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insomnia or trouble sleeping</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moody</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moody</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sadness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sadness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stare a lot or daydream</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stare a lot or daydream</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Talk less with others</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Talk less with others</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics or nervous movements</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics or nervous movements</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleeping problems (difficulty/trouble sleeping, insomnia, nightmares)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleeping problems (difficulty/trouble sleeping, insomnia, nightmares)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nonspecific symptoms</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nonspecific symptoms</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7</p> </td> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Total events</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>438</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>100</b> </p> </td> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Total events</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>213</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>100</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IR: Immediate release</p> </div> </div> <p>There was no difference in the reported cardiovascular adverse events between participants receiving IR methylphenidate and those receiving placebo; however, data on cardiovascular adverse events were reported inconsistently, which prevents a comprehensive analysis. The available reports are described in <a href="#CD013011-tbl-0010">Table 8</a>. </p> <div class="table" id="CD013011-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Cardiovascular events reported narratively in the included studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Electrocardiogram</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Heart rate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Diastolic blood pressure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systolic blood pressure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Blood pressure</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant increase of diastolic blood pressure between baseline and methylphenidate"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased in participants receiving IR methylphenidate (mean = 123 mmHg) compared with placebo (mean 128 = mmHg) (P &lt; 0.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mean heart rate was 4.8 beats/min higher (p=0.002) after IR‐MPH"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The diastolic blood pressure remained virtually unchanged"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The systolic blood pressure was 0.13 mmHg higher after methylphenidate but this was not statistically significant (p=0.954)" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant receiving IR methylphenidate with elevated blood pressure, worst occurrence reported only </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0075"> <li> <p>Increased in electrocardiogram ventricular rate in participants receiving IR methylphenidate in comparison with placebo </p> </li> <li> <p>Corrected QT interval (QTc) increased in participants receiving IR methylphenidate (mean = 0.420, SD = 0.02) compared with placebo (mean = 0.413, SD = 0.02); week 6 vs week 0, P &lt; 0.01 </p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Small but statistically significant increases in pulse (83 ± 13 vs. 76 ± 13 bpm, t=4.4, df(77), p&lt;.001" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No increase in participants receiving IR methylphenidate (mean = 78 mmHg, SD = 9 mmHg) in comparison with placebo (mean = 76 mmHg, SD = 9 mmHg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No increase in participants receiving IR methylphenidate (mean = 128 mmHg, SD = 12 mmHg) in comparison with placebo (mean = 126 mmHg, SD = 14 mmHg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>bpm: beats of the heart per minute<br/>df: degrees of freedom<br/>IR: immediate‐release<br/>SD: standard deviation </p> </div> </div> <p>Additional data were also reported narratively for body weight‐related events, although inconsistent reporting prevented further analysis: </p> <p> <ol id="CD013011-list-0076"> <li> <p>in <a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>, "There was no significant weight loss"; and </p> </li> <li> <p>in <a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>, "Mean body weight was 1.7 kg lower (p &lt; 0.001) after methylphenidate treatment compared to placebo". </p> </li> </ol> </p> </section> </section> <section id="CD013011-sec-0095"> <h5 class="title">Secondary outcomes</h5> <section id="CD013011-sec-0096"> <h6 class="title">Changes in the clinical impression measures of severity</h6> <p>Two trials (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>) reported data from 139 participants on the clinical impression of ADHD symptom severity, measured by the CGI‐S scale (scores range from one (very much improved) to seven (very much worse)). The trials reported change scores and end scores, and the available data were pooled in a meta‐analysis. The results demonstrate a decrease in the severity of ADHD symptoms in participants treated with IR methylphenidate compared to those treated with placebo (MD −0.57, 95% CI −0.85 to −0.28; I<sup>2</sup> = 0%; <a href="./references#CD013011-fig-0010" title="">Analysis 1.5</a>; very low‐certainty evidence). We did not observe changes in the results after excluding the cross‐over trial from the analysis (MD −0.60, 95% CI −0.92 to −0.28). </p> <p>One trial (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>) provided a narrative description of the results: "Response rates based on the primary outcome of CGI response were 64% for bupropion, 50% for IR methylphenidate, and 27% for placebo. There was not a significantly greater response rate observed in the active treatment groups than in the placebo group (p = 0.14)." </p> </section> <section id="CD013011-sec-0097"> <h6 class="title">Changes in the clinical impression measures of improvement</h6> <p>One trial (<a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>) provided data from 49 participants on the clinical impression of improvement of ADHD symptoms, measured by the CGI‐I scale (scores range from one (very much improved) to seven (very much worse)). The results were available for the scores measured at the end of the follow‐up period. The data suggest that IR methylphenidate increased the clinical impression of improvement in ADHD symptoms (MD −0.94, 95% CI −1.37 to −0.51; <a href="./references#CD013011-fig-0011" title="">Analysis 1.6</a>; low‐certainty evidence). </p> </section> <section id="CD013011-sec-0098"> <h6 class="title">Level of functioning</h6> <p>Outcome measurement on level of functioning on the GAF scale (0 to 100) was reported narratively by one trial: "The mean difference between IR methylphenidate and placebo response of completers constitutes an 11% difference from baseline (end point placebo – end point IR methylphenidate/baseline IR methylphenidate; t = 3.4, df = 94, p &lt; .01)" (<a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>). The remaining trials accessing level of functioning did not report results (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). </p> </section> <section id="CD013011-sec-0099"> <h6 class="title">Anxiety and depression</h6> <p>One RCT with a parallel design (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>) provided data from 19 participants on changes in symptoms of anxiety and depression in adults with ADHD. It is uncertain whether, compared with placebo, IR methylphenidate impacts symptoms of anxiety (MD −0.20, 95% CI −4.84 to 4.44; <a href="./references#CD013011-fig-0012" title="">Analysis 1.7</a>; very low‐certainty evidence). Compared with placebo, the effects of IR methylphenidate on symptoms of depression in adults with ADHD were also uncertain (MD 2.80, 95% CI −0.09 to 5.69; <a href="./references#CD013011-fig-0013" title="">Analysis 1.8</a>; very low‐certainty evidence). The results were based on scores on the HAM‐A (scores range from 0 to 56) and HAM‐D (scores range from 0 to 52) scales, respectively. </p> <p>Two other trials provided a narrative description of the results for anxiety and depression.</p> <p> <ol id="CD013011-list-0077"> <li> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>: "Methylphenidate was associated with higher symptom levels of depression and anxiety than placebo, as was apparent from higher HAM‐D and HAM‐A scores: 2.4 (p=0.002) and 2.9 (p=0.002) points, respectively. When defined as a HAM‐D &gt;16, 11% (n=5) had depression after methylphenidate compared to 9% (n=4) after placebo. When defined as a HAM‐A &gt;21, 7% (n=3) had anxiety after methylphenidate compared to 4% (n=2) after placebo". </p> </li> <li> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]">Bouffard 2003</a>: "There was a reduction in anxiety and depression scores with both placebo and methylphenidate. However, methylphenidate was significantly superior to placebo in reducing anxiety scores (P &lt; 0.05), and there was a trend for it to be superior in reducing depression scores". </p> </li> </ol> </p> </section> </section> </section> <section id="CD013011-sec-0100"> <h4 class="title">IR methylphenidate versus OROS methylphenidate</h4> <p>One trial (<a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>) compared the treatment effects of OROS methylphenidate in adults who were respondents to treatment with the IR formulation of methylphenidate and switched to treatment with the OROS formulation of methylphenidate. </p> <section id="CD013011-sec-0101"> <h5 class="title">Primary outcomes</h5> <section id="CD013011-sec-0102"> <h6 class="title">Efficacy: changes in symptoms of ADHD</h6> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a> reported only narrative results on changes in symptoms of ADHD from an analysis of 53 participants: "There was no clinically or statistically significant difference, F(1, 52) = 0.1, p = .7, between the treatment groups in the AISRS rating scale through 6 weeks of treatment". </p> </section> <section id="CD013011-sec-0103"> <h6 class="title">Harms</h6> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a> reported data on changes in cardiac parameters. Additional data on spontaneously‐reported emergent adverse events were described in a figure with non‐extractable data. </p> <p>A total of eight participants reported discontinuing treatment while receiving IR methylphenidate and none while receiving OROS methylphenidate. There were a total of seven adverse events experienced by people receiving IR methylphenidate (median number of events experienced by people who had events = 2, IQR = 1 to 4), while 21 adverse events were experienced by people receiving OROS methylphenidate (median number of events experienced by people who had events = 6, IQR = 1 to 14). <a href="#CD013011-tbl-0011">Table 9</a> summarizes the reported harms according to organ systems and individual events. </p> <div class="table" id="CD013011-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Harms according to organ system classification and number of individual events in participants treated with IR methylphenidate versus OROS methylphenidate</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with IR methylphenidate</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with OROS methylphenidate</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Organ system category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Organ system category</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>%</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic blood pressure &gt; 90 mm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic blood pressure &gt; 90 mm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulse &gt; 90 bpm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulse &gt; 90 bpm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic blood pressure &gt; 140 mm Hg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic blood pressure &gt;140 mm Hg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total events</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total events</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>21</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>bpm: beats per minute<br/>IR: immediate release<br/>OROS: osmotic release oral system </p> </div> </div> </section> </section> <section id="CD013011-sec-0104"> <h5 class="title">Secondary outcomes</h5> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a> did not measure any of the secondary outcomes. </p> </section> </section> <section id="CD013011-sec-0105"> <h4 class="title">IR methylphenidate versus lithium</h4> <p>One trial with a cross‐over design (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>) investigated treatment with IR methylphenidate versus lithium. </p> <section id="CD013011-sec-0106"> <h5 class="title">Primary outcomes</h5> <section id="CD013011-sec-0107"> <h6 class="title">Efficacy: changes in symptoms of ADHD</h6> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a> assessed changes in the symptoms of ADHD using an investigator‐rated scale and reported end scores. Based on the available data from 46 participants, it is uncertain whether IR methylphenidate increases or decreases symptoms of ADHD (MD 0.60, 95% CI −3.11 to 4.31; <a href="./references#CD013011-fig-0014" title="">Analysis 2.1</a>; very low‐certainty evidence) assessed by the CAARS scale (scores range from 0 to 198), compared with lithium. </p> </section> <section id="CD013011-sec-0108"> <h6 class="title">Harms</h6> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a> provided data on the number of participants experiencing adverse events. Three participants were reported to have discontinued treatment while receiving IR methylphenidate and one while receiving lithium. </p> <p>There were a total of five adverse events experienced by people receiving IR methylphenidate (median number of events experienced by people who had events = 1, IQR = 0 to 2), while nine adverse events were experienced by people receiving lithium (median number of events experienced by people who had events = 2, IQR = 1 to 4). <a href="#CD013011-tbl-0012">Table 10</a> summarizes the reported harms according to organ systems and individual events. </p> <div class="table" id="CD013011-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Harms according to organ system classification and number of individual events in participants treated with IR methylphenidate versus lithium</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with IR methylphenidate</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with lithium</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Organ system category</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Organ system category</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orthostatic hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest discomfort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60</p> </td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nervous system disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nervous system disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total events</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total events</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IR: immediate release</p> </div> </div> </section> </section> <section id="CD013011-sec-0109"> <h5 class="title">Secondary outcomes</h5> <section id="CD013011-sec-0110"> <h6 class="title">Anxiety and depression</h6> <p>Data from 46 participants recruited by <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a> were unclear on the effects of IR methylphenidate versus lithium for improving symptoms of anxiety (MD −0.80, 95% CI −4.49 to 2.89; <a href="./references#CD013011-fig-0015" title="">Analysis 2.2</a>), assessed by the HAM‐A (scores range from 0 to 56), and depression (MD −1.20, 95% CI −3.81 to 1.41; <a href="./references#CD013011-fig-0016" title="">Analysis 2.3</a>) assessed by the HAM‐D ( scores range from 0 to 52) scales. We rated the certainty of this evidence as very low. </p> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a> did not report data on changes in the clinical impression of severity and improvement, or assess measures on level of functioning. </p> </section> </section> </section> <section id="CD013011-sec-0111"> <h4 class="title">IR methylphenidate versus extended‐release bupropion</h4> <p>One trial (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>) investigated treatment with IR methylphenidate versus extended‐release (SR) bupropion. The RCT implemented a parallel design and three comparison arms: IR methylphenidate versus bupropion versus placebo. To avoid multiplicity of the effect size, we selected the comparison between IR methylphenidate and placebo as the most relevant to answer our review question and omitted the comparison between IR methylphenidate and bupropion (see <a href="#CD013011-sec-0042">Data synthesis</a>). The IR methylphenidate and the placebo arms contributed data to the comparison between IR methylphenidate and placebo, previously explored in this section. </p> </section> <section id="CD013011-sec-0112"> <h4 class="title">IR methylphenidate versus Pycnogenol®</h4> <p>One trial (<a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>) compared the treatment of adults with ADHD with Pycnogenol® versus placebo in a three‐arm cross‐over trial (IR methylphenidate versus Pycnogenol® versus placebo). The trial reported incomplete data on initial scores from 24 participants on symptoms of ADHD, anxiety and depression, thereby not allowing further analysis. Changes in the clinical impression of severity and improvement, and level of functioning were not assessed or mentioned in the trial report. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013011-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013011-sec-0113"></div> <section id="CD013011-sec-0114"> <h3 class="title" id="CD013011-sec-0114">Summary of main results</h3> <p>In this review, we evaluated the evidence for the treatment of adults with ADHD with IR methylphenidate in comparison with placebo, OROS‐methylphenidate, lithium, SR‐bupropion, and Pycnogenol®. </p> <p>We found very low‐certainty evidence that IR methylphenidate could be more efficacious than a placebo in reducing ADHD symptoms when symptoms were rated by the trial’s investigators (<a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>). However, when participants rated their own symptoms (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]">Schubiner 2002</a>), there was no certain evidence that IR methylphenidate reduced the symptoms of ADHD. Overall, there was only low‐certainty evidence that IR methylphenidate might slightly improve the global clinical impression scores when compared to placebo, and uncertain evidence about its effect on ADHD symptoms when compared with lithium (<a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>). </p> <p>Compared with placebo, there was low‐certainty evidence that treatment with IR methylphenidate might result in a reduction in the clinical impression of the severity of ADHD symptoms (<a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]">Kooij 2004</a>; <a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>). Low‐certainty evidence suggests that, compared with placebo, adults treated with IR methylphenidate could have an increase in the clinical impression of improvement of ADHD symptoms (<a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]">Schrantee 2016</a>). However, we considered this potential treatment benefit at high risk of imprecision caused by single‐study results with small sample sizes (<a href="./references#CD013011-bbs2-0116" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020a</a>). There was very low‐quality evidence for the remaining outcomes across the comparisons among IR methylphenidate, placebo and lithium. Overall, incomplete and under‐reported data precluded further analysis and accurate assessment of treatment effects on the prespecified secondary outcomes among the remaining treatment comparisons of IR methylphenidate, OROS methylphenidate, SR‐bupropion, and Pycnogenol®. </p> <p>We found only narrative data for the comparison between IR and OROS methylphenidate; no clinically relevant difference between the treatment groups was reported (<a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>). Also, the data for the comparison between IR methylphenidate and Pycnogenol® were incomplete, thus precluding any analysis (<a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>). </p> <p>Finally, we did not undertake a pair‐wise comparison between IR methylphenidate and SR bupropion, in order to avoid multiplicity of effect size. The trial providing data on this comparison evaluated eight participants receiving IR methylphenidate in comparison with 11 participants receiving SR bupropion and 11 participants receiving placebo (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>). We judged that to include data on the IR methylphenidate group, it would be better to preserve the sample size for this comparison group. We therefore chose to select only the most relevant comparison to answer the review question (<a href="./references#CD013011-bbs2-0075" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>). Bupropion is not considered an option to treat adults with ADHD, so we focused on exploring whether IR methylphenidate could demonstrate any benefits to patients in comparison with treatment with placebo. </p> <p>In four trials, there was a two‐fold increase in the occurrence of adverse events among adults treated with IR methylphenidate in comparison with those treated with placebo. There was evidence that gastrointestinal (e.g. dry mouth, nausea and stomach aches) and metabolism and nutrition (appetite/weight‐related events) complications were notably more common in the group of participants treated with IR methylphenidate. Cardiovascular complications, which are one of the main concerns among people treated with methylphenidate (<a href="./references#CD013011-bbs2-0044" title="CADDRA - Canadian ADHD Resource Alliance. Canadian ADHD Practice Guidelines. In: CADDRA. 4.1 Edition. Toronto, ON: CADDRA, 2020.">CADDRA 2020</a>), were reported inconsistently and mainly as vague narrative reports. Overall, the information about adverse events is unclear. In all cases, we cannot be sure whether adverse events were not measured, were sought but not detected, or were measured but not included in the full publication. The absence of reporting should not automatically be assumed to equate to the absence of harms (<a href="./references#CD013011-bbs2-0086" title="LokeYK , MattishentK . If nothing happens, is everything all right? Distinguishing genuine reassurance from a false sense of security. Canadian Medical Association Journal2015;187(1):15-6. [DOI: 10.1503/cmaj.141344] [PMC4284159] [PMID: 25404394]">Loke 2015</a>). The lack of data on harms compromises risk assessments of the efficacy of IR methylphenidate for ADHD in adults. </p> <p>Of note, none of the included trials assessed quality of life and few studies included participants with comorbid disorders, which contrasts with the high prevalence of other psychiatric conditions diagnosed in people with ADHD (<a href="./references#CD013011-bbs2-0052" title="ChengYS , ShyuYC , LeeSY , YuanSS , YangCJ , YangKC , et al. Trends, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit hyperactivity disorder: a nationwide survey in Taiwan. Neuropsychiatric Disease and Treatment2017;13:643-51. [DOI: 10.2147/NDT.S126438] [PMC5338966] [PMID: 28280346]">Cheng 2017</a>; <a href="./references#CD013011-bbs2-0082" title="KesslerRC , AdlerL , BarkleyR , BiedermanJ , ConnersCK , DemlerO , et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of Psychiatry2006;163(4):716–23. [DOI: 10.1176/ajp.2006.163.4.716] [PMC2859678] [PMID: 16585449]">Kessler 2006</a>). </p> <p>All the above evidence should be considered in light of the low certainty of the evidence, the limited amount of trials evaluating each comparison, particularly change in symptoms, and the significant number of studies for which we had 'notable concerns' for a potential impact of vested interests on the results analyzed and reported (<a href="./references#CD013011-bbs2-0041" title="BoutronI , PageMJ , HigginsJP , AltmanDG , LundhA , HróbjartssonA . Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Boutron 2020</a>). Authors from four of the trials declared receiving funding from companies with a financial interest in the findings of IR methylphenidate for the treatment of ADHD in adults; authors from two studies omitted information related to the sources of funding and conflict of interests. </p> </section> <section id="CD013011-sec-0115"> <h3 class="title" id="CD013011-sec-0115">Overall completeness and applicability of evidence</h3> <p>The overall completeness and applicability of the evidence relating to the efficacy and harms of IR methylphenidate to treat adults with ADHD is limited by a number of factors. First, while several clinical trials, systematic reviews and meta‐analyses have been published on the effect of treating ADHD in children and adolescents with IR methylphenidate (<a href="./references#CD013011-bbs2-0049" title="CharachA , YeungE , ClimansT , LillieE . Childhood attention-deficit hyperactivity disorder and future substance use disorders: comparative meta-analyses. Journal of the American Academy of Child and Adolescent Psychiatry2011;50(1):9-21. [DOI: 10.1016/j.jaac.2010.09.019] [PMID: 21156266]">Charach 2011</a>; <a href="./references#CD013011-bbs2-0050" title="CharachA , CarsonP , FoxS , AliMU , BeckettJ , LimCG . Interventions for preschool children at high risk for ADHD: a comparative effectiveness review. Pediatrics2013;131(5):e1584–604. [DOI: 10.1542/peds.2012-0974] [PMID: 23545375]">Charach 2013</a>; <a href="./references#CD013011-bbs2-0072" title="HanwellaR , SenanayakeM , De SilvaV . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry2011;11:176. [DOI: 10.1186/1471-244X-11-176] [PMC3229459] [PMID: 22074258]">Hanwella 2011</a>; <a href="./references#CD013011-bbs2-0081" title="KambeitzJ , RomanosM , EttingerU . Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. Pharmacogenomics Journal2014;14(1):77–84. [DOI: 10.1038/tpj.2013.9] [PMID: 23588108]">Kambeitz 2014</a>; <a href="./references#CD013011-bbs2-0090" title="MaiaCR , CorteseS , CayeA , DeakinTK , PolanczykGV , PolanczykCA , et al. Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis. Journal of Attention Disorders2017;21(1):3-13. [DOI: 10.1177/1087054714559643] [PMID: 25501355]">Maia 2017</a>; <a href="./references#CD013011-bbs2-0110" title="PunjaS , ZorzelaL , HartlingL , UrichukL , VohraS . Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy. BMJ Open2013;3(3):e002312. [DOI: 10.1136/bmjopen-2012-002312] [PMC3612754] [PMID: 23503579]">Punja 2013</a>; <a href="./references#CD013011-bbs2-0112" title="ReichowB , VolkmarFR , BlochMH . Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders2013;43(10):2435–41. [DOI: 10.1007/s10803-013-1793-z] [PMC3787525] [PMID: 23468071]">Reichow 2013</a>; <a href="./references#CD013011-bbs2-0123" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009885. [DOI: 10.1002/14651858.CD009885.pub2]">Storebø 2015</a>), there is a dearth of such data on adults. Second, the limited data available do not include the analysis of the efficacy and harms of IR methylphenidate in people with psychiatric comorbidities. This is problematic, considering the high prevalence of psychiatric comorbidities in adults with ADHD (<a href="./references#CD013011-bbs2-0052" title="ChengYS , ShyuYC , LeeSY , YuanSS , YangCJ , YangKC , et al. Trends, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit hyperactivity disorder: a nationwide survey in Taiwan. Neuropsychiatric Disease and Treatment2017;13:643-51. [DOI: 10.2147/NDT.S126438] [PMC5338966] [PMID: 28280346]">Cheng 2017</a>; <a href="./references#CD013011-bbs2-0082" title="KesslerRC , AdlerL , BarkleyR , BiedermanJ , ConnersCK , DemlerO , et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of Psychiatry2006;163(4):716–23. [DOI: 10.1176/ajp.2006.163.4.716] [PMC2859678] [PMID: 16585449]">Kessler 2006</a>). </p> <p>Additionally, despite the high prevalence observed for the co‐occurrence of ADHD and ASD in adults (14% to 78%) (<a href="./references#CD013011-bbs2-0098" title="MuitJJ , BothofN , KanCC . Pharmacotherapy of ADHD in adults with autism spectrum disorder: effectiveness and side effects. Journal of Attention Disorders2020;24(2):215-25. [DOI: 10.1177/1087054719866255] [PMC6939322] [PMID: 31625426]">Muit 2020</a>), the dual diagnosis of ADHD and ASD or other psychiatric disorders was only introduced in the DSM‐5 (<a href="./references#CD013011-bbs2-0065" title="EpsteinJN , LorenRE . Changes in the definition of ADHD in DSM-5: subtle but important. Neuropsychiatry2013;3(5):455-8. [DOI: 10.2217/npy.13.59] [PMC3955126] [PMID: 24644516]">Epstein 2013</a>; <a href="./references#CD013011-bbs2-0104" title="PehlivanidisA , PapanikolaouK , MantasV , KalantziE , KorobiliK , Xenaki L-A, et al. Lifetime co-occurring psychiatric disorders in newly diagnosed adults with attention deficit hyperactivity disorder (ADHD) or/and autism spectrum disorder (ASD). BMC Psychiatry2020;20(1):423.">Pehlivanidis 2020</a>). All included trials in our review, however, used diagnostic criteria developed prior to the DSM‐5. This means that the evidence from our review may not apply to the treatment of people with both ADHD and ASD or other concomitant psychiatric disorders. Our findings should also be interpreted with caution, given the context of the Research Domain Criteria (RDoC) framework and Comparative Effectiveness Research (CER) approaches (<a href="./references#CD013011-bbs2-0102" title="National Institute of Mental Health. Research Domain Criteria (RDoC). www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/about-rdoc.shtml (accessed 1 October 2020).">NIMH 2020</a>), which operate under the framework of a larger spectrum of mental‐related disorders when exploring mental health and illness. </p> <p>The small sample sizes and the short duration of the available RCTs are other limitations of the trials included in this review. The small sample sizes limit the reliability of the findings, and the short durations of the RCTs are contradictory, given the chronic characteristic of ADHD and the need for long‐term treatment. Finally, the high heterogeneity among the clinical rating scales used to ascertain the effects of IR methylphenidate on the treatment of ADHD in adults impacts the interpretation of the available evidence. Obtaining standardized, comparable results from clinical trials is essential to allow for a proper synthesis and appraisal of the evidence. </p> </section> <section id="CD013011-sec-0116"> <h3 class="title" id="CD013011-sec-0116">Quality of the evidence</h3> <p>We judged the certainty of the evidence for most outcomes assessed in this review as very low, due to critical concerns over the 'Risk of bias' profiles of the individual studies, with high or unclear risk of bias in most domains (selection, performance, detection, attrition and reporting biases). </p> <p>Information on random sequence generation was available for only half of the trials; among those, we deemed a proportion (40%) to be at high risk of selection bias. Performance bias for masking of personnel was also inadequate in half of the available trials; it was rated at high risk of bias in three trials and three trials provided insufficient information to permit a judgment. Performance bias related to blinding of participants was the one domain in which we judged most trials (six) to be at low risk of bias. Most trials provided insufficient information to permit a judgment of detection bias, and most were also at high risk of attrition and selective reporting bias. </p> <p>Another reason to downgrade our certainty in the evidence was imprecision. Single‐study results with small sample sizes provided most of the evidence. The maximum number of participants providing data on the assessed outcomes was 157, significantly below the optimal information size (<a href="./references#CD013011-bbs2-0116" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020a</a>). Considering that we have notable concerns about vested interests influencing the results of the included trials, publication bias can be suspected as present and highly influencing the missing information on treatment harms. </p> </section> <section id="CD013011-sec-0117"> <h3 class="title" id="CD013011-sec-0117">Potential biases in the review process</h3> <p>We undertook a systematic and comprehensive search that, to the best of our knowledge, permitted us to identify all IR methylphenidate trials performed in adults with ADHD. We were also able to obtain additional missing data from one of the included trials. We did not, however, contact pharmaceutical industries and corresponding authors of the included publications to enquire about additional studies that we may have missed. We therefore cannot be assured that we found all relevant studies on the topic. </p> <p>Methylphenidate has been associated with potentially harmful effects (<a href="./references#CD013011-bbs2-0062" title="European Medicines Agency. Elements recommended for inclusion in summaries of product characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Methylphenidate_31/WC500011184.pdf (accessed 22 January 2018).">EMA 2009</a>; <a href="./references#CD013011-bbs2-0128" title="United States Food and Drug Administration. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events. tinyurl.com/yxltwhwy (accessed 22 January 2018).">US FDA 2007</a>). However, methods to detect adverse events were not consistently described in the included trials and most (five out nine trials) did not report these methods adequately. All trials lacked adequate reporting of harms experienced by participants. In general, the emphasis of RCT designs to assess treatment efficacy leads to an inadequate and biased assessment of harms (<a href="./references#CD013011-bbs2-0069" title="GolderS , LokeYK , BlandM . Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLOS Medicine2011;8(5):e1001026. [DOI: doi.org/10.1371/journal.pmed.1001026] [PMC3086872] [PMID: 21559325]">Golder 2011</a>; <a href="./references#CD013011-bbs2-0078" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737-9. [DOI: 10.1001/archinternmed.2009.313] [PMID: 19858427]">Ioannidis 2009</a>; <a href="./references#CD013011-bbs2-0086" title="LokeYK , MattishentK . If nothing happens, is everything all right? Distinguishing genuine reassurance from a false sense of security. Canadian Medical Association Journal2015;187(1):15-6. [DOI: 10.1503/cmaj.141344] [PMC4284159] [PMID: 25404394]">Loke 2015</a>; <a href="./references#CD013011-bbs2-0113" title="SainiP , LokeYK , GambleC , AltmanDG , WilliamsonPR , KirkhamJJ . Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ2014;349:g6501. [DOI: 10.1136/bmj.g6501]">Saini 2014</a>; <a href="./references#CD013011-bbs2-0115" title="SchrollJB , PenningaEI , GøtzschePC . Assessment of adverse events in protocols, clinical study reports, and published papers of trials of Orlistat: a document analysis. PLOS Medicine2016;13(8):e1002101. [DOI: 10.1371/journal.pmed.1002101] [PMC4987052] [PMID: 27529343]">Schroll 2016</a>). We are aware that the systematic evaluation of adverse drug events requires the inclusion of data from other study designs, mainly non‐randomized studies, and we are developing an additional systematic review to explore this question (<a href="./references#CD013011-bbs2-0142" title="CândidoRCF , GolderS , Menezes de PaduaCA , PeriniE , JunqueiraDR . Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD013011. [DOI: 10.1002/14651858.CD013011]">Cândido 2018</a>). </p> <p>In addition to the domains used to assess risks of bias, the way a study is conducted, the publication of its full results, the consistency between the comparisons made, and the format in which the results are presented are additional issues that are important to consider when assessing the risks of bias of a study (<a href="./references#CD013011-bbs2-0038" title="BeroL . Addressing bias and conflict of interest among biomedical researchers. JAMA2017;317(17):1723-4. [DOI: 10.1001/jama.2017.3854] [PMID: 28464166]">Bero 2017</a>). A study may be carried out with methodological rigor, and thus present at low risk of bias, and yet its results may be biased (<a href="./references#CD013011-bbs2-0038" title="BeroL . Addressing bias and conflict of interest among biomedical researchers. JAMA2017;317(17):1723-4. [DOI: 10.1001/jama.2017.3854] [PMID: 28464166]">Bero 2017</a>). In this context, conflicts of interest, including research and individual sponsorship, can be a relevant source of bias in a trial’s results (<a href="./references#CD013011-bbs2-0088" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3] [PMID: 28207928]">Lundh 2017a</a>; <a href="./references#CD013011-bbs2-0089" title="LundhA , BeroL . The ties that bind. BMJ2017;356:j176. [DOI: 10.1136/bmj.j176] [PMID: 28096082]">Lundh 2017b</a>). </p> <p>In this review, funding sources and potential conflict of interests were reported in all but two included trials (<a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]">Carpentier 2005</a>; <a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]">Dorrego 2002</a>). Among the studies that received funding from pharmaceutical industries (<a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]">Kuperman 2001</a>; <a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]">Spencer 2005</a>; <a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]">Spencer 2011</a>; <a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]">Tenenbaum 2002</a>), two showed favorable results for the use of IR methylphenidate, and two demonstrated no benefit in the use of the drug. Notably, the trials demonstrating no benefits of IR methylphenidate were designed to evaluate the efficacy of a different drug as a therapeutic alternative for the treatment of ADHD in adults. Caution is therefore recommended in the analysis of the results synthesized from the studies included in this review; besides methodological biases, they also presented with important potential influences from conflicts of interest favoring beneficial results associated with the use of a drug of interest. </p> </section> <section id="CD013011-sec-0118"> <h3 class="title" id="CD013011-sec-0118">Agreements and disagreements with other studies or reviews</h3> <p>Two previous systematic reviews with network meta‐analyses have assessed the effects of methylphenidate for treating ADHD in adults (<a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a>, <a href="./references#CD013011-bbs2-0107" title="PetersonK , McDonaghMS , FuR . Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology2008;197(1):1-11. [DOI: 10.1007/s00213-007-0996-4] [PMID: 18026719]">Peterson 2008</a>). <a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a> estimated the efficacy of different medicines for the improvement of ADHD symptoms in children, adolescents, and adults in double‐blinded RCTs of pharmacological treatment of ADHD. Amphetamines were considered a better option to treat ADHD in adults compared with placebo, followed by methylphenidate (<a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a>). <a href="./references#CD013011-bbs2-0107" title="PetersonK , McDonaghMS , FuR . Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology2008;197(1):1-11. [DOI: 10.1007/s00213-007-0996-4] [PMID: 18026719]">Peterson 2008</a> compared shorter‐acting stimulant drugs (including IR methylphenidate), longer‐acting stimulant drugs and longer‐acting forms of bupropion. They found a higher rate of clinical response of shorter‐acting stimulant drugs compared to placebo, longer‐acting stimulant drugs and longer‐acting forms of bupropion. Methylphenidate was also found to cause appetite loss, sleep disturbances (<a href="./references#CD013011-bbs2-0107" title="PetersonK , McDonaghMS , FuR . Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology2008;197(1):1-11. [DOI: 10.1007/s00213-007-0996-4] [PMID: 18026719]">Peterson 2008</a>), weight loss and increased systolic and diastolic blood pressure (<a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a>). Differences in the methodological and analytical approaches undertaken by <a href="./references#CD013011-bbs2-0055" title="CorteseS , AdamoN , Del GiovaneC , Mohr-JensenC , HayesAJ , CarucciS , et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet. Psychiatry2018;5(9):727-38. [DOI: 10.1016/S2215-0366(18)30269-4] [PMC6109107] [PMID: 30097390]">Cortese 2018</a>, <a href="./references#CD013011-bbs2-0107" title="PetersonK , McDonaghMS , FuR . Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology2008;197(1):1-11. [DOI: 10.1007/s00213-007-0996-4] [PMID: 18026719]">Peterson 2008</a> and our review limit comparison among the results. However, there are similarities among the adverse events found to be induced by treatment with methylphenidate. </p> <p>We rated the certainty of the evidence in this review mainly as very low, which is comparable with the certainty‐of‐evidence ratings reported by other Cochrane Reviews assessing the effects of methylphenidate treatment for ADHD in children and adolescents (<a href="./references#CD013011-bbs2-0046" title="CastellsX , Blanco-SilventeL , CunillR . Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD007813. [DOI: 10.1002/14651858.CD007813.pub3]">Castells 2018</a>; <a href="./references#CD013011-bbs2-0111" title="PunjaS , ShamseerL , HartlingL , UrichukL , VandermeerB , NiklesJ , et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD009996. [DOI: 10.1002/14651858.CD009996.pub2] [PMID: 26844979]">Punja 2016</a>; <a href="./references#CD013011-bbs2-0123" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009885. [DOI: 10.1002/14651858.CD009885.pub2]">Storebø 2015</a>). The validity and certainty of the evidence for the effects of pharmacological treatments for ADHD are limited by factors that include attrition bias, failure to blind participants, personnel, and outcome detection, selection bias, reporting bias and statistical heterogeneity (<a href="./references#CD013011-bbs2-0046" title="CastellsX , Blanco-SilventeL , CunillR . Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD007813. [DOI: 10.1002/14651858.CD007813.pub3]">Castells 2018</a>; <a href="./references#CD013011-bbs2-0111" title="PunjaS , ShamseerL , HartlingL , UrichukL , VandermeerB , NiklesJ , et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD009996. [DOI: 10.1002/14651858.CD009996.pub2] [PMID: 26844979]">Punja 2016</a>; <a href="./references#CD013011-bbs2-0123" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD009885. [DOI: 10.1002/14651858.CD009885.pub2]">Storebø 2015</a>). Improving the validity and the quality of primary studies investigating the efficacy and harms of pharmacological treatments for ADHD is essential to increase the reliability of the findings of this and other systematic reviews. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013011-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram illustrating the results of the study selection process." data-id="CD013011-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram illustrating the results of the study selection process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013011-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013011-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 IR methylphenidate versus Placebo, Outcome: Symptom of ADHD" data-id="CD013011-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Comparison 1 IR methylphenidate versus Placebo, Outcome: Symptom of ADHD</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IR methylphenidate vs Placebo, Outcome: Harms (total of events among patients who had experienced at least one event)" data-id="CD013011-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Comparison 2 IR methylphenidate vs Placebo, Outcome: Harms (total of events among patients who had experienced at least one event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IR methylphenidate versus placebo, Outcome 1:  Efficacy: investigator‐rated (end scores)" data-id="CD013011-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: IR methylphenidate versus placebo, Outcome 1:  Efficacy: investigator‐rated (end scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IR methylphenidate versus placebo, Outcome 2: Efficacy: participant‐rated (change scores)" data-id="CD013011-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: IR methylphenidate versus placebo, Outcome 2: Efficacy: participant‐rated (change scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IR methylphenidate versus placebo, Outcome 3: Efficacy: participant‐rated (end scores)" data-id="CD013011-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: IR methylphenidate versus placebo, Outcome 3: Efficacy: participant‐rated (end scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IR methylphenidate versus placebo, Outcome 4: Harms: patients experiencing at least one adverse event" data-id="CD013011-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: IR methylphenidate versus placebo, Outcome 4: Harms: patients experiencing at least one adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IR methylphenidate versus placebo, Outcome 5: Clinical impression: severity (change scores)" data-id="CD013011-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: IR methylphenidate versus placebo, Outcome 5: Clinical impression: severity (change scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IR methylphenidate versus placebo, Outcome 6: Clinical impression: improvement (end scores)" data-id="CD013011-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: IR methylphenidate versus placebo, Outcome 6: Clinical impression: improvement (end scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IR methylphenidate versus placebo, Outcome 7: Anxiety: investigator‐rated (change scores)" data-id="CD013011-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: IR methylphenidate versus placebo, Outcome 7: Anxiety: investigator‐rated (change scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IR methylphenidate versus placebo, Outcome 8: Depression: investigator‐rated (change scores)" data-id="CD013011-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: IR methylphenidate versus placebo, Outcome 8: Depression: investigator‐rated (change scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: IR methylphenidate versus lithium, Outcome 1: Efficacy: investigator‐rated (end scores)" data-id="CD013011-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: IR methylphenidate versus lithium, Outcome 1: Efficacy: investigator‐rated (end scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: IR methylphenidate versus lithium, Outcome 2: Anxiety: investigator‐rated (end scores)" data-id="CD013011-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: IR methylphenidate versus lithium, Outcome 2: Anxiety: investigator‐rated (end scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013011-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/urn:x-wiley:14651858:media:CD013011:CD013011-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: IR methylphenidate versus lithium, Outcome 3: Depression: investigator‐rated (end scores)" data-id="CD013011-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_t/tCD013011-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: IR methylphenidate versus lithium, Outcome 3: Depression: investigator‐rated (end scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/media/CDSR/CD013011/image_n/nCD013011-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013011-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Immediate‐release methylphenidate versus placebo for attention deficit hyperactivity disorder (ADHD) in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Immediate‐release methylphenidate versus placebo for attention deficit hyperactivity disorder (ADHD) in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with ADHD (available evidence for participants aged between 25 to 53 years old)<br/><b>Setting:</b> outpatients and inpatients<br/><b>Intervention:</b> immediate‐release methylphenidate<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with</b> </p> <p><b>placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with immediate‐release methylphenidate</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy (changes in symptoms of ADHD): investigator‐rated</b><br/>Assessed with: Adult ADHD Investigator Symptom Report Scale (AISRS; scores range from 0 to 54); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy score</p> <p>in the control group was <b>33.8 points</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy score in the intervention group was <b>20.70 points lower</b> (23.97 lower to 17.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may reduce symptoms of ADHD when rated by investigators but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy (changes in symptoms of ADHD): participant‐rated</b> <br/>Assessed with: Barkley's ADHD Problem Behaviours Scale (scores range from 0 to 42); ADHD Rating Scale‐IV (scores range from 0 to 54)); higher scores indicate an increase in symptom occurrence or illness severity </p> <p>Follow‐up: range = 7 weeks to 12 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean efficacy score in the intervention group was <b>0.59 points lower</b> (1.25 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may have a moderate to no effect on symptoms of ADHD when rated by participants but the evidence is very uncertain. </p> <p><i>The effect would represent a moderate difference between the control and the intervention group. As a rule of thumb, 0.2 points represents a small difference, 0.5 a moderate and 0.8 a large effect.</i> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical impression: severity </b><br/>Assessed with: Clinical Global Impression ‐ Severity index (scored from 1 = very much improved to 7 = very much worse)<br/>Follow‐up: range = 7 weeks to 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical impression of symptom severity score in the intervention groups was <b>0.57 points lower</b> (0.85 lower to 0.28 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores and Change scores. IR methylphenidate may reduce clinicians' impressions of the severity of ADHD symptoms but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical impression: improvement</b><br/>Assessed with: Clinical Global Impression ‐ Improvement index (scored from 1 = very much improved to 7 = very much worse)<br/>Follow‐up: mean = 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical impression of improvement score in the control group was <b>3.54 points</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical impression of improvement score in the intervention group was <b>0.94 points lower</b> (1.37 lower to 0.51 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>L<b>ow</b><sup>b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may slightly increase clinicians' impressions of improvement in ADHD symptoms. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anxiety: investigator‐rated</b><br/>Assessed with: Hamilton Anxiety Scale (scores range from 0 to 56); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score in the intervention group was <b>0.20 points lower</b> (4.84 lower to 4.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change scores. There is no clear evidence of an effect, but the evidence is very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression: investigator‐rated</b><br/>Assessed with: Hamilton Depression Scale (scores range from 0 to 52); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression score in the intervention group was <b>2.80 points higher</b> (0.09 lower to 5.69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change scores. There is no clear evidence of an effect, but the evidence is very uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: adverse events</b> (poorly assessed and reported) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Among participants experiencing at least 1 adverse event, the use of IR methylphenidate increased the risk of gastrointestinal complications (RR 1.96, 95% CI 1.13 to 2.95) and loss of appetite (RR 1.77, 95% CI 1.06 to 2.96). Cardiovascular adverse events were reported inconsistently, preventing a comprehensive analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> ‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IR methylphenidate may increase the risk of gastrointestinal adverse events and loss of appetite. It is unclear whether IR methylphenidate induces cardiovascular adverse events. </p> <p>Overall, adverse events were poorly assessed and reported in all included studies. We considered all studies to be at high risk of bias due to selective outcome reporting of harms and masking of the outcome assessor (failure to blind outcome assessor to measure harms). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b>  was the median control group risk across studies. The <b>corresponding risk</b>  (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADHD:</b> Attention deficit hyperactivity disorder; <b>CI:</b> Confidence interval; <b>IR:</b> immediate‐release; <b>IV:</b> Fourth version; <b>MD:</b>  Mean difference; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to high and unclear risk of bias in multiple criteria (random sequence generation, allocation concealment, blinding of outcome assessors, incomplete outcome data, and selective outcome reporting).<br/><sup>b</sup>Downgraded once for imprecision caused by small sample size or single study results, or both.<br/><sup>c</sup>Downgraded twice due to high and unclear risk of bias in multiple criteria (allocation bias, blinding of outcome assessors, incomplete outcome data, and selective outcome reporting).<br/><sup>d</sup>Downgraded once for unclear risk of bias of outcome assessment and selective outcome reporting.<br/><sup>e</sup>Downgraded twice due to high and unclear risk of bias in multiple criteria (random sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessors). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Immediate‐release methylphenidate versus placebo for attention deficit hyperactivity disorder (ADHD) in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013011-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Immediate‐release methylphenidate versus lithium for attention deficit hyperactivity disorder (ADHD) in adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Immediate‐release methylphenidate versus lithium for attention deficit hyperactivity disorder (ADHD) in adults</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with ADHD (available evidence for participants aged between 25 to 53 years old)<br/><b>Setting:</b> inpatients receiving treatment for various substance‐use disorders<br/><b>Intervention:</b> immediate‐release methylphenidate<br/><b>Comparison:</b> lithium </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants</b> </p> <p><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with lithium</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with immediate‐release methylphenidate</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy (changes in symptoms of ADHD): investigator‐rated</b><br/>Assessed with: Conners’ Adult ADHD Rating Scale (scores range from 0 to 198); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 18 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy score in the control group was <b>28.4 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean efficacy score in the intervention group was <b>0.60 points higher</b> (3.11 lower to 4.31 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. It is uncertain whether IR methylphenidate is more effective than lithium.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Efficacy (changes in symptoms of ADHD): participant‐rated ‐ not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical impression: severity</b> <br/><b>‐ not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical impression: improvement</b> <br/><b>‐ not reported</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anxiety: investigator‐rated</b><br/>Assessed with: Hamilton Anxiety Scale (scores range from 0 to 56); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 18 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score in the control group was <b>6.2 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score in the intervention group was <b>0.80 points lower</b> (4.49 lower to 2.89 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may have little to no effect on anxiety but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Depression: investigator‐rated</b><br/>Assessed with: Hamilton Depression Scale (scores range from 0 to 52); higher scores indicate an increase in symptom occurrence or illness severity<br/>Follow‐up: mean = 18 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression score in the control group was <b>7.8 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression score in the intervention group was <b>1.20 points lower</b> (3.81 lower to 1.41 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores. IR methylphenidate may have little to no effect on depression but the evidence is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms:</b>  <b>adverse events</b> (poorly assessed and reported) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 trial comparing IR methylphenidate to lithium reported 5 and 9 adverse events, respectively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were poorly assessed and reported in all included studies. We considered all studies to be at high risk of bias due to selective outcome reporting of harms and masking of the outcome assessor (failure to blind outcome assessor to measure harms). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b>  was the median control group risk across studies. The <b>corresponding risk</b>  (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADHD:</b> Attention deficit hyperactivity disorder; <b>CI:</b> Confidence interval; <b>IR:</b> immediate‐release; <b>MD:</b>  Mean difference; <b>RCT:</b> Randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to unclear risk of bias in several domains (random sequence generation, allocation concealment, blinding of outcome assessment, incomplete and selective outcome reporting) and high risk of bias due to incomplete outcome data.<br/><sup>b</sup>Downgraded once due to small sample size and single‐study effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Immediate‐release methylphenidate versus lithium for attention deficit hyperactivity disorder (ADHD) in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method section</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Reason for non‐use</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Types of outcomes</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to measure the primary efficacy outcome over the short term (within six months) and long term (longer than 6 months) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data were not available as no study lasted more than 4.5 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to measure serious adverse events as the primary outcome of harms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies assessed serious adverse events according to the definition of the International Council for Harmonisation (<a href="./references#CD013011-bbs2-0077" title="International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline for Good Clinical Practice E6(R2). www.ich.org/page/efficacy-guidelines (accessed 10 July 2019).">ICH 2016</a>) </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Selection of studies</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to contact the authors of studies whenever there was insufficient information available to decide whether a study was eligible for inclusion. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This action was not necessary for the ongoing studies</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assessment of risk of bias</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to revise the 'Risk of bias' domains for randomized controlled trials if new guidelines were released during the development of this review. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When we came to the completion of this review, Cochrane had released a new 'risk of bias' tool but had not yet made it mandatory for all Cochrane Reviews; it is being piloted with only a few reviews within Cochrane. Future updates of this review will take any related updates into account </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Measures of treatment effect &gt; Continuous outcomes</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For studies reporting outcome values other than the mean and standard deviation, we planned to apply standard errors, CI, t values and P values to estimate the results, whenever possible </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of these additional data were reported and thus we were not able to estimate any missing results. We contacted study authors to request the additional information but have not received response </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If skewed data were detected, we planned to consult a statistician on the best data transformation approach </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not encounter this situation; therefore, it was not necessary to consult a statistician </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Unit of analysis issues &gt; Cross‐over trials</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to estimate within‐participant differences between the intervention groups at the end of the study follow‐up period, using the MD and standard deviation to conduct a paired analysis and avoid a unit‐of‐analysis error (<a href="./references#CD013011-bbs2-0061" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9. [PMID: 11914310]">Elbourne 2002</a>; <a href="./references#CD013011-bbs2-0075" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial reported participant‐level differences between intervention groups</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assessment of heterogeneity</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to investigate clinical heterogeneity through subgroup analyses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient data evaluated and reported in the included studies to allow us to undertake subgroup analyses </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assessment of reporting bias</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to use funnel plots to investigate the presence of publication bias (the selective publication of trials with positive findings), and other small‐study effects, among the studies included in the review (<a href="./references#CD013011-bbs2-0103" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Page 2020</a>). We planed to use Egger's test to assess for funnel plot asymmetry (<a href="./references#CD013011-bbs2-0060" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMC2127453] [PMID: 9310563]">Egger 1997</a>), providing 10 or more trials were included in a meta‐analysis. We planned to consult a statistician in situations where we were unable to interpret the asymmetries objectively and when we might have considered alternative statistical tests (<a href="./references#CD013011-bbs2-0103" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Page 2020</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We could not assess reporting bias due to there being an insufficient number of trials (fewer than 10) in the quantitative analyses </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Data synthesis</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Where considerable heterogeneity (I<sup>2</sup> statistic greater than 75%) was detected, particularly in the presence of high inconsistency in the direction of effect, we planned not to calculate the average effect of the intervention through a meta‐analysis </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 study contributed data for most of the outcomes and comparisons; therefore, the insufficient data prevented an appropriate assessment of heterogeneity </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Subgroup analysis and investigation of heterogeneity</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to explore potential sources of heterogeneity if the available data from the studies allowed us to stratify participant subgroups by the following characteristics. </p> <p> <ol id="CD013011-list-0004"> <li> <p>Age of participants (trials with participants aged 19 to 35 years, 36 to 54 years or aged 55 years or more) </p> </li> <li> <p>Sex (female versus male participants)</p> </li> <li> <p>Dosage of methylphenidate (low dose (30 mg or less) versus high dose (more than 30 mg)) </p> </li> <li> <p>Multimorbidities (participants with multimorbidity versus participants without multimorbidity)</p> </li> <li> <p>Type of clinical scales used in diagnosis</p> </li> <li> <p>Duration of treatment (short‐term trials (six months or less) versus long‐term trials (more than 6 months)) </p> </li> <li> <p>Subtype of ADHD (predominantly inattentive type, or hyperactive or impulsive type, or combined type) </p> </li> </ol> </p> <p>We planned to calculate a pooled effect size for each subgroup</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient data evaluated and reported in the included studies to allow us to undertake subgroup analyses </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sensitivity analysis</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If there were an adequate number of studies (2 or more), we planned to perform a sensitivity analysis to explore the causes of heterogeneity and test the robustness of the results to decisions made during the development of the review. Specifically, we planned to reanalyze the data: </p> <p> <ol id="CD013011-list-0005"> <li> <p>excluding studies that we judged to be at high risk of selection bias, performance bias, detection bias or reporting bias; </p> </li> <li> <p>excluding studies in which more than 20% of participants were lost to follow‐up; and</p> </li> <li> <p>comparing unpublished versus published studies</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were insufficient studies included in the meta‐analyses to perform any of our preplanned sensitivity analyses </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Summary of findings and assessment of the certainty of the evidence</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We planned to describe the outcomes of interest over short (within 6 months) and long (longer than 6 months) periods of treatment </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials investigated the effects of treatment with IR methylphenidate in adults for a period longer than 18 weeks (4.5 months) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>CI: Confidence interval<br/>IR: immediate release<br/>MD: Mean difference </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Unused methods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to comparators, time points and measurements of the primary outcome of efficacy</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time points</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Investigator measurements</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Self‐report measurements</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measurements with complete data</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with parallel design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0010"> <li> <p>Bupropion SR</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks following a single‐blind, 7‐day placebo lead‐in</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult ADHD Symptom Checklist Severity Scale (ADHDRS); updated and validated for DSM‐IV ADHD criteria </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change scores and end scores</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]"><b>Schrantee 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult ADHD Symptom Checklist Severity Scale (ADHDRS); updated and validated for the DSM‐IV ADHD criteria </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks of treatment (13 weeks in total, including 1 week of baseline testing and 12 weeks of treatment) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barkley's ADHD Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Barkley's ADHD Rating Scale</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores for self‐reported measurements; investigator‐rated scores reported narratively</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult ADHD Investigator Symptom Report Scale (AISRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OROS methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult ADHD Investigator System Symptom Report Scale (AISRS)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data reported narratively</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with cross‐over design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0011"> <li> <p>Conners’ Adult ADHD Rating Scale</p> </li> <li> <p>Barkley ADHD Problem Behaviours Scale</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None. Only incomplete data (end means with P value and range)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]"><b>Carpentier 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks (4 treatment phases of 2 weeks each)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0012"> <li> <p>Barkley ADHD Problem Behaviours Scale</p> </li> <li> <p>ADHD Rating Scale‐IV</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None. Only incomplete data (t‐test values)</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 weeks with a 2‐week washout period in between treatment periods</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperactivity, Impulsivity, Learning Problems, Conduct Disorder, Restlessness, and Antisocial Behavior subscales of the Conners’ Adult ADHD Rating Scale </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 weeks, with 1 week of washout in between treatments periods</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADHD Rating Scale ‐ IV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End scores of the first period of treatment</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]"><b>Tenenbaum 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0013"> <li> <p>Pycnogenol®</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 weeks (2 weeks in each treatment separated by 1 washout week)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0014"> <li> <p>Barkley ADHD Problem Behaviours Scale<sup>a</sup> </p> </li> <li> <p>Attention Deficit Scales for Adults (ADSA)<sup>a</sup> </p> </li> <li> <p>Copeland Symptom Checklist for Adult Attention Deficit Disorders<sup>a</sup> </p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0015"> <li> <p>Barkley ADHD Problem Behaviours Scale</p> </li> <li> <p>Attention Deficit Scales for Adults (ADSA)</p> </li> <li> <p>Barratt Impulsiveness Scale</p> </li> <li> <p>Copeland Symptom Checklist for Adult Attention Deficit Disorders</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None. Only incomplete data (initial scores)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADHD: Attention deficit hyperactivity disorder<br/>OROS: osmotic release oral system<br/>SR: Sustained‐release </p> <p><sup>a</sup>Measurements reported by the individual’s significant other, not the trial investigator. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to comparators, time points and measurements of the primary outcome of efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reporting of harms in RCTs assessing the treatment of ADHD with IR methylphenidate</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reporting of harms outcomes</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0017"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on most common complaints</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0018"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on worst occurrence during the study</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0019"> <li> <p>Data on selected/composite outcomes</p> </li> <li> <p>Specific numbers of the results of the cardiovascular measurement not reported, only statistical results (e.g. “no statistically significant changes”) </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0020"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected cardiovascular events</p> </li> <li> <p>Remaining data not reported or reported in a non‐extractable way</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0021"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected events</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0022"> <li> <p>Physiological, cardiovascular, measures reported as continuous data with statistically significant/non‐significant analysis </p> </li> <li> <p>Data on selected events</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0023"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected events</p> </li> <li> <p>Additional cardiovascular events reported narratively with general statements of statistically significance/non‐significance </p> </li> </ol> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder<br/>IR: immediate release<br/>RCTs: randomized controlled trials </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reporting of harms in RCTs assessing the treatment of ADHD with IR methylphenidate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to the assessment and reporting of outcomes of harms</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Harms assessed?</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measurement method</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Time points</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>What results were reported?</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with parallel design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0024"> <li> <p>Bupropion SR</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At each return visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0025"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on most common complaints</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]"><b>Schrantee 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported, only a general statement included in the paper</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0026"> <li> <p>Adverse Effects Checklist based on <a href="./references#CD013011-bbs2-0035" title="BarkleyRA . Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York (NY): Guilford Press, 1990.">Barkley 1990</a> </p> </li> <li> <p>Cardiac symptoms</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weekly</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0027"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on worst occurrence of the adverse events during the study</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0028"> <li> <p>Open‐ended questions</p> </li> <li> <p>Electrocardiogram, heart rate, and blood pressure</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At each visit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0029"> <li> <p>Data on adverse events that the participant indicated the severity as 'pretty much' or 'very much' on a 4‐point Likert‐type scale ranging from 0 (not at all) to 3 (very much) </p> </li> <li> <p>Specific numbers of the results of the cardiovascular measurement not reported, only statistical results (e.g. “no statistically significant changes”). </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OROS methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0030"> <li> <p>Spontaneous reports prompted by open‐ended questions</p> </li> <li> <p>Tolerability index (Clinical Global Impression (CGI) Scale)</p> </li> <li> <p>Weight, vital signs and electrocardiogram</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0031"> <li> <p>At each visit: spontaneous reports, tolerability, weight and vital signs</p> </li> <li> <p>Study endpoint: electrocardiogram</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0032"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on cardiovascular events: systolic and diastolic blood pleasure, pulse</p> </li> </ol> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with cross‐over design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0033"> <li> <p>Physiological and cardiovascular measures reported as continuous data with statistically significant/non‐significant analysis </p> </li> <li> <p>Data on selected adverse events: weight, appetite loss, trouble sleeping, headache</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]"><b>Carpentier 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported, only a general statement included in the paper</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0034"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected adverse events: headaches, diarrhea, nausea, chest discomfort, orthostatic hypotension </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified Side Effects Rating Scale from <a href="./references#CD013011-bbs2-0036" title="BarkleyRA , MurphyKR . Attention-Deficit Hyperactivity Disorder: A Clinical Workbook. 2nd edition. New York (NY): Guilford Press, 1998.">Barkley 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0035"> <li> <p>Discontinuation due to adverse events</p> </li> <li> <p>Data on selected adverse events: tachycardia, dry mouth, dizziness, loss of appetite, abdominal complains, headache, tics, sleeping problems </p> </li> <li> <p>Additional cardiovascular events reported narratively with general statements of statistically significance/non‐significance </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]"><b>Tenenbaum 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0036"> <li> <p>Pycnogeno®l</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial did not access outcomes of harms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>N/A: not applicable<br/>OROS: osmotic release oral system<br/>SR: sustained release </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to the assessment and reporting of outcomes of harms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to comparators and measurements of the secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Secondary outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measurement methods</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>What results were reported?</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b><i>RCTs with parallel design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0041"> <li> <p>Bupropion SR</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0042"> <li> <p>Clinical impression of improvement</p> </li> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0043"> <li> <p>Clinical Global Impression (CGI) scale – Improvement (‐I)</p> </li> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0044"> <li> <p>Narrative results with general statements: CGI‐I</p> </li> <li> <p>Change scores: HAM‐A and HAM‐D</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]"><b>Schrantee 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0045"> <li> <p>Clinical impression of severity and improvement</p> </li> <li> <p>Global level of functioning</p> </li> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0046"> <li> <p>Clinical Global Impression Scale (CGI) – Severity (‐S) and Improvement (‐I)</p> </li> <li> <p>Global Assessment Functioning (GAF) scale</p> </li> <li> <p>Beck Depression Inventory (BDI)</p> </li> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change scores, end scores and baseline scores: CGI‐I and CGI‐S<sup>a</sup> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0047"> <li> <p>Clinical impression of severity</p> </li> <li> <p>Global level of functioning</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0048"> <li> <p>Clinical Global Impression (CGI) scale – Severity (‐S)</p> </li> <li> <p>Global Assessment Functioning (GAF) scale</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Narrative report with general statements: GAF</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>OROS methylphenidate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0049"> <li> <p>Clinical impression of severity and improvement</p> </li> <li> <p>Global level of functioning</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0050"> <li> <p>Clinical Global Impression (CGI) scale – Severity (‐S) and Improvement (‐I)</p> </li> <li> <p>Global Assessment Functioning (GAF) scale</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b><i>RCTs with cross‐over design</i> </b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0051"> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0052"> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Beck Depression Inventory (BDI)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data reported narratively with general statements for both outcomes</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]"><b>Carpentier 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0053"> <li> <p>Clinical impression improvement</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0054"> <li> <p>Clinical Global Impression (CGI) scale – Improvement (‐I), adapted for ADHD symptoms</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data reported incompletely for all outcomes</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lithium</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0055"> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0056"> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on end scores for both outcomes</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0057"> <li> <p>Clinical impression of severity and improvement</p> </li> <li> <p>Global level of functioning</p> </li> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0058"> <li> <p>Clinical Global Impression (CGI) scale – Severity (‐S)</p> </li> <li> <p>Global assessment of functioning (GAF) scale</p> </li> <li> <p>Hamilton Anxiety Scale (HAM‐A)</p> </li> <li> <p>Hamilton Depression Scale (HAM‐D)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on end scores for CGI‐S</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]"><b>Tenenbaum 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0059"> <li> <p>Pycnogenol®</p> </li> <li> <p>Placebo</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0060"> <li> <p>Anxiety</p> </li> <li> <p>Depression</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0061"> <li> <p>Beck Anxiety Inventory (BAI)</p> </li> <li> <p>Beck Depression Inventory (BDI)</p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data on initial scores for both outcomes</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADHD: attention deficit hyperactivity disorder<br/>OROS: osmotic release oral system<br/>SR: Sustained‐release </p> <p><sup>a</sup>Full dataset shared by the study authors. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Characteristics of included randomized controlled trials (RCTs) according to comparators and measurements of the secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Impact of sources of funding and conflict of interests on the results analyzed from the trials assessing the treatment of adults with ADHD with IR methylphenidate</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Judgment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rationale</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b><i>RCTs with parallel design</i> </b> <br/>  </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0005" title="KupermanS , PerryPJ , GaffneyGR , LundBC , Bever-StilleKA , ArndtS , et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry2001;13(3):129-34. [PMID: 11791949]"><b>Kuperman 2001</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0062"> <li> <p>Trial fully supported by a pharmaceutical company with a vested interest</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0006" title="SchranteeA , TammingaHG , BouzianeC , BottelierMA , BronEE , MutsaertsHJ , et al. Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit/hyperactivity disorder: a randomized clinical trial. JAMA Psychiatry2016;73(9):955-62. [DOI: 10.1001/jamapsychiatry.2016.1572] [PMC5267166 ] [PMID: 27487479]"><b>Schrantee 2016</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0063"> <li> <p>Research support received from research grants</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0064"> <li> <p>Research supported by research grants</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0065"> <li> <p>Authors have received consulting fees and sit on the advisory boards of pharmaceutical companies </p> </li> <li> <p>Research support received from several companies with a vested interest</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0009" title="SpencerTJ , MickE , SurmanCB , HammernessP , DoyleR , AleardiM , et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. Journal of Attention Disorders2011;15(4):286-94. [DOI: 10.1177/1087054710367880] [PMID: 20495161]"><b>Spencer 2011</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable concerns<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0066"> <li> <p>Authors have received consulting fees and sit on the advisory boards of pharmaceutical companies </p> </li> <li> <p>Research support received from several companies with a vested interest</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b><i>RCTs with cross‐over design</i> </b> <br/>  </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0067"> <li> <p>Research supported by research grants</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0002" title="CarpentierPJ , De JongCA , DijkstraBA , VerbruggeCA , KrabbePF . A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction2005;100(12):1868-74. [DOI: 10.1111/j.1360-0443.2005.01272.x] [PMID: 16367988]"><b>Carpentier 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0068"> <li> <p>Sources of funding and conflict of interests not reported </p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0003" title="DorregoMF , CanevaroL , KuzisG , SabeL , StarksteinSE . A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. Journal of Neuropsychiatry and Clinical Neurosciences2002;14(3):289-95. [DOI: 10.1176/jnp.14.3.289] [PMID: 12154153]"><b>Dorrego 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0069"> <li> <p>Sources of funding and conflict of interests not reported</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0070"> <li> <p>Research supported by research grants</p> </li> </ol> </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0010" title="TenenbaumS , PaullJC , SparrowEP , DoddDK , GreenL . An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). Journal of Attention Disorders2002;6(2):49-60. [DOI: 10.1177/108705470200600201] [PMID: 12142861]"><b>Tenenbaum 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Notable concerns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0071"> <li> <p>Research support received from a company with a potential vested interest</p> </li> </ol> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Impact of sources of funding and conflict of interests on the results analyzed from the trials assessing the treatment of adults with ADHD with IR methylphenidate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Harms according to organ system classification and individual events in participants treated with IR methylphenidate versus placebo</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with IR methylphenidate</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Organ system category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Organ system category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tachycardia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tachycardia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Elevated blood pressure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palpitations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="7" scope="col" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dry mouth</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7</p> </td> <th align="left" class="headercell" colspan="1" rowspan="7" scope="col" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal complaints</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal complaints</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal problem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal problem</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or upset stomach</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea or upset stomach</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stomach aches</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metabolism and nutrition disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased in appetite/Loss of appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Metabolism and nutrition disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased in appetite/Loss of appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Nervous system disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.1</p> </td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Nervous system disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.9</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="11" scope="col" valign="top"> <p><b>Psychiatric disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3</p> </td> <th align="left" class="headercell" colspan="1" rowspan="11" scope="col" valign="top"> <p><b>Psychiatric disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxious</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disorientation, insomnia, and anxiety lasting several hours</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Euphoric, unusually happy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Euphoric, unusually happy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insomnia or trouble sleeping</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moody</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moody</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sadness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sadness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stare a lot or daydream</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stare a lot or daydream</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Talk less with others</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Talk less with others</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics or nervous movements</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics or nervous movements</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleeping problems (difficulty/trouble sleeping, insomnia, nightmares)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleeping problems (difficulty/trouble sleeping, insomnia, nightmares)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.2</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nonspecific symptoms</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>6</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nonspecific symptoms</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.7</p> </td> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Total events</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>438</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>100</b> </p> </td> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Total events</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>213</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>100</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>IR: Immediate release</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Harms according to organ system classification and individual events in participants treated with IR methylphenidate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0010"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Cardiovascular events reported narratively in the included studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Electrocardiogram</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Heart rate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Diastolic blood pressure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Systolic blood pressure</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Blood pressure</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0001" title="BouffardR , HechtmanL , MindeK , Iaboni-KassabF . The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]2003;48(8):546-54. [DOI: 10.1177/070674370304800806] [PMID: 4574830]"><b>Bouffard 2003</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"No significant increase of diastolic blood pressure between baseline and methylphenidate"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased in participants receiving IR methylphenidate (mean = 123 mmHg) compared with placebo (mean 128 = mmHg) (P &lt; 0.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0004" title="KooijJJ , BurgerH , BoonstraAM , Van der LindenPD , KalmaLE , BuitelaarJK . Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine2004;34(6):973-82. [DOI: 10.1017/s0033291703001776] [PMID: 15554568]"><b>Kooij 2004</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Mean heart rate was 4.8 beats/min higher (p=0.002) after IR‐MPH"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The diastolic blood pressure remained virtually unchanged"</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The systolic blood pressure was 0.13 mmHg higher after methylphenidate but this was not statistically significant (p=0.954)" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0007" title="SchubinerH , SaulesKK , ArfkenCL , JohansonCE , SchusterCR , LockhartN , et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology2002;10(3):286-94. [PMID: 12233989]"><b>Schubiner 2002</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 participant receiving IR methylphenidate with elevated blood pressure, worst occurrence reported only </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD013011-bbs2-0008" title="SpencerT , BiedermanJ , WilensT , DoyleR , SurmanC , PrinceJ , et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry2005;57(5):456-63. [DOI: 10.1016/j.biopsych.2004.11.043] [PMID: 15737659]"><b>Spencer 2005</b> </a> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ol id="CD013011-list-0075"> <li> <p>Increased in electrocardiogram ventricular rate in participants receiving IR methylphenidate in comparison with placebo </p> </li> <li> <p>Corrected QT interval (QTc) increased in participants receiving IR methylphenidate (mean = 0.420, SD = 0.02) compared with placebo (mean = 0.413, SD = 0.02); week 6 vs week 0, P &lt; 0.01 </p> </li> </ol> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Small but statistically significant increases in pulse (83 ± 13 vs. 76 ± 13 bpm, t=4.4, df(77), p&lt;.001" </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No increase in participants receiving IR methylphenidate (mean = 78 mmHg, SD = 9 mmHg) in comparison with placebo (mean = 76 mmHg, SD = 9 mmHg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No increase in participants receiving IR methylphenidate (mean = 128 mmHg, SD = 12 mmHg) in comparison with placebo (mean = 126 mmHg, SD = 14 mmHg) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>bpm: beats of the heart per minute<br/>df: degrees of freedom<br/>IR: immediate‐release<br/>SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Cardiovascular events reported narratively in the included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0011"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Harms according to organ system classification and number of individual events in participants treated with IR methylphenidate versus OROS methylphenidate</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with IR methylphenidate</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with OROS methylphenidate</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Organ system category</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Organ system category</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>%</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic blood pressure &gt; 90 mm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic blood pressure &gt; 90 mm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulse &gt; 90 bpm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulse &gt; 90 bpm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic blood pressure &gt; 140 mm Hg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic blood pressure &gt;140 mm Hg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total events</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total events</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>21</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>bpm: beats per minute<br/>IR: immediate release<br/>OROS: osmotic release oral system </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Harms according to organ system classification and number of individual events in participants treated with IR methylphenidate versus OROS methylphenidate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013011-tbl-0012"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Harms according to organ system classification and number of individual events in participants treated with IR methylphenidate versus lithium</span></div> <tbody> <tr> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with IR methylphenidate</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Participants treated with lithium</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Organ system category</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Organ system category</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>%</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orthostatic hypotension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cardiovascular disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest discomfort</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>60</p> </td> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nervous system disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Nervous system disorders</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> </tr> <tr> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total events</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Total events</b> </p> </th> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>IR: immediate release</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Harms according to organ system classification and number of individual events in participants treated with IR methylphenidate versus lithium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/full#CD013011-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013011-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IR methylphenidate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1  Efficacy: investigator‐rated (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Efficacy: participant‐rated (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Efficacy: participant‐rated (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐1.25, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 RCT with parallel design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐1.57, ‐0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 RCT with cross‐over design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.71, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Harms: patients experiencing at least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Clinical impression: severity (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.85, ‐0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 RCTs with parallel design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.92, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 RCTs with cross‐over design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐1.05, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Clinical impression: improvement (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Anxiety: investigator‐rated (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Depression: investigator‐rated (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IR methylphenidate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013011-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IR methylphenidate versus lithium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Efficacy: investigator‐rated (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Anxiety: investigator‐rated (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Depression: investigator‐rated (end scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IR methylphenidate versus lithium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013011.pub2/references#CD013011-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013011.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013011-note-0022">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013011-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013011-note-0021">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013011-note-0018">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013011-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013011-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013011-note-0020">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013011-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013011\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013011\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013011\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013011\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013011\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013011.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013011.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013011.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013011.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013011.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728366158"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013011.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728366161"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013011.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec2b7d8499367',t:'MTc0MDcyODM2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 